

2016 Prescription Drug Guide

Humana Formulary

List of covered drugs

Humana Gold Choice H8145-093
(PFFS)

Oregon/Idaho
Select Counties in Oregon and Idaho



PLEASE READ: THIS DOCUMENT CONTAINS
INFORMATION ABOUT THE DRUGS WE
COVER IN THIS PLAN.

This formulary was updated on 09/24/2015. For more recent information or other questions, please contact Humana at 1-800-457-4708 or, for TTY users, 711, 7 days a week, from 8 a.m. - 8 p.m. However, please note that our automated phone system may answer your call during weekends and holidays from Feb. 15 - Sept. 30. Please leave your name and telephone number, and we'll call you back by the end of the next business day, or visit Humana.com.

Humana[®]

Welcome to Humana!

Note to existing members: This formulary changes yearly. If you belonged to the plan in 2015, please review this document to make sure that it still contains the drugs you take.

What is the formulary?

A formulary is the list of covered drugs selected by Humana. Humana worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. Humana will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Humana network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the formulary change?

Generally, we won't discontinue or reduce coverage of the drug during the 2016 coverage year if you take a drug that was covered at the beginning of the year. However, we may change the formulary when a new, less-expensive generic drug becomes available or when new information about the safety or effectiveness of a drug is released.

We'll notify you if you are affected by the following changes to our formulary:

- When we remove a drug from the formulary
- When we add prior authorization, quantity limits, or step-therapy restrictions on a drug
- When we move a drug to a higher cost-sharing tier

What if you're affected by a formulary change?

We'll notify you at least 60 days before one of these changes happens or when you request a refill of the affected drug.

If the Food and Drug Administration (FDA) decides a drug on our formulary is unsafe or the drug's manufacturer takes the drug off the market, we'll immediately remove the drug from our formulary and then notify you if you're taking the drug.

The enclosed formulary is current as of January 1, 2016. We'll update our printed formularies each month and they'll be available on **Humana.com/medicaredruglist**.

To get updated information about the drugs that Humana covers, please visit **Humana.com/medicaredruglist**. The Drug List Search tool lets you search for your drug by name or drug type.

For help and information, call Humana Customer Care at **1-800-457-4708 (TTY: 711)**. You can call us seven days a week, from 8 a.m. - 8 p.m. However, please note that our automated phone system may answer your call during weekends and holidays from Feb. 15 - Sept. 30. Please leave your name and telephone number and we'll call you back by the end of the next business day.

How do I use the formulary?

There are two ways to find your drug in the formulary:

Medical condition

The formulary starts on page 10. We've put the drugs into groups depending on the type of medical conditions that they're used to treat. For example, drugs that treat a heart condition are listed under the category "Cardiovascular Drugs." If you know what medical condition your drug is used for, look for the category name in the list that begins on page 10. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 5 for more information on Utilization Management Requirements).

Alphabetical listing

If you're not sure about your drug's category or group, you can look for your drug in the Index that begins on page 100. The Index is an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed. Look in the Index to search for your drug. Next to each drug, you'll see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

Prescription drugs are grouped into one of five tiers.

Humana covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Generic:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Preferred Generic drugs
- **Tier 3 - Preferred Brand:** Generic or brand drugs that the plan offers at a lower cost to you than Tier 4 Non-Preferred Brand drugs
- **Tier 4 - Non-Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 3 Preferred Brand drugs
- **Tier 5 - Specialty Tier:** Some injectables and other high-cost drugs

How much will I pay for covered drugs?

Humana pays part of the costs for your covered drugs and you pay part of the costs, too.

The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call Customer Care to find out what your costs are.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These are called Utilization Management Requirements. These requirements and limits may include:

- **Prior Authorization (PA):** Humana requires you to get prior authorization for certain drugs to be covered under your plan. This means that you'll need to get approval from Humana before you fill your prescriptions. If you don't get approval, Humana may not cover the drug.
- **Quantity Limits (QL):** For some drugs, Humana limits the amount of the drug that we'll cover. Humana might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it's normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Specialty drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, Humana requires you to first try certain drugs to treat your medical condition before we'll cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Humana may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Humana will then cover Drug B.
- **Part B versus Part D (B vs D):** Some drugs may be covered under Medicare Part B or Part D depending upon the circumstances. Information may need to be submitted to Humana that describes the use and the place where you receive and take the drug so we can make the determination.

For drugs that need prior authorization or step therapy or drugs that fall outside of quantity limits, your doctor can fax information about your condition and need for those drugs to Humana at **1-877-486-2621**. Representatives are available Monday - Friday, 8 a.m. - 6 p.m.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 10.

You can also visit Humana.com/medicaredruglist to get more information about the restrictions applied to specific covered drugs.

You can ask Humana to make an exception to these restrictions or limits. See the section "**How do I request an exception to the formulary?**" on page 6 for information about how to request an exception.

Does healthcare reform impact my coverage?

Since 2011, Medicare has made changes to help with the cost of medicines while members are in the Prescription Drug Plan coverage gap, which is often called the "donut hole." The Centers for Medicare & Medicaid Services (CMS) work with the companies that make prescription drugs and health plans so you receive nearly 55 percent off the cost of many covered, brand-name drugs while you're in the coverage gap. Medicare members who receive the low-income subsidy ("Extra Help") or are covered by a qualified, commercial prescription plan through an employer won't get this discount.

What if my drug isn't on the formulary?

If your drug isn't included in this list of covered drugs, visit Humana.com/medicaredruglist to see if your plan covers your drug. You can also call Customer Care and ask if your drug is covered.

If Humana doesn't cover your drug, you have two options:

- You can ask Customer Care for a list of similar drugs that Humana covers. Show the list to your doctor and ask him or her to prescribe a similar drug that is covered by Humana.
- You can ask Humana to make an exception and cover your drug. See below for information about how to request an exception.

Talk to your doctor to decide if you should switch to another drug that we cover or if you should request a formulary exception so that we'll cover your drug.

How do I request an exception to the formulary?

You can ask Humana to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- **Formulary exception:** You can ask us to cover your drug if it's not on our formulary.
- **Utilization restriction exception:** You can ask us not to apply coverage restrictions or limits on your drug. For example, if your drug has a quantity limit, you can ask us to not apply the limit and to cover more doses of the drug.
- **Tier exception:** You can ask us to provide a higher level of coverage for your drug. For example, if your drug is usually considered a non-preferred drug, you can ask us to cover it as preferred drug instead. This would lower how much money you must pay for your drug. Please remember that you can't ask us to provide a higher level of coverage for the drug if we grant your request to cover a drug that is not on our formulary.

Generally, Humana will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug, or other restrictions wouldn't be as effective in treating your health condition and/or would cause adverse medical effects.

You should contact us to ask for an initial coverage decision for a formulary, tier, or utilization restriction exception. When you ask for an exception, you should submit a statement from your doctor that supports your request. This is called a supporting statement.

Generally, we must make our decision within 72 hours of getting your doctor's supporting statement. You can request a quicker, or expedited, exception if you or your doctor thinks your health would seriously suffer if you wait as long as 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get your doctor's supporting statement.

Will my plan cover my drugs if they are not on the formulary?

You may take drugs that your plan doesn't cover. Or, you may talk to your provider about taking a different drug that your plan covers, but that drug might have a Utilization Management Requirement, such as a Prior Authorization or Step Therapy, that keeps you from getting the drug right away. In certain cases, we may cover as much as a 30-day supply of your drug during the first 90 days you're a member of our plan.

Here is what we'll do for each of your current Part D drugs that aren't on our formulary, or if you have limited ability to get your drugs:

- We'll temporarily cover up to a 30-day supply of your medicine when you go to a pharmacy.
- We won't pay for these drugs after your first 30-day supply, even if you've been a member of the plan for less than 90 days, unless we have granted you a formulary exception.

If you're a resident of a long-term care facility and you take Part D drugs that aren't on our formulary, we'll cover up to a 31-day supply, plus refills for a maximum of a 91-98 day supply of your current drug therapy (unless you have a prescription written for fewer days). We'll cover more than one refill of these drugs for the first 90 days you're a member of our plan. We'll cover a 31-day emergency supply of your drug (unless you have a prescription for fewer days) while you ask for a formulary exception if:

- You need a drug that's not on our formulary *or*
- You have limited ability to get your drugs *and*
- You're past the first 90 days of membership in our plan

Throughout the plan year, you may have a change in your treatment setting (the place where you receive and take your medicine) because of how much care you need. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit

- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, Humana will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. Humana will review these requests for continuation of therapy on a case-by-case basis when you're on a stabilized drug regimen that, if changed, is known to have risks.

Transition extension

Humana will consider on a case-by-case basis an extension of the transition period if your exception request or appeal hasn't been processed by the end of your initial transition period. We'll continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on Humana's Medicare website, **Humana.com**, in the same area where the Prescription Drug Guides are displayed.

Humana-Medicare.com - Find a Plan

Need help choosing the plan that's right for you. Go to **Humana-Medicare.com**, enter your ZIP code, and click "Find a Plan" to use our online comparison tools. You can learn about your coverage choices, compare benefits, and estimate your yearly costs with various plans. You can also estimate your monthly drug costs and get more information about your drugs.

For More Information

For more detailed information about your Humana prescription drug coverage, please read your Evidence of Coverage (EOC) and other plan materials.

If you have questions about Humana, please visit our website at **Humana.com/medicaredruglist**. The Drug List Search tool lets you search for your drug by name or drug type.

You can also call Humana Customer Care at **1-800-457-4708 (TTY: 711)**. You can call us seven days a week, from 8 a.m. - 8 p.m. However, please note that our automated phone system may answer your call during weekends and holidays from Feb. 15 to Sept. 30. Please leave your name and telephone number, and we'll call you back by the end of the next business day.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. TTY users should call **1-877-486-2048**. You can also visit **www.medicare.gov**.

Humana Formulary

The formulary that begins on the next page provides coverage information about some of the drugs covered by Humana. If you have trouble finding your drug in the list, turn to the Index that begins on page 100.

How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

HI - Home Infusion drugs that are covered in the gap

SP - Medicines that are typically available through a specialty pharmacy. Please contact your specialty pharmacy to make sure your drug is available.

MO - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

The second column lists the tier of the drug. See page 4 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. Humana may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your doctor prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 5 for more information about these requirements.

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ANTI-INFECTIVE AGENTS | | |
| abacavir 300 mg tablet MO | 4 | QL (60 per 30 days) |
| abacavir-lamivudine-zidov tab MO | 5 | QL (60 per 30 days) |
| ABELCET 5 MG/ML INTRAVENOUS SUSPENSION MO | 5 | |
| acyclovir 200 mg capsule; acyclovir 400 mg, 800 mg tablet MO | 2 | |
| acyclovir 200 mg/5 ml susp MO | 4 | |
| acyclovir 1,000 mg/20 ml vial HI,MO | 4 | |
| acyclovir sodium 1 gm vial MO | 4 | |
| acyclovir sodium 500 mg vial MO | 3 | |
| adefovir dipivoxil 10 mg tab SP | 5 | |
| ALBENZA 200 MG TABLET MO | 5 | |
| ALINIA 100 MG/5 ML ORAL SUSPENSION MO | 4 | QL (150 per 30 days) |
| ALINIA 500 MG TABLET MO | 4 | QL (40 per 30 days) |
| AMBISOME 50 MG INTRAVENOUS SUSPENSION MO | 4 | |
| amikacin sulf 1 gram/4 ml vial HI,MO | 4 | |
| amikacin sulf 500 mg/2 ml vial MO | 4 | |
| amoxicillin 125 mg, 250 mg tab chew; amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml susp; amoxicillin 250 mg, 500 mg capsule; amoxicillin 500 mg, 875 mg tablet MO | 1 | |
| amox tr-k clv 200-28.5 tab chw; amox tr-k clv 200-28.5/5 susp; amox tr-k clv 250-125 mg, 500-125 mg, 875-125 mg tab; amox tr-k clv 250-62.5/5 susp; amox tr-k clv 400-57 tab chew; amox tr-k clv 400-57/5 susp; amox t MO | | |
| amoxicillin-clav er 1,000-62.5 MO | 3 | |
| amphotericin b 50 mg vial MO | 4 | |
| ampicillin 125 mg/5 ml, 250 mg/5 ml susp; ampicillin 250 mg, 500 mg capsule MO | 2 | |
| ampicillin 1 gm a-v vial; ampicillin 1 gram, 2 gram, 2 gram, 250 mg, 500 mg vial; ampicillin 2 gm a-v vial; ampicillin 2 gm vial MO | 4 | |
| ampicillin 1 gm vial; ampicillin 1 gram, 10 gram, 125 mg vial; ampicillin 10 gm vial HI,MO | 4 | |
| ampicillin-sulb 3 gm add vial; ampicillin-sulbactam 1.5 gm vl MO | 4 | |
| ampicillin-sulbactam 15 gm vl; ampicillin-sulbactam 3 gm vial HI,MO | 4 | |
| APTIVUS 100 MG/ML ORAL SOLUTION SP | 5 | QL (285 per 28 days) |
| APTIVUS 250 MG CAPSULE SP | 5 | QL (120 per 30 days) |
| atovaquone 750 mg/5 ml susp MO | 5 | |
| atovaquone-proguanil 250-100; atovaquone-proguanil 62.5-25 MO | 4 | |
| ATRIPLA 600 MG-200 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| AVELOX 400 MG/250 ML IN SODIUM CHLORIDE(ISO-OSM) INTRAVENOUS PIGGYBACK HI,MO | 4 | PA |
| azithromycin 1 gm pwd packet; azithromycin 100 mg/5 ml, 200 mg/5 ml susp MO | 3 | |
| azithromycin 250 mg, 500 mg, 600 mg tablet MO | 2 | |
| azithromycin i.v. 500 mg vial HI,MO | 2 | |
| aztreonam 1 gm vial HI,MO | 4 | |
| aztreonam 2 gm vial MO | 5 | |
| baciim 50,000 unit intramuscular solution MO | 4 | |
| bacitracin 50,000 units vial MO | 2 | |
| BARACLUDE 0.05 MG/ML ORAL SOLUTION SP | 5 | QL (630 per 30 days) |
| BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION SP | 5 | PA,QL (224 per 28 days) |
| BICILLIN C-R 1,200,000 UNIT/2 ML INTRAMUSCULAR SYRINGE; BICILLIN C-R 900,000 UNIT-300K UNIT/2 ML INTRAMUSCULAR SYRINGE HI,MO | 4 | |
| BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| BILTRICIDE 600 MG TABLET MO | 4 | |
| CANCIDAS 50 MG, 70 MG INTRAVENOUS SOLUTION HI,MO | 5 | |
| CAPASTAT 1 GRAM SOLUTION FOR INJECTION MO | 4 | |
| CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION SP | 5 | PA,QL (84 per 28 days) |
| cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml susp; cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml suspen; cefaclor er 500 mg tablet MO | 3 | |
| cefaclor 250 mg, 500 mg capsule MO | 2 | |
| cefadroxil 1 gm tablet; cefadroxil 250 mg/5 ml, 500 mg/5 ml susp; cefadroxil 500 mg capsule MO | 2 | |
| cefazolin 1 gm add-van vial; cefazolin 1 gram, 10 gram, 20 gram, 500 mg vial; cefazolin 10 gm vial; cefazolin 20 gm bulk vial MO | 3 | |
| cefazolin 1 gm vial HI,MO | 3 | |
| cefazolin 1 gm-d5w bag HI,MO | 3 | |
| cefazolin 2 gm-d5w bag MO | 3 | |
| cefdinir 125 mg/5 ml, 250 mg/5 ml susp MO | 3 | |
| cefdinir 300 mg capsule MO | 2 | |
| cefepime hcl 1 gm vial; cefepime hcl 1 gram, 2 gram vial HI,MO | 4 | |
| cefepime-dextrose 1 gm/50 ml; cefepime-dextrose 2 gm/50 ml MO | 4 | |
| cefepime 1 gm injection; cefepime 2 gm injection MO | 4 | |
| cefotaxime sodium 1 gm vial; cefotaxime sodium 10 gm vial; cefotaxime sodium 2 gm vial HI,MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|-------------|--|
| cefotaxime sodium 500 mg vial MO | 2 | |
| cefotetan 1 gm vial; cefotetan 10 gm vial; cefotetan 2 gm vial MO | 4 | |
| cefotetan-dextr 1 g duplex bag; cefotetan-dextr 2 g duplex bag MO | 4 | |
| cefoxitin 1 gm vial; cefoxitin 10 gm vial; cefoxitin 2 gm vial MO | 4 | |
| cefoxitin 1 gm piggyback bag; cefoxitin 2 gm piggyback bag MO | 4 | |
| cefpodoxime 100 mg, 200 mg tablet; cefpodoxime 100 mg/5 ml, 50 mg/5 ml susp MO | 4 | |
| cefprozil 125 mg/5 ml, 250 mg/5 ml susp; cefprozil 250 mg, 500 mg tablet MO | 3 | |
| ceftazidime 1 gm vial; ceftazidime 2 gm vial; ceftazidime 6 gm vial HI,MO | 3 | |
| ceftazidime 1 gm piggyback; ceftazidime 2 gm piggyback MO | 3 | |
| ceftibuten 180 mg/5 ml susp; ceftibuten 400 mg capsule MO | 4 | |
| ceftriaxone 1 gm vial; ceftriaxone 1 gram, 2 gram, 500 mg vial; ceftriaxone 2 gm add vial HI,MO | 3 | |
| ceftriaxone 10 gm vial; ceftriaxone 10 gram, 2 gram, 250 mg vial; ceftriaxone 2 gm vial MO | 3 | |
| ceftriaxone 1 gm-d5w bag; ceftriaxone 2 gm-d5w bag MO | 3 | |
| cefuroxime axetil 250 mg, 500 mg tab MO | 3 | |
| cefuroxime sod 7.5 gm vial; cefuroxime sod 7.5 gram, 750 mg vial HI,MO | 3 | |
| cefuroxime 1.5 gram/50 ml, 750 mg/50 ml bag; cefuroxime 1.5g/50 ml bag MO | 1 | |
| cephalexin 125 mg/5 ml, 250 mg/5 ml susp; cephalexin 250 mg, 500 mg capsule; cephalexin 250 mg, 500 mg tablet MO | 2 | |
| cephalexin 750 mg capsule MO | 4 | |
| chloramphen na succ 1 gm vl HI,MO | 3 | |
| chloroquine ph 250 mg, 500 mg tablet MO | 2 | |
| cidofovir 375 mg/5 ml vial MO | 4 | |
| ciprofloxacin er 1,000 mg, 500 mg tab; ciprofloxacin er 1,000 mg, 500 mg tablet MO | 2 | |
| ciprofloxacin 0.3% eye drop; ciprofloxacin hcl 100 mg, 250 mg, 500 mg, 750 mg tab MO | 1 | |
| ciprofloxacin-d5w 200 mg/100 ml HI,MO | 2 | |
| ciprofloxacin-d5w 400 mg/200 ml MO | 2 | |
| ciprofloxacin 200 mg/20 ml vl MO | 2 | |
| ciprofloxacin 400 mg/40 ml vl HI,MO | 2 | |
| clarithromycin 125 mg/5 ml, 250 mg/5 ml sus; clarithromycin 250 mg, 500 mg tablet; clarithromycin er 500 mg tab MO | 3 | |
| clindamycin hcl 150 mg, 300 mg, 75 mg capsule MO | 2 | |
| clindamycin-d5w 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml HI,MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| clindamycin 75 mg/5 ml soln MO | 4 | |
| clindamycin pediatric 75 mg/5 ml oral solution MO | 4 | |
| clindamycin 150 mg/ml addvan; clindamycin 2% vaginal cream; clindamycin ph 1% gel; clindamycin ph 1% solution; clindamycin ph 600 mg/4 ml vl; clindamycin phos 1% pledget; clindamycin phosp 1% lotion MO | 3 | |
| COARTEM 20 MG-120 MG TABLET MO | 4 | QL (24 per 30 days) |
| colistimethate 150 mg vial MO | 4 | |
| COMPLERA 200 MG-25 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |
| CRESEMBA 186 MG CAPSULE; CRESEMBA 372 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| CRIXIVAN 200 MG CAPSULE MO | 4 | QL (450 per 30 days) |
| CRIXIVAN 400 MG CAPSULE MO | 4 | QL (270 per 30 days) |
| CUBICIN 500 MG INTRAVENOUS SOLUTION HI,MO | 5 | |
| cycloserine 250 mg capsule MO | 4 | |
| dapsone 100 mg, 25 mg tablet MO | 3 | |
| DARAPRIM 25 MG TABLET MO | 4 | |
| demeclocycline 150 mg, 300 mg tablet MO | 4 | |
| dicloxacillin 250 mg, 500 mg capsule MO | 2 | |
| didanosine dr 125 mg capsule MO | 4 | QL (90 per 30 days) |
| didanosine dr 200 mg capsule MO | 4 | QL (60 per 30 days) |
| didanosine dr 250 mg, 400 mg capsule MO | 4 | QL (30 per 30 days) |
| DORIBAX 250 MG, 500 MG INTRAVENOUS SOLUTION MO | 4 | |
| doxy-100 100 mg intravenous solution MO | 4 | |
| doxycycline hyc 100 mg vial HI,MO | 3 | |
| doxycycline hyclate 100 mg, 20 mg tab; doxycycline hyclate 100 mg, 50 mg cap MO | 3 | |
| doxycycline 25 mg/5 ml susp; doxycycline mono 150 mg cap MO | 4 | |
| doxycycline mono 100 mg, 150 mg, 50 mg, 75 mg tablet MO | 3 | |
| doxycycline mono 100 mg, 50 mg cap MO | 3 | QL (60 per 30 days) |
| doxycycline mono 75 mg capsule MO | 4 | QL (60 per 30 days) |
| E.E.S. 400 400 MG TABLET MO | 4 | |
| EDURANT 25 MG TABLET SP | 5 | QL (30 per 30 days) |
| EMTRIVA 10 MG/ML ORAL SOLUTION MO | 4 | QL (680 per 28 days) |
| EMTRIVA 200 MG CAPSULE MO | 4 | QL (30 per 30 days) |
| entecavir 0.5 mg, 1 mg tablet SP | 5 | QL (30 per 30 days) |
| EPIVIR HBV 25 MG/5 ML (5 MG/ML) ORAL SOLUTION MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| EPZICOM 600 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |
| ERAXIS(WATER DILUENT) 100 MG INTRAVENOUS SOLUTION HI,MO | 4 | |
| ERAXIS(WATER DILUENT) 50 MG INTRAVENOUS SOLUTION MO | 4 | |
| ERY-TAB 250 MG, 333 MG, 500 MG TABLET,DELAYED RELEASE MO | 4 | |
| ERYTHROCIN 500 MG INTRAVENOUS SOLUTION HI,MO | 1 | |
| ERYTHROCIN (AS STEARATE) 250 MG TABLET MO | 2 | |
| erythromycin 250 mg, 500 mg filmtab; erythromycin ec 250 mg cap MO | 4 | |
| erythromycin es 400 mg tab MO | 4 | |
| erythromycin-sulfisox susp MO | 2 | |
| ethambutol hcl 100 mg, 400 mg tablet MO | 4 | |
| EVOTAZ 300 MG-150 MG TABLET SP | 5 | QL (30 per 30 days) |
| famciclovir 125 mg, 250 mg, 500 mg tablet MO | 3 | QL (60 per 30 days) |
| fluconazole 10 mg/ml, 40 mg/ml susp; fluconazole 100 mg, 150 mg, 200 mg, 50 mg tablet MO | 2 | |
| fluconazole-dext 200 mg/100 ml MO | 2 | |
| fluconazole-dext 400 mg/200 ml HI,MO | 2 | |
| fluconazole-nacl 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml; fluconazole-ns 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml MO | 2 | |
| flucytosine 250 mg, 500 mg capsule MO | 5 | |
| foscarnet 24 mg/ml infus bttl MO | 3 | B vs D |
| FUZEON 90 MG SUBCUTANEOUS SOLUTION SP | 5 | QL (60 per 30 days) |
| ganciclovir 500 mg vial HI,MO | 4 | |
| gentamicin 80 mg/2 ml vial HI,MO | 2 | |
| gentamicin 70 mg/ns 50 ml pb; gentamicin 90 mg/ns 100 ml pb; iso gentamicin 100 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml; isoton gentamicin 100 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml MO | | |
| iso gentamicin 100 mg/50 ml, 120 mg/100 ml; isoton gentamicin 100 mg/50 ml, 120 mg/100 ml MO | 3 | |
| gentamicin ped 20 mg/2 ml vial MO | 2 | |
| gentamicin 10 mg/ml vial MO | 2 | |
| griseofulvin 125 mg/5 ml susp; griseofulvin micro 500 mg tab MO | 4 | |
| griseofulvin ultra 125 mg, 250 mg tab MO | 4 | |
| HARVONI 90 MG-400 MG TABLET SP | 5 | PA,QL (28 per 28 days) |
| hydroxychloroquine 200 mg tab MO | 2 | |
| imipenem-cilastatin 250 mg vl HI,MO | 4 | |
| imipenem-cilastatin 500 mg vl HI,MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| INFERGEN 15 MCG/0.5 ML VIAL SP | 5 | QL (30 per 30 days) |
| INFERGEN 9 MCG/0.3 ML VIAL SP | 5 | QL (12 per 30 days) |
| INTELENCE 100 MG TABLET SP | 5 | QL (120 per 30 days) |
| INTELENCE 200 MG TABLET SP | 5 | QL (60 per 30 days) |
| INTELENCE 25 MG TABLET SP | 4 | QL (120 per 30 days) |
| INTRON A 10 MILLION UNIT (1 ML), 10 MILLION UNIT/ML, 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML), 6 MILLION UNIT/ML INJECTION SOLUTION; INTRON A 10 MILLION UNIT (1 ML), 10 MILLION UNIT/ML, 18 MILLION UNIT (1 ML), 50 MILLION UNIT (MO | | |
| INVANZ 1 GRAM INTRAVENOUS SOLUTION MO | 4 | |
| INVANZ 1 GRAM SOLUTION FOR INJECTION HI,MO | 4 | |
| INVIRASE 200 MG CAPSULE SP | 5 | QL (300 per 30 days) |
| INVIRASE 500 MG TABLET SP | 5 | QL (120 per 30 days) |
| ISENTRESS 100 MG CHEWABLE TABLET SP | 5 | QL (180 per 30 days) |
| ISENTRESS 100 MG ORAL POWDER PACKET SP | 3 | QL (300 per 30 days) |
| ISENTRESS 25 MG CHEWABLE TABLET SP | 4 | QL (180 per 30 days) |
| ISENTRESS 400 MG TABLET SP | 5 | QL (120 per 30 days) |
| <i>isoniazid 100 mg, 300 mg tablet; isoniazid 100 mg/ml, 50 mg/5 ml solution; isoniazid 100 mg/ml, 50 mg/5 ml vial</i> MO | 1 | |
| <i>itraconazole 100 mg capsule</i> MO | 4 | QL (120 per 30 days) |
| <i>ivermectin 3 mg tablet</i> MO | 3 | |
| KALETRA 100 MG-25 MG TABLET SP | 4 | QL (300 per 30 days) |
| KALETRA 200 MG-50 MG TABLET SP | 5 | QL (150 per 30 days) |
| KALETRA 400 MG-100 MG/5 ML ORAL SOLUTION SP | 5 | |
| KETEK 300 MG, 400 MG TABLET MO | 4 | |
| <i>ketoconazole 2% cream; ketoconazole 2% shampoo; ketoconazole 200 mg tablet</i> MO | 2 | |
| <i>lamivudine 10 mg/ml oral soln</i> MO | 4 | QL (960 per 30 days) |
| <i>lamivudine 150 mg tablet</i> MO | 4 | QL (60 per 30 days) |
| <i>lamivudine 300 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| <i>lamivudine hbv 100 mg tablet</i> MO | 4 | |
| <i>lamivudine-zidovudine tablet</i> MO | 4 | QL (60 per 30 days) |
| <i>levofloxacin 0.5% eye drops; levofloxacin 250 mg, 500 mg, 750 mg tablet</i> MO | 2 | |
| <i>levofloxacin 25 mg/ml solution</i> MO | 3 | |
| <i>levofloxacin 500 mg/20 ml vial</i> HI,MO | 4 | |
| <i>levofloxacin-d5w 250 mg/50 ml, 750 mg/150 ml</i> MO | 4 | |
| <i>levofloxacin-d5w 500 mg/100 ml</i> HI,MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| LEXIVA 50 MG/ML ORAL SUSPENSION ^{SP} | 3 | QL (1575 per 28 days) |
| LEXIVA 700 MG TABLET ^{SP} | 5 | QL (120 per 30 days) |
| LINCOCIN 300 MG/ML INJECTION SOLUTION ^{HI,MO} | 4 | |
| linezolid 600 mg tablet ^{MO} | 5 | |
| linezolid 600 mg/300 ml iv sol ^{HI,MO} | 5 | |
| linezolid-0.9% nacl 600 mg/300 ^{MO} | 5 | |
| mefloquine hcl 250 mg tablet ^{MO} | 3 | |
| meropenem iv 1 gm vial ^{MO} | 4 | |
| meropenem iv 500 mg vial ^{HI,MO} | 4 | |
| methenamine hipp 1 gm tablet ^{MO} | 4 | |
| metronidazole 0.75% cream; metronidazole 0.75% lotion; metronidazole 375 mg capsule; metronidazole topical 0.75% gl; metronidazole topical 1% gel; metronidazole topical 1% gel ^{MO} | 4 | |
| metronidazole 250 mg, 500 mg tablet; metronidazole vaginal 0.75% gl ^{MO} | 2 | |
| metronidazole 500 mg/100 ml ^{HI,MO} | 4 | |
| minocycline 100 mg, 50 mg, 75 mg capsule ^{MO} | 2 | |
| minocycline hcl 100 mg, 50 mg, 75 mg tablet ^{MO} | 3 | |
| MONUROL 3 GRAM ORAL PACKET ^{MO} | 4 | |
| moxifloxacin hcl 400 mg tablet ^{MO} | 4 | |
| moxifloxacin 400 mg/250 ml bag ^{MO} | 4 | |
| MYCAMINE 100 MG, 50 MG INTRAVENOUS SOLUTION ^{MO} | 5 | |
| nafcillin 1 gm add-van vial; nafcillin 2 gm add-vant vial; nafcillin 2 gm vial ^{MO} | 5 | |
| nafcillin 1 gm vial ^{HI,MO} | 4 | |
| nafcillin 10 gm vial ^{HI,MO} | 5 | |
| nafcillin 1 gm/ 50 ml inj ^{HI,MO} | 4 | |
| nafcillin 2 gm/ 100 ml inj ^{MO} | 5 | |
| NEBUPENT 300 MG SOLUTION FOR INHALATION ^{MO} | 4 | B vs D |
| neomycin 500 mg tablet ^{MO} | 3 | |
| nevirapine 200 mg tablet ^{MO} | 2 | QL (60 per 30 days) |
| nevirapine 50 mg/5 ml susp ^{MO} | 4 | QL (1200 per 30 days) |
| nevirapine er 400 mg tablet ^{MO} | 4 | QL (30 per 30 days) |
| nitrofurantoin 25 mg/5 ml susp ^{MO} | 4 | PA,QL (7590 per 120 days) |
| nitrofurantoin mcr 100 mg, 50 mg cap ^{MO} | 4 | PA |
| nitrofurantoin mono-mcr 100 mg ^{MO} | 4 | PA |
| NOROXIN 400 MG TABLET ^{MO} | 4 | |
| NORVIR 100 MG CAPSULE; NORVIR 100 MG TABLET ^{MO} | 4 | QL (360 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| NORVIR 80 MG/ML ORAL SOLUTION MO | 4 | QL (480 per 30 days) |
| NOXAFIL 100 MG TABLET,DELAYED RELEASE MO | 5 | PA,QL (93 per 30 days) |
| NOXAFIL 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION MO | 5 | PA,QL (840 per 28 days) |
| NOXAFIL 300 MG/16.7 ML INTRAVENOUS SOLUTION MO | 5 | PA |
| <i>nystatin 100,000 unit/gm cream; nystatin 100,000 unit/gm powd; nystatin 100,000 units/gm oint; nystatin 100,000 units/ml susp; nystatin 500,000 unit oral tab</i> MO | 2 | |
| <i>ofloxacin 0.3% ear drops; ofloxacin 0.3% eye drops; ofloxacin 200 mg, 300 mg, 400 mg tablet</i> MO | 2 | |
| <i>oxacillin 1 gm add-vantage vl; oxacillin 2 gm add-vantage vl</i> MO | 4 | |
| <i>oxacillin 1 gm vial</i> HI,MO | 4 | |
| <i>oxacillin 10 gm vial</i> HI,MO | 5 | |
| <i>oxacillin 2 gm vial</i> MO | 5 | |
| <i>oxacillin 1 gm/ 50 ml inj</i> HI,MO | 4 | |
| <i>oxacillin 2 gm/ 50 ml inj</i> HI,MO | 5 | |
| <i>paromomycin 250 mg capsule</i> MO | 4 | |
| PASER GRANULES DELAYED-RELEASE PACKET MO | 2 | |
| PCE 333 MG, 500 MG PARTICLES IN TABLET MO | 4 | |
| PEGINTRON 120 MCG/0.5 ML, 150 MCG/0.5 ML, 50 MCG/0.5 ML, 80 MCG/0.5 ML SUBCUTANEOUS KIT SP | 5 | PA,QL (2 per 28 days) |
| PEGINTRON REDIPEN 120 MCG/0.5 ML, 150 MCG/0.5 ML, 50 MCG/0.5 ML, 80 MCG/0.5 ML SUBCUTANEOUS KIT SP | 5 | PA,QL (2 per 28 days) |
| <i>pen g k 1 million unit/50 ml</i> MO | 3 | |
| <i>pen g k 2 million unit/50 ml, 3 million unit/50 ml</i> HI,MO | 3 | |
| <i>penicillin g k 5 million unit</i> HI,MO | 3 | |
| <i>penicillin gk 20 million unit</i> MO | 3 | |
| <i>pen g 1.2 million unit/2 ml, 600,000 unit/ml; penicillin g 600,000 unit/1 ml</i> MO | 4 | |
| <i>penicillin g na 5 million unit</i> HI,MO | 3 | |
| <i>penicillin vk 125 mg/5 ml, 250 mg/5 ml soln; penicillin vk 250 mg, 500 mg tablet</i> MO | 2 | |
| PENTAM 300 MG SOLUTION FOR INJECTION MO | 4 | |
| <i>pfizerpen-g 20 million unit, 5 million unit solution for injection</i> MO | 3 | |
| <i>piperacil-tazobact 2.25 gm vl; piperacil-tazobact 2.25 gram, 40.5 gram</i> MO | 4 | |
| <i>piperacil-tazobact 3.375 gm vl; piperacil-tazobact 4.5 gm vial</i> HI,MO | 4 | |
| <i>polymyxin b sulfate vial</i> HI,MO | 3 | |
| PREZCOBIX 800 MG-150 MG TABLET SP | 5 | QL (30 per 30 days) |
| PREZISTA 100 MG/ML ORAL SUSPENSION SP | 5 | QL (360 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| PREZISTA 150 MG TABLET SP | 4 | QL (240 per 30 days) |
| PREZISTA 400 MG TABLET SP | 5 | QL (90 per 30 days) |
| PREZISTA 600 MG TABLET SP | 5 | QL (60 per 30 days) |
| PREZISTA 75 MG TABLET SP | 4 | QL (480 per 30 days) |
| PREZISTA 800 MG TABLET SP | 5 | QL (30 per 30 days) |
| PRIFTIN 150 MG TABLET MO | 4 | |
| <i>primaquine 26.3 mg tablet</i> MO | 3 | |
| PRIMSOL 50 MG/5 ML ORAL SOLUTION MO | 2 | |
| PYLERA 140 MG-125 MG-125 MG CAPSULE MO | 4 | QL (144 per 30 days) |
| <i>pyrazinamide 500 mg tablet</i> MO | 4 | |
| <i>quinine sulfate 324 mg capsule</i> MO | 4 | PA,QL (42 per 7 days) |
| REBETOL 40 MG/ML ORAL SOLUTION MO | 4 | QL (1000 per 30 days) |
| RELENZA DISKHALER 5 MG/ACTUATION POWDER FOR INHALATION MO | 4 | QL (60 per 180 days) |
| RESCRIPTOR 100 MG DISPERSIBLE TABLET MO | 4 | QL (360 per 30 days) |
| RESCRIPTOR 200 MG TABLET MO | 4 | QL (180 per 30 days) |
| RETROVIR 10 MG/ML INTRAVENOUS SOLUTION MO | 4 | |
| REYATAZ 150 MG, 200 MG CAPSULE SP | 5 | QL (60 per 30 days) |
| REYATAZ 300 MG CAPSULE SP | 5 | QL (30 per 30 days) |
| REYATAZ 50 MG ORAL POWDER PACKET SP | 4 | |
| <i>ribasphere 200 mg capsule; ribasphere 200 mg tablet</i> MO | 3 | QL (168 per 28 days) |
| <i>ribavirin 200 mg capsule; ribavirin 200 mg tablet</i> MO | 3 | QL (168 per 28 days) |
| <i>rifabutin 150 mg capsule</i> MO | 4 | |
| RIFAMATE 300 MG-150 MG CAPSULE MO | 4 | |
| <i>rifampin 150 mg, 300 mg capsule</i> MO | 3 | |
| <i>rifampin iv 600 mg vial</i> MO | 2 | |
| RIFATER 50 MG-120 MG-300 MG TABLET MO | 4 | |
| <i>rimantadine hcl 100 mg tablet</i> MO | 3 | |
| SELZENTRY 150 MG TABLET SP | 5 | QL (240 per 30 days) |
| SELZENTRY 300 MG TABLET SP | 5 | QL (120 per 30 days) |
| SIRTURO 100 MG TABLET MO | 5 | PA,QL (68 per 28 days) |
| SIVEXTRO 200 MG INTRAVENOUS SOLUTION; SIVEXTRO 200 MG TABLET MO | 5 | QL (6 per 28 days) |
| SOVALDI 400 MG TABLET SP | 5 | PA,QL (28 per 28 days) |
| <i>stavudine 1 mg/ml solution</i> MO | 3 | QL (2400 per 30 days) |
| <i>stavudine 15 mg, 20 mg capsule</i> MO | 3 | QL (120 per 30 days) |
| <i>stavudine 30 mg, 40 mg capsule</i> MO | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| streptomycin sulf 1 gm vial HI,MO | 3 | |
| STRIBILD 150 MG-150 MG-200 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |
| sulfadiazine 500 mg tablet MO | 4 | |
| sulfamethoxazole-tmp ds tablet; sulfamethoxazole-tmp inj vial; sulfamethoxazole-tmp ss tablet MO | 1 | |
| sulfamethoxazole-tmp susp MO | 3 | |
| sulfasalazine 500 mg, 500 mg tablet; sulfasalazine dr 500 mg, 500 mg tab MO | 2 | |
| sulfazine 500 mg tablet MO | 2 | |
| sulfazine ec 500 mg tablet, delayed release MO | 2 | |
| SUSTIVA 200 MG CAPSULE SP | 5 | QL (120 per 30 days) |
| SUSTIVA 50 MG CAPSULE SP | 4 | QL (480 per 30 days) |
| SUSTIVA 600 MG TABLET SP | 5 | QL (30 per 30 days) |
| SYLATRON 200 MCG, 300 MCG, 600 MCG SUBCUTANEOUS KIT SP | 5 | PA,QL (2 per 28 days) |
| SYLATRON 200 MCG, 300 MCG 4-PACK SP | 5 | PA,QL (2 per 28 days) |
| SYNAGIS 100 MG/ML, 50 MG/0.5 ML INTRAMUSCULAR SOLUTION MO | 5 | PA |
| SYNERCID 500 MG INTRAVENOUS SOLUTION HI,MO | 5 | |
| TAMIFLU 30 MG CAPSULE MO | 4 | QL (112 per 365 days) |
| TAMIFLU 45 MG, 75 MG CAPSULE MO | 4 | QL (56 per 365 days) |
| TAMIFLU 6 MG/ML ORAL SUSPENSION MO | 4 | QL (720 per 365 days) |
| TEFLARO 400 MG, 600 MG INTRAVENOUS SOLUTION MO | 4 | |
| terbinafine hcl 250 mg tablet MO | 2 | QL (90 per 365 days) |
| tetracycline 250 mg, 500 mg capsule MO | 3 | |
| TIMENTIN 3.1 GM VIAL HI,MO | 4 | |
| TIMENTIN 31 GRAM INTRAVENOUS SOLUTION MO | 4 | |
| tinidazole 250 mg, 500 mg tablet MO | 3 | |
| TIVICAY 50 MG TABLET SP | 5 | QL (60 per 30 days) |
| TOBI PODHALER 28 MG, 28 MG CAPSULE WITH INHALATION DEVICE; TOBI PODHALER 28 MG, 28 MG CAPSULES FOR INHALATION SP | 5 | PA,QL (224 per 28 days) |
| tobramycin 80 mg/100 ml ns HI,MO | 2 | |
| tobramycin 1.2 gm vial MO | 5 | |
| tobramycin 40 mg/ml vial HI,MO | 2 | |
| TRECTOR 250 MG TABLET MO | 4 | |
| trimethoprim 100 mg tablet MO | 2 | |
| TRIUMEQ 600 MG-50 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |
| TRIZIVIR 300 MG-150 MG-300 MG TABLET MO | 5 | QL (60 per 30 days) |
| TRUVADA 200 MG-300 MG TABLET SP | 5 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| TYGACIL 50 MG INTRAVENOUS SOLUTION ^{HI,MO} | 5 | |
| TYZEKA 600 MG TABLET ^{SP} | 5 | QL (30 per 30 days) |
| valacyclovir hcl 1 gram tablet ^{MO} | 3 | QL (90 per 30 days) |
| valacyclovir hcl 500 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| VALCYTE 50 MG/ML ORAL SOLUTION ^{MO} | 5 | |
| valganciclovir 450 mg tablet ^{MO} | 5 | |
| vancomycin 1 gm vial; vancomycin 1,000 mg, 10 gram, 500 mg vial; vancomycin hcl 10 gm vial ^{HI,MO} | 3 | |
| vancomycin hcl 125 mg, 250 mg capsule ^{MO} | 5 | |
| vancomycin hcl 5 gm vial; vancomycin hcl 5 gram, 750 mg vial ^{MO} | 3 | |
| vancomycin hcl 1g/200 ml bag; vancomycin-d5w 1 gram/200 ml, 500 mg/100 ml ^{MO} | 4 | |
| vancomycin 750 mg/150 ml bag ^{MO} | 4 | |
| VIDEX 2 GRAM PEDIATRIC 10 MG/ML (FINAL CONC.) ORAL SOLUTION ^{MO} | 4 | QL (1200 per 30 days) |
| VIDEX 4 GRAM PEDIATRIC 10 MG/ML (FINAL CONC.) ORAL SOLUTION ^{MO} | 4 | QL (1200 per 30 days) |
| VIRACEPT 250 MG TABLET ^{SP} | 5 | QL (300 per 30 days) |
| VIRACEPT 625 MG TABLET ^{SP} | 5 | QL (120 per 30 days) |
| VIRAMUNE XR 100 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | QL (120 per 30 days) |
| VIRAZOLE 6 GRAM SOLUTION FOR INHALATION ^{MO} | 5 | B vs D |
| VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET ^{SP} | 5 | QL (30 per 30 days) |
| VIREAD 40 MG/SCOOP (40 MG/GRAM) ORAL POWDER ^{SP} | 5 | QL (240 per 30 days) |
| VITEKTA 150 MG, 85 MG TABLET ^{SP} | 5 | QL (30 per 30 days) |
| voriconazole 200 mg vial ^{HI,MO} | 4 | |
| voriconazole 200 mg, 50 mg tablet ^{MO} | 5 | PA,QL (120 per 30 days) |
| voriconazole 40 mg/ml susp ^{MO} | 5 | PA,QL (400 per 30 days) |
| XIFAXAN 200 MG TABLET ^{MO} | 5 | PA,QL (9 per 30 days) |
| XIFAXAN 550 MG TABLET ^{MO} | 5 | PA,QL (60 per 30 days) |
| ZERBAXA 1.5 GRAM INTRAVENOUS SOLUTION ^{MO} | 5 | |
| ZIAGEN 20 MG/ML ORAL SOLUTION ^{MO} | 4 | QL (960 per 30 days) |
| zidovudine 100 mg capsule ^{MO} | 3 | QL (180 per 30 days) |
| zidovudine 300 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| zidovudine 50 mg/5 ml syrup ^{MO} | 3 | QL (1680 per 28 days) |
| ZYVOX 100 MG/5 ML ORAL SUSPENSION; ZYVOX 200 MG/100 ML INTRAVENOUS SOLUTION; ZYVOX 600 MG TABLET ^{MO} | 5 | |
| ANTIHISTAMINE DRUGS | | |
| cetirizine hcl 1 mg/ml syrup ^{MO} | 2 | QL (300 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>clemastine 0.5 mg/5 ml syrup</i> ^{MO} | 3 | PA |
| <i>clemastine fum 2.68 mg tab</i> ^{MO} | 4 | PA |
| <i>cyproheptadine 4 mg tablet</i> ^{MO} | 4 | PA |
| <i>diphenhydramine 50 mg/ml vial</i> ^{MO} | 4 | PA |
| <i>levocetirizine 5 mg tablet</i> ^{MO} | 2 | QL (30 per 30 days) |
| <i>promethazine 12.5 mg, 25 mg, 50 mg tablet; promethazine 6.25 mg/5 ml syrup</i> ^{MO} | 3 | PA |
| ANTINEOPLASTIC AGENTS | | |
| ABRAXANE 100 MG INTRAVENOUS SUSPENSION ^{MO} | 5 | PA,QL (180 per 21 days) |
| <i>adriamycin 10 mg, 10 mg/5 ml, 20 mg, 20 mg/10 ml, 50 mg/25 ml vial; adriamycin 2 mg/ml vial</i> ^{MO} | 3 | B vs D |
| ADRIAMYCIN 50 MG VIAL ^{MO} | 3 | B vs D |
| <i>adriamycin 200 mg/100 ml vial</i> ^{MO} | 3 | B vs D |
| AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET ^{SP} | 5 | PA,QL (30 per 30 days) |
| AFINITOR DISPERZ TABLET FOR ORAL SUSPENSION ^{SP} | 5 | PA |
| ALIMTA 100 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (68 per 21 days) |
| ALIMTA 500 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| ALKERAN 2 MG TABLET ^{MO} | 5 | B vs D |
| ALKERAN 50 MG INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>anastrozole 1 mg tablet</i> ^{MO} | 2 | QL (30 per 30 days) |
| ARRANON 250 MG/50 ML INTRAVENOUS SOLUTION ^{MO} | 5 | |
| ARZERRA 1,000 MG/50 ML, 100 MG/5 ML INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (400 per 28 days) |
| AVASTIN 25 MG/ML INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| <i>azacitidine 100 mg vial</i> ^{MO} | 5 | PA |
| BELEODAQ 500 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| <i>bexarotene 75 mg capsule</i> ^{SP} | 5 | PA,QL (300 per 30 days) |
| <i>bicalutamide 50 mg tablet</i> ^{MO} | 3 | QL (30 per 30 days) |
| BICNU 100 MG INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>bleomycin sulfate 15 unit, 30 unit vial</i> ^{MO} | 3 | B vs D |
| BOSULIF 100 MG TABLET ^{SP} | 5 | PA,QL (120 per 30 days) |
| BOSULIF 500 MG TABLET ^{SP} | 5 | PA,QL (30 per 30 days) |
| BUSULFEX 60 MG/10 ML INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CAMPTOSAR 100 MG/5 ML INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CAMPTOSAR 300 MG/15 ML, 40 MG/2 ML INTRAVENOUS SOLUTION ^{MO} | 5 | B vs D |
| CAPRELSA 100 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |
| CAPRELSA 300 MG TABLET ^{SP} | 5 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| carboplatin 50 mg/5 ml vial MO | 3 | B vs D |
| cisplatin 50 mg/50 ml vial MO | 3 | B vs D |
| cladribine 10 mg/10 ml vial MO | 5 | |
| CLOLAR 20 MG/20 ML INTRAVENOUS SOLUTION MO | 5 | B vs D |
| COMETRIQ 100 MG/DAY(80 MGÝ1"-20 MGÝ1") CAPSULE SP | 5 | PA,QL (56 per 28 days) |
| COMETRIQ 140 MG/DAY(80 MGÝ1"-20 MGÝ3") CAPSULE SP | 5 | PA,QL (112 per 28 days) |
| COMETRIQ 60 MG/DAY (20 MG Ý3"/DAY) CAPSULE SP | 5 | PA,QL (84 per 28 days) |
| COSMEGEN 0.5 MG INTRAVENOUS SOLUTION MO | 5 | B vs D |
| cyclophosphamide 1 gm vial; cyclophosphamide 1 gram, 2 gram, 500 mg vial; cyclophosphamide 2 gm vial; cyclophosphamide 25 mg, 50 mg capsule; cyclophosphamide 25 mg, 50 mg tab; cyclophosphamide 25 mg, 50 mg tablet MO | 4 | B vs D |
| CYRAMZA 10 MG/ML INTRAVENOUS SOLUTION MO | 5 | PA,QL (200 per 28 days) |
| cytarabine 20 mg/ml vial MO | 1 | B vs D |
| cytarabine 1 gm vial; cytarabine 1 gram, 100 mg, 2 gram/20 ml (100 mg/ml), 500 mg vial; cytarabine 2 g/20 ml vial MO | 1 | B vs D |
| dacarbazine 100 mg, 200 mg vial MO | 4 | B vs D |
| daunorubicin 20 mg/4 ml vial MO | 1 | B vs D |
| DAUNOXOME 2 MG/ML INTRAVENOUS SOLUTION MO | 4 | B vs D |
| decitabine 50 mg vial MO | 5 | PA |
| DEPOCYT (PF) 50 MG/5 ML (10 MG/ML) INTRATHECAL SUSPENSION MO | 5 | B vs D |
| DOCEFREZ 20 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| DOCEFREZ 80 MG INTRAVENOUS SOLUTION MO | 5 | B vs D |
| docetaxel 140 mg/7 ml vial; docetaxel 160 mg/16 ml vial; docetaxel 160 mg/8 ml vial; docetaxel 20 mg/0.5 ml vial; docetaxel 20 mg/2 ml vial; docetaxel 20 mg/ml vial; docetaxel 200 mg/20 ml vial; docetaxel 80 mg/2 ml vial; docetaxel MO | | |
| doxorubicin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg, 50 mg/25 ml vial; doxorubicin 150 mg/75 ml vial MO | 4 | B vs D |
| doxorubicin liposome 20mg/10ml MO | 4 | B vs D |
| DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO | 4 | |
| ELIGARD 22.5 MG (3 MONTH), 30 MG (4 MONTH), 45 MG (6 MONTH), 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE SP | 4 | PA |
| ELLENC 200 MG/100 ML, 50 MG/25 ML INTRAVENOUS SOLUTION MO | 5 | B vs D |
| EMCYT 140 MG CAPSULE MO | 4 | |
| epirubicin 200 mg, 200 mg/100 ml, 50 mg, 50 mg/25 ml vial; epirubicin hcl 200 mg, 200 mg/100 ml, 50 mg, 50 mg/25 ml vial MO | 4 | B vs D |
| ERBITUX 100 MG/50 ML, 200 MG/100 ML INTRAVENOUS SOLUTION MO | 5 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ERIVEDGE 150 MG CAPSULE ^{SP} | 5 | PA,QL (28 per 28 days) |
| ERWINAZE 10,000 UNIT INTRAMUSCULAR SOLUTION ^{MO} | 5 | PA,QL (60 per 28 days) |
| ETOPOPHOS 100 MG INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>etoposide 100 mg/5 ml vial</i> ^{MO} | 3 | B vs D |
| <i>exemestane 25 mg tablet</i> ^{MO} | 4 | QL (60 per 30 days) |
| FARESTON 60 MG TABLET ^{SP} | 5 | QL (30 per 30 days) |
| FARYDAK 10 MG, 15 MG, 20 MG CAPSULE ^{SP} | 5 | PA,QL (6 per 21 days) |
| FASLODEX 250 MG/5 ML INTRAMUSCULAR SYRINGE ^{MO} | 5 | B vs D,QL (30 per 30 days) |
| FIRMAGON 120 MG SUBCUTANEOUS SOLUTION ^{MO} | 5 | PA |
| FIRMAGON 80 MG SUBCUTANEOUS SOLUTION ^{MO} | 4 | PA |
| FIRMAGON KIT WITH DILUENT SYRINGE 120 MG SUBCUTANEOUS SOLUTION ^{MO} | 5 | PA |
| FIRMAGON KIT WITH DILUENT SYRINGE 80 MG SUBCUTANEOUS SOLUTION ^{MO} | 4 | PA |
| <i>floxuridine 500 mg vial</i> ^{MO} | 1 | B vs D |
| <i>fludarabine 50 mg, 50 mg/2 ml vial</i> ^{MO} | 4 | B vs D |
| <i>fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial; fluorouracil 1,000 mg/20 ml vl; fluorouracil 2,500 mg/50 ml vl; fluorouracil 5,000 mg/100 ml</i> ^{MO} | 4 | B vs D |
| <i>flutamide 125 mg capsule</i> ^{MO} | 4 | |
| FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| GAZYVA 1,000 MG/40 ML INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (120 per 28 days) |
| <i>gemcitabine 1 gram/26.3 ml vl; gemcitabine 2 gram/52.6 ml vl; gemcitabine 200 mg/5.26 ml vl; gemcitabine hcl 1 gram, 1 gram/26.3 ml (38 mg/ml), 2 gram, 2 gram/52.6 ml (38 mg/ml), 200 mg, 200 mg/5.26 ml (38 mg/ml) vial</i> ^{MO} | 5 | B vs D |
| GILOTRIF 20 MG, 30 MG, 40 MG TABLET ^{SP} | 5 | PA,QL (30 per 30 days) |
| GLEEVEC 100 MG TABLET ^{SP} | 5 | PA,QL (180 per 30 days) |
| GLEEVEC 400 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |
| GLEOSTINE 10 MG, 100 MG, 40 MG CAPSULE ^{MO} | 4 | |
| HALAVEN 1 MG/2 ML (0.5 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| HERCEPTIN 440 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| HEXALEN 50 MG CAPSULE ^{SP} | 5 | |
| HYCANTIN 4 MG INTRAVENOUS SOLUTION ^{MO} | 5 | B vs D |
| <i>hydroxyurea 500 mg capsule</i> ^{MO} | 2 | |
| IBRANCE 100 MG, 125 MG, 75 MG CAPSULE ^{SP} | 5 | PA,QL (21 per 28 days) |
| ICLUSIG 15 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ICLUSIG 45 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| IDAMYCIN PFS 1 MG/ML INTRAVENOUS SOLUTION MO | 5 | B vs D |
| <i>idarubicin pfs 10 mg/10 ml vl</i> MO | 5 | B vs D |
| <i>ifosfamide 1 gm vial; ifosfamide 1 gm/20 ml vial; ifosfamide 3 gm vial; ifosfamide 3 gm/ 60 ml vial</i> MO | 3 | B vs D |
| IMBRUVICA 140 MG CAPSULE SP | 5 | PA,QL (120 per 30 days) |
| INLYTA 1 MG TABLET SP | 5 | PA,QL (180 per 30 days) |
| INLYTA 5 MG TABLET SP | 5 | PA,QL (60 per 30 days) |
| IRESSA 250 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| <i>irinotecan hcl 100 mg/5 ml, 40 mg/2 ml, 500 mg/25 ml vial; irinotecan hcl 100 mg/5 ml, 40 mg/2 ml, 500 mg/25 ml vl</i> MO | 4 | B vs D |
| ISTODAX 10 MG/2 ML INTRAVENOUS SOLUTION MO | 5 | PA |
| IXEMPRA 15 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (45 per 21 days) |
| IXEMPRA 45 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET SP | 5 | PA,QL (60 per 30 days) |
| JEVTANA 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION MO | 5 | PA |
| KADCYLA 100 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| KADCYLA 160 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (24 per 21 days) |
| KEYTRUDA 100 MG/4 ML (25 MG/ML), 50 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| LENVIMA 10 MG/DAY (10 MG Ý1"/DAY) CAPSULE SP | 5 | PA,QL (30 per 30 days) |
| LENVIMA 14 MG (10 MG Ý1"-4 MG Ý1")/DAY, 20 MG/DAY (10 MG Ý2"/DAY) CAPSULE; LENVIMA 14 MG (10 MG Ý1"-4 MG Ý1")/DAY CAPSULE SP | 5 | PA,QL (60 per 30 days) |
| LENVIMA 24 MG (10 MG Ý2"-4 MG Ý1")/DAY CAPSULE SP | 5 | PA,QL (90 per 30 days) |
| <i>letrozole 2.5 mg tablet</i> MO | 2 | QL (30 per 30 days) |
| LEUKERAN 2 MG TABLET MO | 3 | |
| <i>leuprolide 2wk 1 mg/0.2 ml kit</i> MO | 3 | PA,QL (2.8 per 14 days) |
| <i>lipodox 2 mg/ml intravenous suspension</i> MO | 5 | B vs D |
| <i>lipodox 50 2 mg/ml intravenous suspension</i> MO | 5 | B vs D |
| <i>lomustine 10 mg, 100 mg, 40 mg capsule</i> MO | 4 | |
| LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 30 days) |
| LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT MO | 5 | PA,QL (1 per 30 days) |
| LUPRON DEPOT (3 MONTH) 11.25 MG, 22.5 MG INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 90 days) |
| LUPRON DEPOT (4 MONTH) 30 MG INTRAMUSCULAR SYRINGE KIT MO | 4 | PA,QL (1 per 112 days) |
| LUPRON DEPOT (6 MONTH) 45 MG INTRAMUSCULAR SYRINGE KIT MO | 5 | PA,QL (1 per 168 days) |
| LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) INTRAMUSCULAR KIT MO | 5 | PA,QL (1 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| LUPRON DEPOT-PED (3 MONTH) 11.25 MG, 30 MG INTRAMUSCULAR SYRINGE KIT MO | 5 | PA,QL (1 per 90 days) |
| LYNPARZA 50 MG CAPSULE SP | 5 | PA,QL (448 per 28 days) |
| LYSODREN 500 MG TABLET SP | 5 | |
| MATULANE 50 MG CAPSULE SP | 5 | |
| megestrol 20 mg, 40 mg tablet; megestrol acet 40 mg/ml susp; megestrol acet 400 mg/10 ml MO | 3 | PA |
| MEKINIST 0.5 MG TABLET SP | 5 | PA,QL (120 per 30 days) |
| MEKINIST 2 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| melphalan hcl 50 mg vial MO | 1 | B vs D |
| mercaptopurine 50 mg tablet MO | 3 | |
| methotrexate 2.5 mg tablet MO | 2 | B vs D |
| methotrexate 50 mg/2 ml vial MO | 2 | |
| methotrexate 1 gm vial; methotrexate 50 mg/2 ml vial MO | 2 | |
| mitomycin 20 mg, 40 mg, 5 mg vial MO | 4 | B vs D |
| mitoxantrone 20 mg/10 ml vial MO | 3 | |
| MUSTARGEN 10 MG SOLUTION FOR INJECTION MO | 4 | B vs D |
| NEXAVAR 200 MG TABLET SP | 5 | PA,QL (120 per 30 days) |
| NILANDRON 150 MG TABLET SP | 5 | QL (60 per 30 days) |
| NIPENT 10 MG INTRAVENOUS SOLUTION MO | 5 | B vs D |
| ONCASPAR 750 UNIT/ML INJECTION SOLUTION MO | 5 | B vs D |
| OPDIVO 100 MG/10 ML, 40 MG/4 ML INTRAVENOUS SOLUTION MO | 5 | PA,QL (80 per 28 days) |
| oxaliplatin 100 mg, 100 mg/20 ml, 50 mg, 50 mg/10 ml (5 mg/ml) vial; oxaliplatin 50 mg/10 ml vial MO | 5 | B vs D |
| paclitaxel 100 mg/16.7 ml vial MO | 3 | B vs D |
| pentostatin 10 mg vial MO | 1 | B vs D |
| PERJETA 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION MO | 5 | PA |
| POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE SP | 5 | PA,QL (21 per 28 days) |
| PROLEUKIN 22 MILLION UNIT INTRAVENOUS SOLUTION MO | 5 | |
| PURINETHOL 50 MG TABLET MO | 4 | |
| PURIXAN 20 MG/ML ORAL SUSPENSION SP | 5 | QL (300 per 30 days) |
| REVLIMID 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG CAPSULE SP | 5 | PA,QL (28 per 28 days) |
| RHEUMATREX 2.5 MG TABLETS IN A DOSE PACK MO | 4 | B vs D |
| RITUXAN 10 MG/ML CONCENTRATE, INTRAVENOUS MO | 5 | PA |
| SOLTAMOX 10 MG/5 ML ORAL SOLUTION MO | 4 | |
| SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET SP | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| SPRYCEL 140 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| SPRYCEL 20 MG TABLET SP | 5 | PA,QL (90 per 30 days) |
| STIVARGA 40 MG TABLET SP | 5 | PA,QL (84 per 28 days) |
| SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE SP | 5 | PA,QL (28 per 28 days) |
| SYLVANT 100 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (65 per 30 days) |
| SYLVANT 400 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (80 per 30 days) |
| SYNRIBO 3.5 MG SUBCUTANEOUS SOLUTION MO | 5 | PA,QL (28 per 28 days) |
| TABLOID 40 MG TABLET MO | 4 | |
| TAFINLAR 50 MG CAPSULE SP | 5 | PA,QL (180 per 30 days) |
| TAFINLAR 75 MG CAPSULE SP | 5 | PA,QL (120 per 30 days) |
| <i>tamoxifen 10 mg, 20 mg tablet</i> MO | 2 | |
| TARCEVA 100 MG, 150 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| TARCEVA 25 MG TABLET SP | 5 | PA,QL (90 per 30 days) |
| TARGRETIN 75 MG CAPSULE SP | 5 | PA,QL (300 per 30 days) |
| TASIGNA 150 MG, 200 MG CAPSULE SP | 5 | PA,QL (120 per 30 days) |
| TAXOTERE 20 MG/ML (1 ML), 80 MG/4 ML (20 MG/ML) INTRAVENOUS SOLUTION MO | 5 | B vs D |
| TEMODAR 100 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (27 per 30 days) |
| <i>teniposide 50 mg/5 ml ampule</i> MO | 4 | B vs D |
| <i>thiotepa 15 mg vial</i> MO | 1 | B vs D |
| <i>toposar 20 mg/ml intravenous solution</i> MO | 4 | B vs D |
| <i>topotecan hcl 4 mg, 4 mg/4 ml (1 mg/ml) vial; topotecan hcl 4 mg/4 ml vial</i> MO | 5 | B vs D |
| TORISEL 30 MG/3 ML (10 MG/ML) (FIRST DILUTION) INTRAVENOUS SOLUTION MO | 5 | PA,QL (8 per 28 days) |
| TREANDA 100 MG INTRAVENOUS POWDER FOR SOLUTION MO | 5 | PA,QL (120 per 21 days) |
| TREANDA 180 MG/2 ML INTRAVENOUS SOLUTION MO | 5 | PA,QL (6 per 21 days) |
| TREANDA 25 MG INTRAVENOUS POWDER FOR SOLUTION MO | 5 | PA,QL (60 per 21 days) |
| TREANDA 45 MG/0.5 ML INTRAVENOUS SOLUTION MO | 5 | PA |
| TRELSTAR 11.25 MG/2 ML, 22.5 MG/2 ML INTRAMUSCULAR SYRINGE; TRELSTAR 22.5 MG INTRAMUSCULAR SUSPENSION MO | 4 | PA |
| TRELSTAR 3.75 MG/2 ML INTRAMUSCULAR SYRINGE MO | 5 | PA |
| TRELSTAR DEPOT 3.75 MG INTRAMUSCULAR SUSPENSION MO | 4 | PA,QL (1 per 28 days) |
| TRELSTAR LA 11.25 MG INTRAMUSCULAR SUSPENSION MO | 4 | PA,QL (1 per 84 days) |
| <i>tretinoin 10 mg capsule</i> SP | 5 | |
| TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET MO | 4 | B vs D |
| TRISENOX 10 MG/10 ML INTRAVENOUS SOLUTION MO | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| TYKERB 250 MG TABLET ^{SP} | 5 | PA,QL (150 per 30 days) |
| UNITUXIN 3.5 MG/ML INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (40 per 30 days) |
| VALSTAR 40 MG/ML INTRAVESICAL SOLUTION ^{MO} | 5 | PA,QL (80 per 28 days) |
| VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| VELCADE 3.5 MG SOLUTION FOR INJECTION ^{MO} | 5 | PA,QL (14 per 21 days) |
| vinblastine 1 mg/ml, 10 mg vial; vinblastine sulf 1 mg/ml, 10 mg vial ^{MO} | 3 | B vs D |
| vincasar pfs 1 mg/ml, 2 mg/2 ml intravenous solution ^{MO} | 1 | B vs D |
| vincristine 1 mg/ml, 2 mg/2 ml vial ^{MO} | 3 | B vs D |
| vinorelbine 10 mg/ml, 50 mg/5 ml vial ^{MO} | 4 | B vs D |
| VOTRIENT 200 MG TABLET ^{SP} | 5 | PA,QL (120 per 30 days) |
| XALKORI 200 MG, 250 MG CAPSULE ^{SP} | 5 | PA,QL (60 per 30 days) |
| XTANDI 40 MG CAPSULE ^{SP} | 5 | PA,QL (120 per 30 days) |
| YERVOY 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (40 per 21 days) |
| YERVOY 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (70 per 21 days) |
| ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (40 per 28 days) |
| ZANOSAR 1 GRAM INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| ZELBORAF 240 MG TABLET ^{SP} | 5 | PA,QL (240 per 30 days) |
| ZOLADEX 10.8 MG SUBCUTANEOUS IMPLANT ^{MO} | 4 | PA,QL (1 per 84 days) |
| ZOLADEX 3.6 MG SUBCUTANEOUS IMPLANT ^{MO} | 4 | PA,QL (1 per 28 days) |
| ZOLINZA 100 MG CAPSULE ^{SP} | 5 | PA,QL (120 per 30 days) |
| ZYDELIG 100 MG, 150 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |
| ZYKADIA 150 MG CAPSULE ^{SP} | 5 | PA,QL (150 per 30 days) |
| ZYTIGA 250 MG TABLET ^{SP} | 5 | PA,QL (120 per 30 days) |
| AUTONOMIC DRUGS | | |
| albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml solution; albuterol sul 0.63 mg/3 ml, 1.25 mg/3 m ^{MO} | | |
| albuterol sulf 2 mg/5 ml syrup ^{MO} | 2 | |
| albuterol sulfate 2 mg, 4 mg tab; albuterol sulfate er 4 mg, 8 mg tab ^{MO} | 4 | |
| alfuzosin hcl er 10 mg tablet ^{MO} | 2 | QL (30 per 30 days) |
| ANORO ELLIPTA 62.5 MCG-25 MCG/ACTUATION POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |
| ARCAPTA NEOHALER 75 MCG CAPSULE WITH INHALATION DEVICE ^{MO} | 4 | QL (30 per 30 days) |
| atropine 0.05 mg/ml, 0.1 mg/ml syringe; atropine 0.4 mg/ml, 1 mg/ml vial; atropine 1% eye ointment ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| ATROVENT HFA 17 MCG/ACTUATION AEROSOL INHALER MO | 4 | QL (30 per 30 days) |
| <i>baclofen 10 mg, 20 mg tablet</i> MO | 2 | |
| <i>bethanechol 10 mg, 25 mg, 5 mg tablet</i> MO | 3 | |
| <i>bethanechol 50 mg tablet</i> MO | 4 | |
| CAFERGOT 1 MG-100 MG TABLET MO | 4 | |
| CANTIL 25 MG TABLET MO | 4 | |
| CHANTIX 0.5 MG, 1 MG TABLET MO | 4 | QL (56 per 28 days) |
| CHANTIX CONTINUING MONTH BOX 1 MG TABLET MO | 4 | QL (56 per 28 days) |
| CHANTIX STARTING MONTH BOX 0.5 MG (11)-1 MG (42) TABLETS IN DOSE PACK MO | 4 | QL (56 per 28 days) |
| COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION MO | 4 | QL (4 per 20 days) |
| <i>dantrolene sodium 100 mg, 25 mg, 50 mg cap</i> MO | 4 | |
| <i>dicyclomine 10 mg capsule; dicyclomine 20 mg tablet</i> MO | 1 | |
| <i>dicyclomine 10 mg/5 ml soln</i> MO | 2 | |
| <i>dihydroergotamine 1 mg/ml am</i> MO | 4 | |
| <i>dobutamine 12.5 mg/ml vial</i> MO | 2 | |
| <i>dobutamine 1 gm-d5w 250 ml; dobutamine 250 mg-d5w 250 ml; dobutamine 500 mg-d5w 250 ml</i> MO | 2 | |
| <i>donepezil hcl 10 mg tablet</i> MO | 1 | QL (60 per 30 days) |
| <i>donepezil hcl 10 mg, 5 mg, 5 mg tablet; donepezil hcl odt 10 mg, 5 mg, 5 mg tablet</i> MO | 1 | QL (30 per 30 days) |
| <i>dopamine 160 mg/ml vial; dopamine 40 mg/ml vial; dopamine 80 mg/ml vial</i> MO | 1 | |
| <i>dopamine 200 mg-d5w 250 ml; dopamine 400 mg-d5w 250 ml; dopamine 400 mg-d5w 500 ml; dopamine 800 mg-d5w 250 ml; dopamine 800 mg-d5w 500 ml</i> MO | 1 | |
| DUONEB 0.5 MG-3 MG/3 ML SOLN MO | 4 | B vs D |
| <i>epinephrine 0.1 mg/ml syringe; epinephrine 1 mg/ml ampul; epinephrine 1 mg/ml vial</i> MO | 1 | |
| EPIPEN 2-PAK INJECTION,AUTO-INJECTOR MO | 3 | |
| EPIPEN JR 2-PAK INJECTION,AUTO-INJECTOR MO | 3 | |
| ERGOMAR 2 MG SUBLINGUAL TABLET MO | 2 | |
| EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HR, 9.5 MG/24 HR TRANSDERMAL MO | 4 | QL (30 per 30 days) |
| FORADIL AEROLIZER 12 MCG CAPSULE WITH INHALATION DEVICE MO | 3 | QL (60 per 30 days) |
| <i>galantamine 4 mg/ml oral soln</i> MO | 4 | QL (200 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| galantamine er 16 mg, 24 mg, 8 mg capsule ^{MO} | 4 | QL (30 per 30 days) |
| galantamine hbr 12 mg, 4 mg, 8 mg tablet ^{MO} | 4 | QL (60 per 30 days) |
| glycopyrrolate 0.2 mg/ml vial ^{MO} | 4 | |
| glycopyrrolate 1 mg, 2 mg tablet ^{MO} | 3 | |
| guanidine hcl 125 mg tablet ^{MO} | 2 | |
| ipratropium br 0.02% soln ^{MO} | 2 | B vs D |
| iprat-albut 0.5-3(2.5) mg/3 ml ^{MO} | 2 | B vs D |
| ISUPREL 0.2 MG/ML INJECTION SOLUTION ^{MO} | 4 | |
| LIORESAL 2,000 MCG/ML INTRATHECAL SOLUTION ^{MO} | 5 | B vs D |
| LIORESAL 50 MCG/ML, 500 MCG/ML INTRATHECAL SOLUTION ^{MO} | 4 | B vs D |
| MESTINON TIMESPAN 180 MG TABLET,EXTENDED RELEASE ^{MO} | 5 | |
| metaproterenol 10 mg, 20 mg tablet; metaproterenol 10 mg/5 ml syr ^{MO} | 4 | |
| methocarbamol 500 mg, 750 mg tablet ^{MO} | 4 | PA |
| methscopolamine brom 2.5 mg, 5 mg tab; methscopolamine brom 2.5 mg, 5 mg tb ^{MO} | 4 | |
| midodrine hcl 10 mg, 2.5 mg, 5 mg tablet ^{MO} | 3 | |
| neostigmine 1:1,000 vial; neostigmine 1:2,000 vial ^{MO} | 2 | |
| NICOTROL NS 10 MG/ML NASAL SPRAY ^{MO} | 4 | |
| norepinephrine 1 mg/ml vial ^{MO} | 1 | |
| NORTHERA 100 MG CAPSULE ^{SP} | 5 | PA,QL (42 per 365 days) |
| NORTHERA 200 MG, 300 MG CAPSULE ^{SP} | 5 | PA,QL (90 per 365 days) |
| orphenadrine er 100 mg tablet ^{MO} | 3 | PA |
| PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION ^{MO} | 4 | PA,QL (120 per 30 days) |
| phentolamine 5 mg vial ^{MO} | 3 | |
| phenylephrine 10 mg/ml vial ^{MO} | 1 | |
| pilocarpine hcl 5 mg, 7.5 mg tablet ^{MO} | 4 | |
| propantheline 15 mg tablet ^{MO} | 2 | |
| PROSTIGMIN 15 MG TABLET ^{MO} | 4 | |
| pyridostigmine br 60 mg tablet ^{MO} | 3 | |
| pyridostigmine er 180 mg tab ^{MO} | 4 | |
| RAPAFLO 4 MG, 8 MG CAPSULE ^{MO} | 3 | QL (30 per 30 days) |
| REGONOL 5 MG/ML INJECTION SOLUTION ^{MO} | 4 | |
| revonto 20 mg intravenous solution ^{MO} | 3 | |
| rivastigmine 1.5 mg, 3 mg capsule ^{MO} | 4 | QL (90 per 30 days) |
| rivastigmine 4.5 mg, 6 mg capsule ^{MO} | 4 | QL (60 per 30 days) |
| SEREVENT DISKUS 50 MCG/DOSE POWDER FOR INHALATION ^{MO} | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| SPIRIVA RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION ^{MO} | 3 | QL (4 per 28 days) |
| SPIRIVA WITH HANDIHALER 18 MCG & INHALATION CAPSULES ^{MO} | 3 | QL (30 per 30 days) |
| tamsulosin hcl 0.4 mg capsule ^{MO} | 2 | QL (60 per 30 days) |
| terbutaline sulf 1 mg/ml vial ^{MO} | 5 | |
| terbutaline sulfate 2.5 mg, 5 mg tab ^{MO} | 4 | |
| tizanidine hcl 2 mg, 4 mg tablet ^{MO} | 2 | |
| TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED ^{MO} | 4 | QL (1 per 30 days) |
| VENTOLIN HFA 90 MCG/ACTUATION AEROSOL INHALER ^{MO} | 3 | QL (36 per 30 days) |
| BLOOD FORMATION, COAGULATION & THROMBOSIS | | |
| aminocaproic acid 1,000 mg, 500 mg tab; aminocaproic acid 25% solution ^{SP} | 4 | |
| aminocaproic acid 5 g/20 ml vl ^{MO} | 4 | |
| anagrelide hcl 0.5 mg, 1 mg capsule ^{MO} | 3 | |
| argatroban 250 mg/2.5 ml vial ^{MO} | 1 | |
| BRILINTA 60 MG, 90 MG TABLET ^{MO} | 3 | QL (60 per 30 days) |
| cilostazol 100 mg, 50 mg tablet ^{MO} | 2 | |
| clopidogrel 300 mg tablet ^{MO} | 2 | QL (1 per 30 days) |
| clopidogrel 75 mg tablet ^{MO} | 1 | QL (30 per 30 days) |
| COUMADIN 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG TABLET; COUMADIN 5 MG VIAL ^{MO} | 4 | |
| CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) INTRAVENOUS SOLUTION ^{MO} | 3 | PA |
| EFFIENT 10 MG, 5 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| ELIQUIS 2.5 MG TABLET ^{MO} | 3 | QL (60 per 30 days) |
| ELIQUIS 5 MG TABLET ^{MO} | 3 | QL (74 per 30 days) |
| enoxaparin 100 mg/ml, 150 mg/ml syringe ^{HI,MO} | 4 | QL (28 per 28 days) |
| enoxaparin 120 mg/0.8 ml, 80 mg/0.8 ml syr ^{HI,MO} | 4 | QL (22.4 per 28 days) |
| enoxaparin 30 mg/0.3 ml, 60 mg/0.6 ml syr ^{HI,MO} | 4 | QL (16.8 per 28 days) |
| enoxaparin 300 mg/3 ml vial ^{MO} | 4 | QL (84 per 28 days) |
| enoxaparin 40 mg/0.4 ml syr ^{HI,MO} | 4 | QL (11.2 per 28 days) |
| EPOGEN 10,000 UNIT/ML, 20,000 UNIT/ML INJECTION SOLUTION ^{SP} | 5 | PA,QL (14 per 30 days) |
| EPOGEN 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION ^{SP} | 4 | PA,QL (14 per 30 days) |
| EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION ^{SP} | 4 | PA,QL (28 per 30 days) |
| fondaparinux 10 mg/0.8 ml syr ^{HI,MO} | 5 | QL (24 per 30 days) |
| fondaparinux 2.5 mg/0.5 ml syr ^{HI,MO} | 4 | QL (15 per 30 days) |
| fondaparinux 5 mg/0.4 ml syr ^{HI,MO} | 5 | QL (12 per 30 days) |
| fondaparinux 7.5 mg/0.6 ml syr ^{HI,MO} | 5 | QL (18 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| FRAGMIN 10,000 ANTI-XA UNIT/ML SUBCUTANEOUS SYRINGE MO | 5 | QL (30 per 30 days) |
| FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SUBCUTANEOUS SYRINGE MO | 5 | QL (15 per 30 days) |
| FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SUBCUTANEOUS SYRINGE MO | 5 | QL (18 per 30 days) |
| FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SUBCUTANEOUS SYRINGE MO | 5 | QL (21.6 per 30 days) |
| FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SUBCUTANEOUS SYRINGE MO | 4 | QL (6 per 30 days) |
| FRAGMIN 25,000 ANTI-XA UNIT/ML SUBCUTANEOUS SOLUTION MO | 5 | QL (22.8 per 30 days) |
| FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SUBCUTANEOUS SYRINGE MO | 5 | QL (9 per 30 days) |
| GRANIX 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (7 per 28 days) |
| GRANIX 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (11.2 per 28 days) |
| heparin 30,000 unit/30 ml vial; heparin sod 5,000 unit/ml syr MO | 3 | |
| heparin 40,000 units/4 ml vial; heparin sod 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vial; heparin sod 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vl HI,MO | 3 | |
| heparin-d5w 12,500 unit/250 ml, 20,000 unit/500 ml (40 unit/ml), 25,000 unit/250 ml(100 unit/ml), 25,000 unit/500 ml (50 unit/ml); heparin-d5w 20,000 unit/500 ml; heparin-d5w 25,000 unit/250 ml; heparin-d5w 25,000 MO | | |
| heparin-ns 1,000 units/500 ml MO | 1 | |
| heparin-ns 2,000 unit/1,000 ml HI,MO | 1 | |
| heparin-1/2ns 12,500 units/250 MO | 1 | |
| heparin-1/2ns 25,000 units/250; heparin-1/2ns 25,000 units/500 HI,MO | 1 | |
| heparin 2,000 unit/2 ml vial; heparin sod 5,000 unit/ 0.5 ml; heparin sod 5,000 unit/0.5 ml MO | 3 | |
| jantoven 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet MO | 1 | |
| LEUKINE 250 MCG SOLUTION FOR INJECTION SP | 5 | PA |
| MOZOBIL 24 MG/1.2 ML (20 MG/ML) SUBCUTANEOUS SOLUTION MO | 5 | PA,QL (9.6 per 30 days) |
| NEULASTA WITH WEARABLE SUBCUTANEOUS INJECTOR; NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (1.2 per 28 days) |
| NEUMEGA 5 MG VIAL SP | 5 | QL (42 per 30 days) |
| NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE SP | 5 | PA,QL (7 per 30 days) |
| NEUPOGEN 300 MCG/ML INJECTION SOLUTION SP | 5 | PA,QL (14 per 30 days) |
| NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE SP | 5 | PA,QL (11.2 per 30 days) |
| NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION SP | 5 | PA,QL (22.4 per 30 days) |
| pentoxifylline er 400 mg tab MO | 2 | |
| PRADAXA 150 MG, 75 MG CAPSULE MO | 4 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION ^{SP} | 4 | PA,QL (14 per 30 days) |
| PROCRIT 20,000 UNIT/2 ML INJECTION SOLUTION ^{SP} | 4 | PA,QL (28 per 30 days) |
| PROCRIT 20,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION ^{SP} | 5 | PA,QL (14 per 30 days) |
| PROMACTA 12.5 MG, 75 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |
| PROMACTA 25 MG TABLET ^{SP} | 5 | PA,QL (30 per 30 days) |
| PROMACTA 50 MG TABLET ^{SP} | 5 | PA,QL (90 per 30 days) |
| protamine 250 mg/25 ml vial ^{MO} | 1 | |
| REOPRO 10 MG/5 ML INTRAVENOUS SOLUTION ^{MO} | 5 | |
| ticlopidine 250 mg tablet ^{MO} | 4 | PA |
| TNKASE 50 MG INTRAVENOUS KIT ^{MO} | 5 | |
| tranexamic acid 1,000 mg/10 ml ^{MO} | 3 | PA |
| tranexamic acid 650 mg tablet ^{MO} | 4 | QL (30 per 5 days) |
| warfarin sodium 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet ^{MO} | 1 | |
| XARELTO 10 MG TABLET ^{MO} | 3 | QL (35 per 60 days) |
| XARELTO 15 MG (42)-20 MG (9) TABLETS IN A DOSE PACK ^{MO} | 3 | QL (51 per 30 days) |
| XARELTO 15 MG TABLET ^{MO} | 3 | QL (60 per 30 days) |
| XARELTO 20 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| ZARXIO 300 MCG/0.5 ML INJECTION SYRINGE ^{SP} | 5 | PA,QL (7 per 30 days) |
| ZARXIO 480 MCG/0.8 ML INJECTION SYRINGE ^{SP} | 5 | PA,QL (11.2 per 30 days) |
| ZONTIVITY 2.08 MG TABLET ^{MO} | 4 | PA,QL (30 per 30 days) |
| CARDIOVASCULAR DRUGS | | |
| acebutolol 200 mg, 400 mg capsule ^{MO} | 2 | |
| ADALAT CC 30 MG, 60 MG, 90 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | QL (60 per 30 days) |
| ADCIRCA 20 MG TABLET ^{SP} | 5 | PA,QL (60 per 30 days) |
| adenosine 12 mg/4 ml syringe; adenosine 6 mg/2 ml vial ^{MO} | 1 | |
| afeditab cr 30 mg, 60 mg tablet,extended release ^{MO} | 3 | QL (60 per 30 days) |
| AGGRENOX 25 MG-200 MG CAPSULE, EXTENDED RELEASE ^{MO} | 4 | PA |
| amiodarone 150 mg/3 ml syringe; amiodarone 150 mg/3 ml vial; amiodarone hcl 200 mg tablet ^{MO} | 2 | |
| amiodarone hcl 100 mg, 400 mg tablet ^{MO} | 4 | |
| amlodipine besylate 10 mg, 2.5 mg, 5 mg tab ^{MO} | 1 | |
| amlodipine-atorvast 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg ^{MO} | 3 | QL (30 per 30 days) |
| amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg; amlodipine-benazepril 2.5-10 ^{MO} | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| amlodipine-benazepril 10-40 mg, 5-40 mg ^{MO} | 3 | QL (30 per 30 days) |
| amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg ^{MO} | 4 | QL (30 per 30 days) |
| amlod-valsarta-hctz 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg; amlod-valsarta-hctz 10-160-12.5mg ^{MO} | 3 | QL (30 per 30 days) |
| AMTURNIDE 150-5-12.5 MG, 300-10-12.5 MG, 300-10-25 MG, 300-5-12.5 MG, 300-5-25 MG TAB ^{MO} | 3 | QL (30 per 30 days) |
| aspirin-dipyridam er 25-200 mg ^{MO} | 4 | |
| atenolol 100 mg, 25 mg, 50 mg tablet ^{MO} | 1 | |
| atenolol-chlorthalidone 100-25; atenolol-chlorthalidone 50-25 ^{MO} | 2 | |
| atorvastatin 10 mg, 20 mg, 40 mg, 80 mg tablet ^{MO} | 2 | QL (30 per 30 days) |
| AZOR 10 MG-20 MG TABLET; AZOR 10 MG-40 MG TABLET; AZOR 5 MG-20 MG TABLET; AZOR 5 MG-40 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| benazepril hcl 10 mg, 20 mg, 40 mg, 5 mg tablet ^{MO} | 1 | |
| benazepril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg tab ^{MO} | 2 | |
| BENICAR 20 MG, 40 MG, 5 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| BENICAR HCT 20 MG-12.5 MG TABLET; BENICAR HCT 40 MG-12.5 MG TABLET; BENICAR HCT 40 MG-25 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| BIDIL 20 MG-37.5 MG TABLET ^{MO} | 3 | QL (180 per 30 days) |
| bisoprolol fumarate 10 mg, 5 mg tab ^{MO} | 2 | |
| bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tab; bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tb ^{MO} | 2 | |
| BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) (20 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV; BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV ^{MO} | 4 | |
| BYSTOLIC 10 MG TABLET ^{MO} | 3 | QL (120 per 30 days) |
| BYSTOLIC 2.5 MG, 5 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| BYSTOLIC 20 MG TABLET ^{MO} | 3 | QL (60 per 30 days) |
| candesartan cilexetil 16 mg, 4 mg, 8 mg tab; candesartan cilexetil 16 mg, 4 mg, 8 mg tb ^{MO} | 3 | QL (60 per 30 days) |
| candesartan cilexetil 32 mg tb ^{MO} | 3 | QL (30 per 30 days) |
| candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tab; candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tb ^{MO} | 3 | QL (30 per 30 days) |
| captopril 100 mg, 12.5 mg, 25 mg, 50 mg tablet ^{MO} | 1 | |
| captopril-hctz 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg tablet ^{MO} | 3 | |
| CARDENE SR 30 MG, 60 MG CAPSULE; CARDENE SR 30 MG, 60 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | QL (60 per 30 days) |
| cartia xt 120 mg, 180 mg, 240 mg capsule,extended release ^{MO} | 2 | QL (60 per 30 days) |
| cartia xt 300 mg capsule,extended release ^{MO} | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg tablet ^{MO} | 1 | |
| cholestyramine packet; cholestyramine powder ^{MO} | 3 | |
| cholestyramine light 4 gram, 4 gram oral powder; cholestyramine light 4 gram, 4 gram powder for susp in a packet ^{MO} | 3 | |
| clonidine 0.1 mg/day patch; clonidine 0.2 mg/day patch; clonidine 0.3 mg/day patch ^{MO} | 4 | QL (4 per 28 days) |
| clonidine hcl 0.1 mg, 0.2 mg, 0.3 mg tablet ^{MO} | 2 | |
| clonidine hcl er 0.1 mg tablet ^{MO} | 4 | QL (120 per 30 days) |
| clorpres 0.1 mg-15 mg tablet; clorpres 0.2 mg-15 mg tablet; clorpres 0.3 mg-15 mg tablet ^{MO} | 4 | |
| colestipol hcl granules; colestipol hcl granules packet; colestipol micronized 1 gm tab ^{MO} | 3 | |
| COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE, EXTENDED RELEASE ^{MO} | 4 | QL (30 per 30 days) |
| CORLOPAM 10 MG/ML INTRAVENOUS SOLUTION ^{MO} | 4 | |
| CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| digitek 125 mcg tablet ^{MO} | 2 | QL (30 per 30 days) |
| digitek 250 mcg tablet ^{MO} | 2 | PA |
| digox 125 mcg tablet ^{MO} | 2 | QL (30 per 30 days) |
| digox 250 mcg tablet ^{MO} | 2 | PA |
| digoxin 125 mcg tablet ^{MO} | 2 | QL (30 per 30 days) |
| digoxin 250 mcg tablet; digoxin 50 mcg/ml solution ^{MO} | 2 | PA |
| digoxin 500 mcg/2 ml ampule ^{MO} | 1 | PA |
| DILATRATE-SR 40 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | |
| dilt-cd 120 mg, 180 mg, 240 mg capsule ^{MO} | 2 | QL (60 per 30 days) |
| dilt-cd er 300 mg capsule ^{MO} | 2 | QL (30 per 30 days) |
| dilt-xr 120 mg, 180 mg, 240 mg capsule, extended release ^{MO} | 2 | QL (60 per 30 days) |
| diltiazem 120 mg, 30 mg, 60 mg, 90 mg tablet; diltiazem 12hr er 120 mg, 60 mg, 90 mg cap; diltiazem 50 mg/10 ml vial ^{MO} | 2 | |
| diltiazem 24hr cd 120 mg, 180 mg, 240 mg cap; diltiazem 24hr er 120 mg, 180 mg, 240 mg cap; diltiazem er 120 mg, 180 mg, 240 mg, 240 mg capsule; diltiazem hcl er 120 mg, 180 mg, 240 mg, 240 mg cap ^{MO} | 2 | QL (60 per 30 days) |
| diltiazem 24hr er 300 mg cap; diltiazem hcl er 300 mg, 360 mg, 420 mg cap ^{MO} | 2 | QL (30 per 30 days) |
| diltiazem hcl 100 mg vial ^{MO} | 4 | |
| diltzac er 120 mg, 180 mg, 240 mg capsule ^{MO} | 2 | QL (60 per 30 days) |
| diltzac er 300 mg, 360 mg capsule ^{MO} | 2 | QL (30 per 30 days) |
| disopyramide 100 mg, 150 mg capsule ^{MO} | 2 | PA |
| doxazosin mesylate 1 mg, 2 mg, 4 mg, 8 mg tab ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| EDARBI 40 MG, 80 MG TABLET MO | 3 | QL (30 per 30 days) |
| EDARBYCLOR 40 MG-12.5 MG TABLET; EDARBYCLOR 40 MG-25 MG TABLET MO | 3 | QL (30 per 30 days) |
| enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tab; enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tablet MO | 1 | |
| enalapril-hctz 10-25 mg, 5-12.5 mg tab; enalapril-hctz 10-25 mg, 5-12.5 mg tablet MO | 1 | |
| enalaprilat 1.25 mg/ml vial MO | 2 | |
| eplerenone 25 mg, 50 mg tablet MO | 4 | |
| esmolol hcl 100 mg/10 ml vial MO | 1 | |
| felodipine er 10 mg, 2.5 mg, 5 mg tablet MO | 3 | QL (30 per 30 days) |
| fenofibrate 160 mg tablet MO | 2 | QL (30 per 30 days) |
| fenofibrate 54 mg tablet MO | 2 | QL (60 per 30 days) |
| fenofibrate 130 mg, 43 mg capsule MO | 4 | QL (30 per 30 days) |
| fenofibrate 134 mg, 200 mg capsule MO | 3 | QL (30 per 30 days) |
| fenofibrate 67 mg capsule MO | 3 | QL (60 per 30 days) |
| fenofibrate 145 mg tablet MO | 4 | QL (30 per 30 days) |
| fenofibrate 48 mg tablet MO | 4 | QL (60 per 30 days) |
| fenofibric acid dr 135 mg, 45 mg cap MO | 4 | QL (30 per 30 days) |
| flecainide acetate 100 mg, 150 mg, 50 mg tab MO | 3 | |
| fosinopril sodium 10 mg, 20 mg, 40 mg tab MO | 1 | |
| fosinopril-hctz 10-12.5 mg, 20-12.5 mg tab MO | 2 | |
| gemfibrozil 600 mg tablet MO | 2 | QL (60 per 30 days) |
| guanfacine 1 mg, 2 mg tablet MO | 2 | PA |
| hydralazine 10 mg, 100 mg, 25 mg, 50 mg tablet; hydralazine 20 mg/ml vial MO | 2 | |
| ibutilide fum 1 mg/10 ml vial MO | 1 | |
| irbesartan 150 mg, 300 mg, 75 mg tablet MO | 2 | QL (30 per 30 days) |
| irbesartan-hctz 150-12.5 mg, 300-12.5 mg tb MO | 2 | QL (30 per 30 days) |
| isosorbide dn 10 mg, 2.5 mg, 20 mg, 30 mg, 5 mg, 5 mg tab sl; isosorbide dn 10 mg, 2.5 mg, 20 mg, 30 mg, 5 mg, 5 mg tablet; isosorbide dn 10 mg, 2.5 mg, 20 mg, 30 mg, 5 mg, 5 mg tablet sl MO | 2 | |
| isosorbide dn er 40 mg tablet MO | 3 | |
| isosorbide mn 10 mg, 20 mg tablet; isosorbide mn er 120 mg, 30 mg, 60 mg tab; isosorbide mn er 120 mg, 30 mg, 60 mg tablet MO | 2 | |
| isradipine 2.5 mg, 5 mg capsule MO | 4 | |
| KYNAMRO 200 MG/ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (4 per 28 days) |
| labetalol hcl 100 mg, 200 mg, 300 mg tablet; labetalol hcl 100 mg/20 ml vl; labetalol hcl 20 mg/4 ml crpj MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| LANOXIN 125 MCG, 62.5 MCG TABLET MO | 4 | QL (30 per 30 days) |
| LANOXIN 187.5 MCG TABLET MO | 4 | PA,QL (30 per 30 days) |
| LANOXIN 250 MCG TABLET; LANOXIN 250 MCG/ML INJECTION SOLUTION MO | 4 | PA |
| LANOXIN PEDIATRIC 100 MCG/ML INJECTION SOLUTION MO | 4 | PA |
| LESCOL XL 80 MG TABLET,EXTENDED RELEASE MO | 4 | ST,QL (30 per 30 days) |
| LEVATOL 20 MG TABLET MO | 4 | |
| <i>lidocaine hcl 1% ampul; lidocaine hcl 1% syringe; lidocaine hcl 1.5% ampul; lidocaine hcl 2% luer-jet; lidocaine hcl 2% vial; lidocaine hcl 4% ampul</i> MO | 2 | |
| <i>lidocaine 0.4% in d5w soln; lidocaine 0.8% in d5w soln</i> MO | 1 | |
| LIPTRUZET 10 MG-10 MG TABLET; LIPTRUZET 10 MG-20 MG TABLET; LIPTRUZET 10 MG-40 MG TABLET; LIPTRUZET 10 MG-80 MG TABLET MO | 4 | QL (30 per 30 days) |
| <i>lisinopril 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg tablet</i> MO | 1 | |
| <i>lisinopril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab</i> MO | 1 | |
| LIVALO 1 MG, 2 MG, 4 MG TABLET MO | 4 | ST,QL (30 per 30 days) |
| <i>losartan potassium 100 mg, 25 mg, 50 mg tab</i> MO | 1 | QL (60 per 30 days) |
| <i>losartan-hctz 100-12.5 mg, 100-25 mg, 50-12.5 mg tab</i> MO | 1 | QL (60 per 30 days) |
| <i>lovastatin 10 mg, 20 mg, 40 mg tablet</i> MO | 1 | QL (60 per 30 days) |
| <i>metoprolol succ er 100 mg, 200 mg, 25 mg, 50 mg tab</i> MO | 2 | QL (60 per 30 days) |
| <i>metoprolol-hctz 100-25 mg, 100-50 mg, 50-25 mg tab</i> MO | 3 | |
| <i>metoprolol 1 mg/ml carpject; metoprolol tart 5 mg/5 ml vial; metoprolol tartrate 100 mg, 25 mg, 50 mg tab</i> MO | 1 | |
| <i>mexiletine 150 mg, 200 mg, 250 mg capsule</i> MO | 4 | |
| <i>minoxidil 10 mg, 2.5 mg tablet</i> MO | 2 | |
| <i>moexipril hcl 15 mg, 7.5 mg tablet</i> MO | 2 | |
| <i>moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tab; moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tablet</i> MO | 2 | |
| MULTAQ 400 MG TABLET MO | 3 | QL (60 per 30 days) |
| <i>nadolol 20 mg, 40 mg, 80 mg tablet</i> MO | 3 | |
| <i>nadolol-bendroflu 40-5 mg, 80-5 mg tab</i> MO | 3 | |
| NATRECOR 1.5 MG INTRAVENOUS SOLUTION MO | 4 | |
| NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) INTRAVENOUS SOLUTION MO | 4 | |
| <i>niacin er 1,000 mg, 500 mg, 750 mg tablet</i> MO | 4 | |
| <i>niacor 500 mg tablet</i> MO | 2 | |
| <i>nicardipine 20 mg, 30 mg capsule</i> MO | 3 | |
| <i>nicardipine 25 mg/10 ml ampule</i> MO | 2 | |
| <i>nifedical xl 30 mg, 60 mg tablet,extended release</i> MO | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| nifedipine er 30 mg tablet; nifedipine er 60 mg, 90 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| nimodipine 30 mg capsule ^{MO} | 4 | |
| nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr patch ^{MO} | 2 | QL (30 per 30 days) |
| nitroglycerin 0.4 mg/hr patch ^{MO} | 2 | QL (60 per 30 days) |
| nitroglycerin 5 mg/ml vial ^{MO} | 2 | |
| nitroglycerin lingual 0.4 mg ^{MO} | 4 | |
| ntg 0.2 mg/ml in d5w; ntg 100 mg/250 ml in d5w; ntg 200 mg/500 ml in d5w; ntg 25 mg/250 ml in d5w; ntg 50 mg/500 ml in d5w ^{MO} | 2 | |
| NITROLINGUAL 400 MCG/SPRAY ^{MO} | 4 | |
| NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET ^{MO} | 3 | |
| omega-3 ethyl esters 1 gm cap ^{MO} | 4 | QL (120 per 30 days) |
| PACERONE 100 MG, 400 MG TABLET ^{MO} | 4 | |
| pacerone 200 mg tablet ^{MO} | 2 | |
| perindopril erbumine 2 mg, 4 mg, 8 mg tab ^{MO} | 2 | |
| pindolol 10 mg, 5 mg tablet ^{MO} | 3 | |
| pravastatin sodium 10 mg, 20 mg, 80 mg tab ^{MO} | 2 | QL (30 per 30 days) |
| pravastatin sodium 40 mg tab ^{MO} | 2 | QL (60 per 30 days) |
| prazosin 1 mg, 2 mg, 5 mg capsule ^{MO} | 2 | |
| prevalite 4 gram, 4 gram oral powder; prevalite 4 gram, 4 gram powder for susp in a packet ^{MO} | 3 | |
| procainamide 100 mg/ml, 500 mg/ml vial ^{MO} | 1 | |
| propafenone hcl 150 mg, 225 mg, 300 mg tab; propafenone hcl 150 mg, 225 mg, 300 mg tablet ^{MO} | 3 | |
| propafenone hcl er 225 mg, 325 mg, 425 mg cap ^{MO} | 4 | |
| propranolol 1 mg/ml, 20 mg/5 ml, 40 mg/5 ml soln; propranolol 1 mg/ml, 20 mg/5 ml, 40 mg/5 ml vial; propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg tablet ^{MO} | 2 | |
| propranolol er 120 mg, 160 mg, 60 mg, 80 mg capsule ^{MO} | 4 | |
| propranolol-hctz 40-25 mg, 80-25 mg tab ^{MO} | 3 | |
| quinapril 10 mg, 20 mg, 40 mg, 5 mg tablet ^{MO} | 1 | |
| quinapril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab ^{MO} | 2 | |
| quinidine gluc 80 mg/ml vial ^{MO} | 2 | |
| quinidine gluc er 324 mg tab ^{MO} | 4 | |
| quinidine sulf er 200 mg, 300 mg, 300 mg tab; quinidine sulfate 200 mg, 300 mg, 300 mg tab ^{MO} | 2 | |
| ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg capsule ^{MO} | 1 | |
| RANEXA 1,000 MG, 500 MG TABLET, EXTENDED RELEASE ^{MO} | 3 | ST, QL (120 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| reserpine 0.1 mg, 0.25 mg tablet ^{MO} | 2 | PA |
| REVATIO 10 MG/ML ORAL SUSPENSION ^{SP} | 5 | PA,QL (180 per 30 days) |
| sildenafil 20 mg tablet ^{MO} | 3 | PA,QL (90 per 30 days) |
| simvastatin 10 mg, 20 mg, 40 mg, 5 mg, 80 mg tablet ^{MO} | 1 | QL (30 per 30 days) |
| sorine 120 mg, 160 mg, 240 mg, 80 mg tablet ^{MO} | 2 | |
| sotalol 120 mg, 160 mg, 240 mg, 80 mg tablet; sotalol hcl 150 mg/10 ml vial ^{MO} | 2 | |
| sotalol af 120 mg, 160 mg, 80 mg tablet ^{MO} | 2 | |
| spironolactone-hctz 25-25 tab ^{MO} | 2 | |
| spironolactone 100 mg, 25 mg, 50 mg tablet ^{MO} | 2 | |
| taztia xt 120 mg, 180 mg, 240 mg capsule,extended release ^{MO} | 2 | QL (60 per 30 days) |
| taztia xt 300 mg, 360 mg capsule,extended release ^{MO} | 2 | QL (30 per 30 days) |
| TEKAMLO 150 MG-10 MG TABLET; TEKAMLO 150 MG-5 MG TABLET; TEKAMLO 300 MG-10 MG TABLET; TEKAMLO 300 MG-5 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| TEKTURNA 150 MG, 300 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| TEKTURNA HCT 150 MG-12.5 MG TABLET; TEKTURNA HCT 150 MG-25 MG TABLET; TEKTURNA HCT 300 MG-12.5 MG TABLET; TEKTURNA HCT 300 MG-25 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| telmisartan 20 mg, 40 mg tablet ^{MO} | 4 | QL (30 per 30 days) |
| telmisartan 80 mg tablet ^{MO} | 4 | QL (60 per 30 days) |
| telmisartan-amlodipine 40-10; telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg; telmisartan-amlodipine 80-10 ^{MO} | 4 | QL (30 per 30 days) |
| terazosin 1 mg, 10 mg, 2 mg, 5 mg capsule ^{MO} | 1 | |
| TIAZAC 120 MG, 180 MG, 240 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | QL (60 per 30 days) |
| TIAZAC 300 MG, 360 MG, 420 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | QL (30 per 30 days) |
| TIKOSYN 125 MCG CAPSULE ^{MO} | 4 | QL (240 per 30 days) |
| TIKOSYN 250 MCG CAPSULE ^{MO} | 4 | QL (120 per 30 days) |
| TIKOSYN 500 MCG CAPSULE ^{MO} | 4 | QL (60 per 30 days) |
| timolol 0.25% eye drops; timolol 0.5% eye drops; timolol maleate 10 mg, 20 mg, 5 mg tablet ^{MO} | 2 | |
| TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | QL (60 per 30 days) |
| trandolapril 1 mg, 2 mg, 4 mg tablet ^{MO} | 2 | |
| TRIBENZOR 20 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-25 MG TABLET; TRIBENZOR 40 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-5 MG-25 MG TABLET ^{MO} | 3 | QL (30 per 30 days) |
| valsartan 160 mg, 320 mg, 40 mg, 80 mg tablet ^{MO} | 3 | QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| valsartan-hctz 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg tab MO | 2 | QL (30 per 30 days) |
| VASCEPA 1 GRAM CAPSULE MO | 4 | QL (120 per 30 days) |
| verapamil 120 mg, 180 mg, 240 mg, 360 mg cap pellet; verapamil er 120 mg, 180 mg, 240 mg, 360 mg capsule; verapamil er pm 200 mg capsule MO | 2 | QL (60 per 30 days) |
| verapamil 120 mg, 40 mg, 80 mg tablet MO | 1 | |
| verapamil 2.5 mg/ml syringe; verapamil 2.5 mg/ml vial; verapamil er 120 mg, 180 mg, 240 mg tablet MO | 2 | |
| verapamil er pm 100 mg, 300 mg capsule MO | 2 | QL (30 per 30 days) |
| VYTORIN 10 MG-10 MG TABLET MO | 4 | QL (30 per 30 days) |
| VYTORIN 10 MG-20 MG TABLET MO | 4 | QL (30 per 30 days) |
| VYTORIN 10 MG-40 MG TABLET MO | 4 | QL (30 per 30 days) |
| VYTORIN 10 MG-80 MG TABLET MO | 4 | QL (30 per 30 days) |
| WELCHOL 3.75 GRAM ORAL POWDER PACKET; WELCHOL 625 MG TABLET MO | 4 | PA |
| ZETIA 10 MG TABLET MO | 3 | QL (30 per 30 days) |
| CENTRAL NERVOUS SYSTEM AGENTS | | |
| ABILIFY 9.7 MG/1.3 ML VIAL MO | 4 | QL (120 per 30 days) |
| ABILIFY DISCMELT 10 MG, 15 MG TABLET MO | 5 | PA,QL (60 per 30 days) |
| ABILIFY MAINTENA SUSPENSION,EXTENDED REL. INTRAMUSCULAR SYRINGE; ABILIFY MAINTENA 400 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE MO | 5 | QL (1 per 28 days) |
| ABILIFY MAINTENA 300 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE MO | 5 | QL (1.5 per 28 days) |
| acamprosate calc dr 333 mg tab MO | 4 | |
| acetamin-codein 300-30 mg/12.5; acetaminop-codeine 120-12 mg/5 MO | 3 | QL (5010 per 30 days) |
| acetaminophen-cod #2 tablet; acetaminophen-cod #3 tablet; acetaminophen-cod #4 tablet MO | 3 | QL (390 per 30 days) |
| alprazolam 0.25 mg, 0.5 mg tablet MO | 2 | QL (120 per 30 days) |
| alprazolam 1 mg tablet MO | 2 | QL (240 per 30 days) |
| alprazolam 2 mg tablet MO | 2 | QL (150 per 30 days) |
| ALSUMA 6 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR MO | 4 | QL (6 per 30 days) |
| amantadine 100 mg capsule; amantadine 100 mg tablet MO | 4 | |
| amantadine 50 mg/5 ml solution MO | 3 | |
| amitriptyline hcl 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tab MO | 1 | PA |
| amoxapine 100 mg, 150 mg, 25 mg, 50 mg tablet MO | 2 | |
| amphetamine salt combo 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tablet MO | 3 | QL (90 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| amphetamine salt combo 30 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| APOKYN 10 MG/ML SUBCUTANEOUS CARTRIDGE ^{SP} | 5 | QL (60 per 28 days) |
| APTIOM 200 MG, 400 MG, 800 MG TABLET ^{MO} | 4 | PA,QL (30 per 30 days) |
| APTIOM 600 MG TABLET ^{MO} | 4 | PA,QL (60 per 30 days) |
| aripiprazole 1 mg/ml solution ^{MO} | 4 | QL (750 per 30 days) |
| aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg tablet ^{MO} | 4 | QL (30 per 30 days) |
| AZILECT 0.5 MG, 1 MG TABLET ^{MO} | 3 | |
| BANZEL 200 MG TABLET ^{MO} | 4 | PA,QL (480 per 30 days) |
| BANZEL 40 MG/ML ORAL SUSPENSION ^{MO} | 5 | PA,QL (2760 per 30 days) |
| BANZEL 400 MG TABLET ^{MO} | 5 | PA,QL (240 per 30 days) |
| benztropine 2 mg/2 ml ampule; benztropine mes 0.5 mg, 1 mg, 2 mg tab; benztropine mes 0.5 mg, 1 mg, 2 mg tablet ^{MO} | 2 | PA |
| BRINTELLIX 10 MG, 20 MG, 5 MG TABLET ^{MO} | 4 | ST,QL (30 per 30 days) |
| bromocriptine 2.5 mg tablet; bromocriptine 5 mg capsule ^{MO} | 4 | |
| budeprion sr 100 mg tablet ^{MO} | 3 | QL (120 per 30 days) |
| budeprion sr 150 mg tablet ^{MO} | 3 | QL (90 per 30 days) |
| BUPRENEX 0.3 MG/ML INJECTION SOLUTION ^{MO} | 5 | PA,QL (240 per 30 days) |
| buprenorphine 0.3 mg/ml syrn ^{MO} | 4 | PA,QL (240 per 30 days) |
| buprenorphine 2 mg, 8 mg tablet sl ^{MO} | 4 | PA,QL (90 per 30 days) |
| buproban 150 mg tablet, extended release ^{MO} | 3 | QL (90 per 30 days) |
| bupropion hcl 100 mg tablet ^{MO} | 3 | QL (180 per 30 days) |
| bupropion hcl 75 mg tablet ^{MO} | 3 | |
| bupropion hcl sr 100 mg tablet ^{MO} | 3 | QL (120 per 30 days) |
| bupropion hcl sr 150 mg tablet; bupropion hcl xl 150 mg, 300 mg tablet ^{MO} | 3 | QL (90 per 30 days) |
| bupropion hcl sr 200 mg tab ^{MO} | 3 | QL (60 per 30 days) |
| buspirone hcl 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg tablet ^{MO} | 2 | |
| butalbital-acetaminophn 50-325 ^{MO} | 4 | PA,QL (180 per 30 days) |
| butalb-acetamin-caff 50-325-40; butalbit-acetaminophen-caff cp ^{MO} | 4 | PA,QL (180 per 30 days) |
| butalbital-asa-caffeine cap; butalbital-asa-caffeine tablet ^{MO} | 4 | PA,QL (180 per 30 days) |
| BUTISOL 30 MG, 50 MG TABLET; BUTISOL SODIUM 30 MG, 50 MG TABLET; BUTISOL SODIUM 30 MG/5 ML ELX ^{MO} | 4 | PA |
| butorphanol 1 mg/ml vial ^{MO} | 3 | QL (960 per 30 days) |
| butorphanol 10 mg/ml spray ^{MO} | 3 | QL (5 per 28 days) |
| butorphanol 2 mg/ml vial ^{MO} | 3 | QL (480 per 30 days) |
| caffeine cit 60 mg/3 ml oral; caffeine cit 60 mg/3 ml vial ^{MO} | 1 | |
| caffeine-sod benzoat 250 mg/ml ^{MO} | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| CAPITAL WITH CODEINE 120 MG-12 MG/5 ML ORAL SUSPENSION MO | 4 | QL (5010 per 30 days) |
| carbamazepine 100 mg tab chew MO | 2 | |
| carbamazepine 100 mg/5 ml susp; carbamazepine er 100 mg, 200 mg, 300 mg cap; carbamazepine xr 200 mg, 400 mg tablet MO | 4 | |
| carbamazepine 200 mg tablet MO | 3 | |
| CARBATROL 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE MO | 4 | |
| carbidopa-levo 10-100 mg, 25-100 mg, 25-250 mg odt MO | 4 | |
| carbidopa-levo er 25-100 tab; carbidopa-levo er 50-200 tab MO | 3 | |
| carbidopa-levodopa 10-100 tab; carbidopa-levodopa 25-100 tab; carbidopa-levodopa 25-250 tab MO | 2 | |
| celecoxib 100 mg, 200 mg, 400 mg, 50 mg capsule MO | 4 | QL (60 per 30 days) |
| CELONTIN 300 MG CAPSULE MO | 4 | |
| chlorpromazine 10 mg, 25 mg tablet MO | 3 | B vs D |
| chlorpromazine 100 mg, 200 mg, 50 mg tablet; chlorpromazine 25 mg/ml amp MO | 3 | |
| citalopram hbr 10 mg, 40 mg tablet MO | 1 | QL (30 per 30 days) |
| citalopram hbr 10 mg/5 ml soln MO | 3 | |
| citalopram hbr 20 mg tablet MO | 1 | QL (60 per 30 days) |
| clomipramine 25 mg, 50 mg, 75 mg capsule MO | 4 | PA |
| clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tab; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tablet; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg odt MO | 4 | |
| clonazepam 0.5 mg, 1 mg, 2 mg tablet MO | 3 | |
| clorazepate 15 mg, 3.75 mg, 7.5 mg tablet MO | 4 | |
| clozapine 100 mg, 200 mg, 25 mg, 50 mg tablet MO | 3 | |
| clozapine odt 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg tablet MO | 4 | ST |
| codeine sulfate 15 mg, 30 mg tablet MO | 3 | QL (360 per 30 days) |
| codeine sulfate 60 mg tablet MO | 3 | QL (180 per 30 days) |
| CYCLOSET 0.8 MG TABLET MO | 4 | PA,QL (180 per 30 days) |
| DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR DAILY PATCH MO | 4 | QL (30 per 30 days) |
| DEPACON 500 MG/5 ML (100 MG/ML) INTRAVENOUS SOLUTION MO | 4 | |
| desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tablet MO | 4 | |
| dexmethylphenidate 10 mg, 2.5 mg, 5 mg tab MO | 3 | QL (60 per 30 days) |
| dexmethylphenidate er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg cap; dexmethylphenidate er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg cp MO | 4 | QL (30 per 30 days) |
| d-amphetamine er 10 mg capsule; dextroamphetamine 10 mg tab MO | 4 | QL (180 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| d-amphetamine er 15 mg capsule MO | 4 | QL (120 per 30 days) |
| d-amphetamine er 5 mg capsule MO | 4 | QL (60 per 30 days) |
| dextroamphetamine 5 mg tab MO | 4 | QL (150 per 30 days) |
| dextroamp-amphet er 10 mg, 15 mg, 5 mg cap MO | 4 | QL (30 per 30 days) |
| dextroamp-amphet er 20 mg, 25 mg, 30 mg cap MO | 4 | QL (60 per 30 days) |
| diazepam 10 mg rectal gel syst; diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg rectal gel sys; diazepam 20 mg rectal gel syst MO | 4 | |
| diazepam 10 mg tablet MO | 4 | QL (120 per 30 days) |
| diazepam 2 mg, 5 mg tablet MO | 4 | QL (90 per 30 days) |
| diazepam 5 mg/5 ml solution; diazepam 5 mg/ml oral conc MO | 4 | QL (1200 per 30 days) |
| diazepam intensol 5 mg/ml oral concentrate MO | 4 | QL (1200 per 30 days) |
| diclofenac pot 50 mg tablet MO | 2 | |
| diclofenac 0.1% eye drops; diclofenac sod ec 25 mg, 50 mg, 75 mg tab; diclofenac sod er 100 mg tab MO | 2 | |
| diclofenac 1.5% topical soln MO | 4 | |
| diflunisal 500 mg tablet MO | 4 | |
| dilantin 30 mg capsule MO | 4 | |
| dilantin extended 100 mg capsule MO | 4 | |
| DILANTIN INFATABS 50 MG CHEWABLE TABLET MO | 4 | |
| DILANTIN-125 125 MG/5 ML ORAL SUSPENSION MO | 4 | |
| divalproex sod dr 125 mg, 250 mg, 500 mg tab; divalproex sodium 125 mg cap MO | 2 | |
| divalproex sod er 250 mg, 500 mg tab MO | 3 | |
| doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg capsule; doxepin 10 mg/ml oral conc MO | 2 | PA |
| droperidol 2.5 mg/ml vial MO | 3 | |
| duloxetine hcl dr 20 mg, 30 mg, 60 mg cap MO | 3 | QL (60 per 30 days) |
| duloxetine hcl dr 40 mg cap MO | 4 | QL (60 per 30 days) |
| DURAMORPH (PF) 0.5 MG/ML INJECTION SOLUTION MO | 4 | QL (7200 per 30 days) |
| DURAMORPH (PF) 1 MG/ML INJECTION SOLUTION MO | 4 | QL (3600 per 30 days) |
| EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH MO | 5 | QL (30 per 30 days) |
| endocet 10 mg-325 mg tablet; endocet 2.5 mg-325 mg tablet; endocet 5 mg-325 mg tablet; endocet 7.5 mg-325 mg tablet MO | 3 | QL (360 per 30 days) |
| entacapone 200 mg tablet MO | 4 | QL (300 per 30 days) |
| epitol 200 mg tablet MO | 1 | |
| EQUETRO 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| escitalopram 10 mg tablet MO | 1 | QL (45 per 30 days) |
| escitalopram 20 mg, 5 mg tablet MO | 1 | QL (30 per 30 days) |
| escitalopram oxalate 5 mg/5 ml MO | 4 | QL (600 per 30 days) |
| eszopiclone 1 mg, 2 mg, 3 mg tablet MO | 4 | PA |
| ethosuximide 250 mg capsule; ethosuximide 250 mg/5 ml soln MO | 4 | |
| etodolac 200 mg, 300 mg capsule; etodolac 400 mg, 500 mg tablet; etodolac er 400 mg, 500 mg, 600 mg tablet MO | 3 | |
| FANAPT 1 MG, 10 MG, 12 MG, 1MG(2)-2MG(2)- 4MG(2)-6MG(2), 2 MG, 4 MG, 6 MG, 8 MG TABLET; FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK MO | 4 | PA,QL (60 per 30 days) |
| FAZACLO 100 MG, 12.5 MG, 150 MG, 200 MG, 25 MG DISINTEGRATING TABLET MO | 4 | ST |
| felbamate 400 mg, 600 mg tablet MO | 4 | |
| felbamate 600 mg/5 ml susp MO | 5 | |
| fenopropfen 600 mg tablet; fenopropfen calcium 400 mg cap MO | 4 | |
| fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour patch; fentanyl 37.5 mcg/hr patch; fentanyl 62.5 mcg/hr patch; fentanyl 87.5 mcg/hr patch MO | 4 | QL (20 per 30 days) |
| fentanyl cit otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg; fentanyl citrate otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg MO | 5 | PA,QL (120 per 30 days) |
| fentanyl 0.05 mg/ml ampul MO | 4 | QL (720 per 30 days) |
| fentanyl 0.05 mg/ml syringe MO | 4 | QL (240 per 30 days) |
| FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE,EXTENDED RELEASE MO | 4 | PA,QL (30 per 30 days) |
| FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK MO | 4 | PA,QL (28 per 28 days) |
| FLECTOR TRANSDERMAL 12 HOUR PATCH MO | 4 | PA,QL (60 per 30 days) |
| flumazenil 0.1 mg/ml vial MO | 2 | |
| fluoxetine 20 mg/5 ml solution; fluoxetine hcl 10 mg tablet MO | 2 | |
| fluoxetine dr 90 mg capsule MO | 4 | QL (4 per 28 days) |
| fluoxetine hcl 10 mg, 40 mg capsule MO | 2 | QL (60 per 30 days) |
| fluoxetine hcl 20 mg capsule MO | 1 | QL (120 per 30 days) |
| fluoxetine hcl 20 mg tablet MO | 3 | |
| fluoxetine hcl 60 mg tablet MO | 3 | QL (30 per 30 days) |
| fluphenazine dec 25 mg/ml vial MO | 4 | |
| fluphenazine 1 mg, 10 mg, 2.5 mg, 5 mg tablet; fluphenazine 2.5 mg/ml vial; fluphenazine 5 mg/ml conc MO | 2 | |
| fluphenazine 2.5 mg/5 ml elix MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| flurbiprofen 100 mg, 50 mg tablet ^{MO} | 2 | |
| fluvoxamine er 100 mg, 150 mg capsule ^{MO} | 4 | QL (60 per 30 days) |
| fluvoxamine maleate 100 mg, 25 mg, 50 mg tab ^{MO} | 2 | QL (90 per 30 days) |
| fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml; fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml vial ^{MO} | 1 | |
| FYCOMPA 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET ^{MO} | 4 | PA,QL (30 per 30 days) |
| gabapentin 100 mg, 300 mg, 400 mg capsule ^{MO} | 2 | QL (270 per 30 days) |
| gabapentin 250 mg/5 ml soln; gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) soln; gabapentin 300 mg/6 ml soln ^{MO} | 3 | |
| gabapentin 600 mg, 800 mg tablet ^{MO} | 2 | QL (180 per 30 days) |
| GEODON 20 MG/ML (FINAL CONCENTRATION) INTRAMUSCULAR SOLUTION ^{MO} | 4 | |
| haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg tablet ^{MO} | 2 | |
| haloperidol dec 100 mg/ml, 50 mg/ml vial; haloperidol decan 100 mg/ml, 50 mg/ml amp ^{MO} | 4 | |
| haloperidol lac 2 mg/ml conc; haloperidol lac 5 mg/ml vial ^{MO} | 2 | |
| HETLIOZ 20 MG CAPSULE ^{SP} | 5 | PA,QL (30 per 30 days) |
| hydrocodon-acetaminoph 2.5-325; hydrocodon-acetaminoph 7.5-325; hydrocodon-acetaminophen 5-325; hydrocodon-acetaminophn 10-325 ^{MO} | 3 | QL (360 per 30 days) |
| hydrocodone-acetamin 10-325/15; hydrocodone-acetamin 5-163/7.5 ^{MO} | 3 | QL (5520 per 30 days) |
| hydrocodone-ibuprofen 10-200; hydrocodone-ibuprofen 10-200 mg, 2.5-200 mg, 5-200 mg; hydrocodone-ibuprofen 2.5-200 ^{MO} | 4 | QL (150 per 30 days) |
| hydrocodone-ibuprofen 7.5-200 ^{MO} | 3 | QL (150 per 30 days) |
| hydromorphone 0.5 mg/0.5 ml, 1 mg/ml; hydromorphone 0.5 mg/0.5 ml, 1 mg/ml syringe ^{MO} | 4 | QL (720 per 30 days) |
| hydromorphone 2 mg, 4 mg tablet ^{MO} | 3 | QL (360 per 30 days) |
| hydromorphone 2 mg/ml syringe; hydromorphone 2 mg/ml vial ^{MO} | 4 | QL (360 per 30 days) |
| hydromorphone 3 mg suppos ^{MO} | 4 | QL (120 per 30 days) |
| hydromorphone 4 mg/ml syrin ^{MO} | 4 | QL (180 per 30 days) |
| hydromorphone 8 mg tablet ^{MO} | 3 | QL (240 per 30 days) |
| hydromorphone 10 mg/ml vial ^{MO} | 4 | QL (144 per 30 days) |
| hydromorphone hcl 1 mg/ml amp ^{MO} | 4 | QL (720 per 30 days) |
| hydromorphone hcl 2 mg/ml amp ^{MO} | 4 | QL (360 per 30 days) |
| hydromorphone hcl 4 mg/ml amp ^{MO} | 4 | QL (180 per 30 days) |
| ibuprofen 100 mg/5 ml susp; ibuprofen 400 mg, 600 mg, 800 mg tablet ^{MO} | 1 | |
| oxycodone-ibuprofen 5-400 tab ^{MO} | 3 | QL (240 per 30 days) |
| imipramine hcl 10 mg, 25 mg, 50 mg tablet ^{MO} | 2 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg cap</i> ^{MO} | 4 | PA |
| INFUMORPH P/F 10 MG/ML INJECTION SOLUTION ^{MO} | 4 | QL (360 per 30 days) |
| INFUMORPH P/F 25 MG/ML INJECTION SOLUTION ^{MO} | 4 | QL (150 per 30 days) |
| INVEGA 1.5 MG, 3 MG, 9 MG TABLET,EXTENDED RELEASE ^{MO} | 5 | ST,QL (30 per 30 days) |
| INVEGA 6 MG TABLET,EXTENDED RELEASE ^{MO} | 5 | ST,QL (60 per 30 days) |
| INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 5 | QL (1.5 per 30 days) |
| INVEGA SUSTENNA 156 MG/ML INTRAMUSCULAR SYRINGE ^{MO} | 5 | QL (1 per 30 days) |
| INVEGA SUSTENNA 39 MG/0.25 ML, 78 MG/0.5 ML INTRAMUSCULAR SYRINGE ^{MO} | 4 | QL (1.5 per 30 days) |
| IRENKA 40 MG CAPSULE,DELAYED RELEASE ^{MO} | 4 | QL (60 per 30 days) |
| <i>ketoprofen 50 mg, 75 mg capsule</i> ^{MO} | 2 | |
| LAMICTAL DISPER TABLET ^{MO} | 4 | |
| LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG DISINTEGRATING TABLET ^{MO} | 4 | |
| LAMICTAL ODT STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,DISINTEGRATING ^{MO} | 4 | |
| LAMICTAL ODT STARTER (GREEN) 50 MG (42)-100 MG (14) TABLET,DISINTEGRAT ^{MO} | 4 | |
| LAMICTAL ODT STARTER(ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,DISINT ^{MO} | 4 | |
| LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLETS IN A DOSE PACK ^{MO} | 4 | |
| LAMICTAL STARTER (GREEN) KIT 25 MG (84)-100 MG (14) TABLETS, DOSE PACK ^{MO} | 4 | |
| LAMICTAL STARTER (ORANGE) KIT 25 MG (42)-100 MG (7) TABLETS, DOSE PACK ^{MO} | 4 | |
| LAMICTAL XR STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,EXTEND RELEASE ^{MO} | 4 | |
| LAMICTAL XR STARTER (GREEN) 50 MG(14)-100 MG(14)-200 MG(7) TAB,EXT.REL ^{MO} | 4 | |
| LAMICTAL XR STARTER (ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,EXT.REL ^{MO} | 4 | |
| <i>lamotrigine disper tab; lamotrigine disper tablet; lamotrigine 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (35) tablet; lamotrigine 25 mg tb start kit</i> ^{MO} | 2 | |
| <i>lamotrigine er 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg tablet; lamotrigine odt 100 mg, 200 mg, 25 mg, 50 mg tablet</i> ^{MO} | 4 | |
| LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET ^{MO} | 5 | PA,QL (30 per 30 days) |
| LATUDA 80 MG TABLET ^{MO} | 5 | PA,QL (60 per 30 days) |
| LAZANDA 100 MCG/SPRAY, 400 MCG/SPRAY NASAL SPRAY ^{MO} | 5 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| levetiracetam 1,000 mg, 250 mg, 500 mg, 750 mg tablet; levetiracetam 100 mg/ml soln; levetiracetam er 500 mg, 750 mg tablet MO | 2 | |
| levetiracetam 500 mg/5 ml soln; levetiracetam 500 mg/5 ml, 500 mg/5 ml (5 ml) vial MO | 4 | |
| levetiracetam-nacl 1,000mg/100; levetiracetam-nacl 1,500mg/100; levetiracetam-nacl 500 mg/100 MO | 2 | |
| levorphanol 2 mg tablet MO | 4 | QL (240 per 30 days) |
| lithium carbonate 150 mg, 300 mg, 600 mg cap; lithium carbonate 300 mg, 300 mg, 450 mg tab; lithium carbonate er 300 mg, 300 mg, 450 mg tb MO | 2 | |
| lithium 8 meq/5 ml solution MO | 2 | |
| lorazepam 0.5 mg, 1 mg tablet MO | 2 | QL (90 per 30 days) |
| lorazepam 2 mg tablet MO | 2 | QL (150 per 30 days) |
| lorazepam 2 mg/ml oral concent MO | 3 | QL (150 per 30 days) |
| LORAZEPAM INTENSOL 2 MG/ML ORAL CONCENTRATE MO | 3 | QL (150 per 30 days) |
| loxapine 10 mg, 25 mg, 5 mg, 50 mg capsule MO | 2 | |
| LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE MO | 4 | QL (90 per 30 days) |
| LYRICA 20 MG/ML ORAL SOLUTION MO | 4 | QL (900 per 30 days) |
| LYRICA 225 MG, 300 MG CAPSULE MO | 4 | QL (60 per 30 days) |
| magnesium chl 200 mg/ml vial MO | 2 | |
| magnesium sulfate 50% syringe; magnesium sulfate 50% vial MO | 2 | |
| magnesium-d5w 1 gm/100 ml soln MO | 2 | |
| magnesium sulf 4% iv soln; magnesium sulf 8% iv soln MO | 2 | |
| maprotiline 25 mg, 50 mg, 75 mg tablet MO | 4 | |
| MARPLAN 10 MG TABLET MO | 4 | |
| meclofenamate 100 mg, 50 mg capsule MO | 4 | |
| meloxicam 15 mg tablet MO | 1 | QL (30 per 30 days) |
| meloxicam 7.5 mg tablet MO | 1 | QL (60 per 30 days) |
| meloxicam 7.5 mg/5 ml susp MO | 3 | QL (300 per 30 days) |
| memantine 5-10 mg titration pk MO | 3 | PA,QL (98 per 30 days) |
| memantine hcl 10 mg, 5 mg tablet MO | 3 | PA,QL (60 per 30 days) |
| methadone 10 mg/5 ml solution MO | 3 | QL (1800 per 30 days) |
| methadone 10 mg/ml oral conc; methadone hcl 10 mg/ml vial MO | 3 | QL (360 per 30 days) |
| methadone 5 mg/5 ml solution MO | 3 | QL (3600 per 30 days) |
| methadone hcl 10 mg tablet MO | 3 | QL (240 per 30 days) |
| methadone hcl 5 mg tablet MO | 3 | QL (480 per 30 days) |
| methadone intensol 10 mg/ml oral concentrate MO | 3 | QL (360 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| METHADOSE 10 MG/ML ORAL CONCENTRATE ^{MO} | 3 | QL (360 per 30 days) |
| METHYLIN 10 MG CHEWABLE TABLET ^{MO} | 4 | QL (180 per 30 days) |
| METHYLIN 2.5 MG, 5 MG CHEWABLE TABLET ^{MO} | 4 | QL (150 per 30 days) |
| <i>methylphenidate 10 mg chew tab</i> ^{MO} | 4 | QL (180 per 30 days) |
| <i>methylphenidate 10 mg, 20 mg, 5 mg tablet</i> ^{MO} | 3 | QL (90 per 30 days) |
| <i>methylphenidate 10 mg/5 ml sol</i> ^{MO} | 4 | QL (900 per 30 days) |
| <i>methylphenidate 2.5 mg, 5 mg chew tab; methylphenidate 2.5 mg, 5 mg chew tb</i> ^{MO} | 4 | QL (150 per 30 days) |
| <i>methylphenidate 5 mg/5 ml soln</i> ^{MO} | 4 | QL (1800 per 30 days) |
| <i>methylphenidate er 10 mg, 20 mg tab</i> ^{MO} | 4 | QL (90 per 30 days) |
| <i>methylphenidate la 20 mg, 40 mg cap</i> ^{MO} | 4 | QL (30 per 30 days) |
| <i>methylphenidate la 30 mg cap</i> ^{MO} | 4 | QL (60 per 30 days) |
| <i>mirtazapine 15 mg, 30 mg, 45 mg odt</i> ^{MO} | 4 | QL (30 per 30 days) |
| <i>mirtazapine 15 mg, 30 mg, 45 mg tablet</i> ^{MO} | 2 | QL (30 per 30 days) |
| <i>mirtazapine 7.5 mg tablet</i> ^{MO} | 2 | |
| <i>modafinil 100 mg, 200 mg tablet</i> ^{MO} | 4 | PA,QL (60 per 30 days) |
| <i>morphine 10 mg/ml carpject; morphine 10 mg/ml vial; morphine 10 mg/ml, 10 mg/ml isecure syr; morphine 10 mg/ml, 10 mg/ml syringe</i> ^{MO} | 3 | QL (360 per 30 days) |
| <i>morphine 15 mg/ml carpject; morphine sulfate 50 mg/ml vial</i> ^{MO} | 3 | QL (240 per 30 days) |
| <i>morphine 2 mg/ml carpject; morphine 2 mg/ml, 2 mg/ml isecure syr; morphine 2 mg/ml, 2 mg/ml syringe</i> ^{MO} | 3 | QL (1800 per 30 days) |
| <i>morphine 300 mg/20 ml vial</i> ^{MO} | 3 | QL (600 per 30 days) |
| <i>morphine 4 mg/ml carpject; morphine 4 mg/ml isecure syr</i> ^{MO} | 3 | QL (900 per 30 days) |
| <i>morphine 5 mg/ml syringe; morphine 5 mg/ml vial</i> ^{MO} | 3 | QL (720 per 30 days) |
| <i>morphine 8 mg/ml isecure syr; morphine 8 mg/ml syringe; morphine 8 mg/ml vial</i> ^{MO} | 3 | QL (450 per 30 days) |
| <i>morphine sulf 10 mg, 20 mg, 30 mg, 5 mg suppos; morphine sulf er 100 mg, 15 mg, 30 mg tablet; morphine sulfate ir 100 mg, 15 mg, 30 mg tab</i> ^{MO} | 3 | QL (180 per 30 days) |
| <i>morphine sulf 10 mg/5 ml soln</i> ^{MO} | 3 | QL (2700 per 30 days) |
| <i>morphine sulf 20 mg/5 ml soln</i> ^{MO} | 3 | QL (1350 per 30 days) |
| <i>morphine sulf er 15 mg, 30 mg, 60 mg tablet</i> ^{MO} | 3 | QL (120 per 30 days) |
| <i>morphine sulf er 200 mg tablet</i> ^{MO} | 3 | QL (90 per 30 days) |
| <i>morphine sulfate 100 mg/4 ml, 25 mg/ml vial; morphine sulfate 25 mg/ml vl</i> ^{MO} | 3 | QL (150 per 30 days) |
| <i>morphine sulfate er 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg cap; morphine sulfate er 120 mg, 60 mg, 75 mg, 90 mg cap</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>morphine sulfate er 30 mg, 45 mg cap</i> ^{MO} | 3 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>morphine 0.5 mg/ml vial</i> ^{MO} | 3 | QL (7200 per 30 days) |
| <i>morphine 1 mg/ml, 30 mg/30 ml vial p-f; morphine sulfate 1 mg/ml vial</i> ^{MO} | 3 | QL (3600 per 30 days) |
| <i>morphine sulf 100 mg/5 ml soln</i> ^{MO} | 3 | QL (600 per 30 days) |
| <i>nabumetone 500 mg, 750 mg tablet</i> ^{MO} | 2 | |
| <i>nalbuphine 100 mg/10 ml vial</i> ^{MO} | 4 | QL (240 per 30 days) |
| <i>nalbuphine 200 mg/10 ml vial</i> ^{MO} | 4 | QL (120 per 30 days) |
| NALFON 400 MG CAPSULE ^{MO} | 4 | |
| <i>naloxone 0.4 mg/ml vial; naloxone 0.4 mg/ml, 1 mg/ml syringe; naloxone 2 mg/2 ml syringe</i> ^{MO} | 2 | |
| <i>naltrexone 50 mg tablet</i> ^{MO} | 2 | |
| NAMENDA 10 MG/5 ML ORAL SOLUTION ^{MO} | 3 | PA,QL (360 per 30 days) |
| NAMENDA XR CAPSULE SPRINKLE,EXTENDED RELEASE ^{MO} | 3 | PA,QL (30 per 30 days) |
| NAMENDA XR 7 MG-14 MG-21 MG-28 MG CAPSULE,SPRINKLE,ER 24HR,DOSE PACK ^{MO} | 3 | PA,QL (28 per 28 days) |
| <i>naproxen 125 mg/5 ml suspen</i> ^{MO} | 3 | |
| <i>naproxen 250 mg, 375 mg, 375 mg, 500 mg, 500 mg tablet; naproxen dr 250 mg, 375 mg, 375 mg, 500 mg, 500 mg tablet</i> ^{MO} | 2 | |
| <i>naproxen sodium 275 mg, 550 mg tab</i> ^{MO} | 1 | |
| <i>naratriptan hcl 1 mg, 2.5 mg tablet</i> ^{MO} | 3 | QL (9 per 30 days) |
| <i>nefazodone hcl 100 mg, 150 mg, 200 mg, 250 mg, 50 mg tablet</i> ^{MO} | 4 | |
| NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH ^{MO} | 4 | QL (30 per 30 days) |
| <i>nortriptyline 10 mg/5 ml sol</i> ^{MO} | 3 | |
| <i>nortriptyline hcl 10 mg, 25 mg, 50 mg, 75 mg cap</i> ^{MO} | 2 | |
| NUEDEXTA 20 MG-10 MG CAPSULE ^{MO} | 3 | QL (60 per 30 days) |
| NUVIGIL 150 MG, 200 MG, 250 MG TABLET ^{MO} | 3 | PA,QL (30 per 30 days) |
| NUVIGIL 50 MG TABLET ^{MO} | 3 | PA,QL (60 per 30 days) |
| <i>olanzapine 10 mg vial; olanzapine 15 mg, 20 mg tablet</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>olanzapine 10 mg, 2.5 mg, 5 mg, 7.5 mg tablet</i> ^{MO} | 3 | QL (30 per 30 days) |
| <i>olanzapine odt 10 mg, 5 mg tablet</i> ^{MO} | 4 | QL (30 per 30 days) |
| <i>olanzapine odt 15 mg, 20 mg tablet</i> ^{MO} | 4 | QL (60 per 30 days) |
| ONFI 10 MG, 20 MG TABLET ^{MO} | 4 | PA,QL (60 per 30 days) |
| ONFI 2.5 MG/ML ORAL SUSPENSION ^{MO} | 4 | PA,QL (480 per 30 days) |
| OPANA ER TABLET, CRUSH RESISTANT, EXTENDED RELEASE ^{MO} | 3 | QL (60 per 30 days) |
| ORAP 1 MG, 2 MG TABLET ^{MO} | 4 | |
| <i>oxaprozin 600 mg tablet</i> ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| oxazepam 10 mg, 15 mg, 30 mg capsule ^{MO} | 4 | |
| oxcarbazepine 150 mg, 300 mg, 600 mg tablet ^{MO} | 3 | |
| oxcarbazepine 300 mg/5 ml susp ^{MO} | 4 | |
| oxycodone hcl 10 mg, 15 mg, 20 mg, 30 mg, 5 mg tablet; oxycodone hcl 5 mg capsule ^{MO} | 3 | QL (360 per 30 days) |
| oxycodone hcl 100 mg/5 ml soln ^{MO} | 4 | QL (270 per 30 days) |
| oxycodone hcl 5 mg/5 ml soln ^{MO} | 3 | QL (5400 per 30 days) |
| oxycodon-acetaminophen 2.5-325; oxycodon-acetaminophen 7.5-325; oxycodone-acetaminophen 10-325; oxycodone-acetaminophen 5-325 ^{MO} | 3 | QL (360 per 30 days) |
| oxycodone-aspirin 4.8355-325 ^{MO} | 4 | QL (360 per 30 days) |
| paroxetine cr 12.5 mg, 37.5 mg tablet; paroxetine er 12.5 mg, 37.5 mg tablet ^{MO} | 4 | QL (60 per 30 days) |
| paroxetine cr 25 mg tablet ^{MO} | 4 | QL (90 per 30 days) |
| paroxetine hcl 10 mg, 20 mg tablet ^{MO} | 1 | QL (30 per 30 days) |
| paroxetine hcl 30 mg, 40 mg tablet ^{MO} | 1 | QL (60 per 30 days) |
| PAXIL 10 MG/5 ML ORAL SUSPENSION ^{MO} | 4 | |
| PEGANONE 250 MG TABLET ^{MO} | 4 | |
| perphenazine 16 mg, 2 mg, 4 mg, 8 mg tablet ^{MO} | 4 | |
| perphen-amitrip 2 mg-10 mg tab; perphen-amitrip 2 mg-25 mg tab; perphen-amitrip 4 mg-10 mg tab; perphen-amitrip 4 mg-25 mg tab; perphen-amitrip 4 mg-50 mg tab ^{MO} | 3 | PA |
| phenelzine sulfate 15 mg tab ^{MO} | 3 | |
| phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg tablet ^{MO} | 3 | PA,QL (90 per 30 days) |
| phenobarbital 15 mg, 60 mg tablet ^{MO} | 3 | PA,QL (120 per 30 days) |
| phenobarbital 20 mg/5 ml elix ^{MO} | 3 | PA,QL (1500 per 30 days) |
| phenobarbital 30 mg tablet ^{MO} | 3 | PA,QL (300 per 30 days) |
| PHENYTEK 200 MG, 300 MG CAPSULE ^{MO} | 4 | |
| phenytoin 100 mg/4 ml, 125 mg/5 ml susp; phenytoin 50 mg tablet chew ^{MO} | 2 | |
| phenytoin 50 mg/ml syringe; phenytoin 50 mg/ml vial ^{MO} | 2 | |
| phenytoin sod ext 100 mg, 200 mg, 300 mg cap ^{MO} | 2 | |
| piroxicam 10 mg, 20 mg capsule ^{MO} | 3 | |
| POTIGA 200 MG, 300 MG, 400 MG TABLET ^{MO} | 5 | PA |
| POTIGA 50 MG TABLET ^{MO} | 4 | PA |
| pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg tablet ^{MO} | 2 | |
| PRIALT 100 MCG/ML, 25 MCG/ML INTRATHECAL SOLUTION ^{MO} | 5 | B vs D |
| primidone 250 mg, 50 mg tablet ^{MO} | 2 | |
| PRISTIQ 100 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| protriptyline hcl 10 mg, 5 mg tablet MO | 4 | |
| quetiapine fumarate 100 mg, 300 mg, 400 mg tab MO | 2 | QL (90 per 30 days) |
| quetiapine fumarate 200 mg, 25 mg, 50 mg tab MO | 2 | QL (120 per 30 days) |
| revia 50 mg tablet MO | 4 | |
| REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| riluzole 50 mg tablet SP | 4 | |
| RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML, 37.5 MG/2 ML INTRAMUSCULAR SYRINGE MO | 4 | QL (4 per 28 days) |
| RISPERDAL CONSTA 50 MG/2 ML INTRAMUSCULAR SYRINGE MO | 5 | QL (4 per 28 days) |
| risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg odt MO | 4 | QL (60 per 30 days) |
| risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg tablet MO | 1 | QL (60 per 30 days) |
| risperidone 0.5 mg odt MO | 4 | QL (120 per 30 days) |
| risperidone 0.5 mg tablet MO | 1 | QL (120 per 30 days) |
| risperidone 1 mg/ml solution MO | 2 | |
| rizatriptan 10 mg, 5 mg odt MO | 4 | QL (12 per 30 days) |
| rizatriptan 10 mg, 5 mg tablet MO | 3 | QL (12 per 30 days) |
| ropinirole hcl 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg tablet MO | 2 | |
| ropinirole hcl er 12 mg, 2 mg, 4 mg, 6 mg, 8 mg tablet MO | 4 | QL (90 per 30 days) |
| ROXICET 5-325 ORAL SOLUTION MO | 3 | QL (1830 per 30 days) |
| ROXICET 5-325 TABLET MO | 3 | QL (360 per 30 days) |
| SABRIL 500 MG ORAL POWDER PACKET; SABRIL 500 MG TABLET SP | 5 | PA,QL (180 per 30 days) |
| SAPHRIS (BLACK CHERRY) 10 MG, 2.5 MG SUBLINGUAL TABLET MO | 5 | PA,QL (60 per 30 days) |
| SAPHRIS (BLACK CHERRY) 5 MG SUBLINGUAL TABLET MO | 4 | PA,QL (60 per 30 days) |
| SAVELLA 100 MG, 12.5 MG, 12.5 MG (5)-25 MG(8)-50 MG(42), 25 MG, 50 MG TABLET; SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK MO | 3 | QL (60 per 30 days) |
| selegiline hcl 5 mg capsule; selegiline hcl 5 mg tablet MO | 4 | |
| SEROQUEL XR 150 MG TABLET,EXTENDED RELEASE MO | 3 | QL (90 per 30 days) |
| SEROQUEL XR 200 MG TABLET,EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| SEROQUEL XR 300 MG, 400 MG TABLET,EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| SEROQUEL XR 50 MG TABLET,EXTENDED RELEASE MO | 3 | QL (120 per 30 days) |
| sertraline 20 mg/ml oral conc MO | 2 | |
| sertraline hcl 100 mg tablet MO | 1 | QL (60 per 30 days) |
| sertraline hcl 25 mg, 50 mg tablet MO | 1 | QL (90 per 30 days) |
| SILENOR 3 MG, 6 MG TABLET MO | 4 | QL (30 per 30 days) |
| STAVZOR DR 125 MG, 250 MG, 500 MG CAPSULE MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE ^{MO} | 4 | PA,QL (60 per 30 days) |
| STRATTERA 100 MG, 60 MG, 80 MG CAPSULE ^{MO} | 4 | PA,QL (30 per 30 days) |
| SUBOXONE 12 MG-3 MG SUBLINGUAL FILM ^{MO} | 4 | PA,QL (60 per 30 days) |
| SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM; SUBOXONE 4 MG-1 MG SUBLINGUAL FILM; SUBOXONE 8 MG-2 MG SUBLINGUAL FILM ^{MO} | 4 | PA,QL (90 per 30 days) |
| sufentanil 250 mcg/5 ml ampul ^{MO} | 3 | QL (1440 per 30 days) |
| sulindac 150 mg, 200 mg tablet ^{MO} | 2 | |
| sumatriptan 20 mg nasal spray; sumatriptan 5 mg nasal spray ^{MO} | 4 | QL (12 per 30 days) |
| sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml cart; sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml inject; sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml refill; sumatriptan 6 mg/0.5 ml syrng; sumatriptan 6 mg/0.5 ml vial ^{MO} | 4 | QL (6 per 30 days) |
| sumatriptan succ 100 mg, 25 mg, 50 mg tablet ^{MO} | 2 | QL (9 per 30 days) |
| SURMONTIL 100 MG, 25 MG, 50 MG CAPSULE ^{MO} | 4 | PA |
| TASMAR 100 MG TABLET ^{MO} | 4 | PA |
| TEGRETOL XR 100 MG, 200 MG, 400 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | |
| temazepam 15 mg, 30 mg capsule ^{MO} | 4 | QL (30 per 30 days) |
| tetrabenazine 12.5 mg tablet ^{SP} | 5 | PA,QL (240 per 30 days) |
| tetrabenazine 25 mg tablet ^{SP} | 5 | PA,QL (120 per 30 days) |
| thioridazine 10 mg, 100 mg, 25 mg, 50 mg tablet ^{MO} | 2 | PA |
| thiothixene 1 mg, 10 mg, 2 mg, 5 mg capsule ^{MO} | 3 | |
| tiagabine hcl 2 mg, 4 mg tablet ^{MO} | 4 | |
| tolcapone 100 mg tablet ^{MO} | 4 | PA |
| tolmetin sodium 200 mg tab ^{MO} | 3 | |
| tolmetin sodium 400 mg cap; tolmetin sodium 600 mg tab ^{MO} | 4 | |
| topiramate 100 mg, 200 mg, 50 mg tablet ^{MO} | 2 | QL (120 per 30 days) |
| topiramate 15 mg, 25 mg sprinkle cap ^{MO} | 2 | |
| topiramate 25 mg tablet ^{MO} | 2 | QL (90 per 30 days) |
| tramadol hcl 50 mg tablet ^{MO} | 2 | QL (240 per 30 days) |
| tramadol-acetaminophn 37.5-325 ^{MO} | 3 | QL (240 per 30 days) |
| tranylcypromine sulf 10 mg tab ^{MO} | 4 | |
| trazodone 100 mg, 150 mg, 50 mg tablet ^{MO} | 1 | |
| trazodone 300 mg tablet ^{MO} | 2 | |
| trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg tablet ^{MO} | 3 | |
| trihexyphenidyl 2 mg, 5 mg tablet; trihexyphenidyl 2 mg/5 ml elx ^{MO} | 2 | PA |
| trimipramine maleate 100 mg, 25 mg, 50 mg cap; trimipramine maleate 100 mg, 25 mg, 50 mg cp ^{MO} | 4 | PA |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ULTIVA 1 MG INTRAVENOUS SOLUTION MO | 4 | QL (450 per 30 days) |
| ULTIVA 2 MG INTRAVENOUS SOLUTION MO | 4 | QL (240 per 30 days) |
| ULTIVA 5 MG INTRAVENOUS SOLUTION MO | 4 | QL (90 per 30 days) |
| valproate sod 500 mg/5 ml vl MO | 2 | |
| valproic acid 250 mg capsule MO | 2 | |
| valproic acid 250 mg/5 ml soln; valproic acid 250 mg/5 ml, 250 mg/5 ml (5 ml) soln MO | 2 | |
| venlafaxine hcl 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tablet MO | 2 | |
| venlafaxine hcl er 150 mg cap MO | 2 | QL (60 per 30 days) |
| venlafaxine hcl er 150 mg, 225 mg, 37.5 mg tab MO | 4 | QL (30 per 30 days) |
| venlafaxine hcl er 37.5 mg cap MO | 2 | QL (30 per 30 days) |
| venlafaxine hcl er 75 mg cap MO | 2 | QL (90 per 30 days) |
| venlafaxine hcl er 75 mg tab MO | 4 | QL (60 per 30 days) |
| VERSACLOZ 50 MG/ML ORAL SUSPENSION MO | 4 | ST,QL (540 per 30 days) |
| VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK; VIIBRYD 10 MG, 10 MG (7)- 20 MG (23), 10 MG (7)-20 MG (7)-40 MG (16), 20 MG, 40 MG TABLET; VIIBRYD 10-20-40 MG STARTER PK MO | 4 | PA,QL (30 per 30 days) |
| VIMPAT 10 MG/ML ORAL SOLUTION MO | 4 | PA,QL (1395 per 30 days) |
| VIMPAT 100 MG, 150 MG, 200 MG, 50 MG, 50 MG (14)- 100 MG (14) TABLET; VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION; VIMPAT 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK MO | 4 | PA |
| VIVITROL 380 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE MO | 5 | PA |
| VOLTAREN 1 % TOPICAL GEL MO | 4 | |
| XENAZINE 12.5 MG TABLET SP | 5 | PA,QL (240 per 30 days) |
| XENAZINE 25 MG TABLET SP | 5 | PA,QL (120 per 30 days) |
| XYREM 500 MG/ML ORAL SOLUTION SP | 5 | PA,QL (540 per 30 days) |
| zaleplon 10 mg, 5 mg capsule MO | 2 | QL (90 per 365 days) |
| zenzedi 10 mg tablet MO | 4 | QL (180 per 30 days) |
| ZENZEDI 15 MG TABLET MO | 4 | QL (120 per 30 days) |
| ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET MO | 4 | QL (90 per 30 days) |
| ZENZEDI 30 MG TABLET MO | 4 | QL (60 per 30 days) |
| zenzedi 5 mg tablet MO | 4 | QL (150 per 30 days) |
| ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg capsule MO | 4 | QL (60 per 30 days) |
| zolpidem tartrate 10 mg, 5 mg tablet MO | 1 | QL (90 per 365 days) |
| zonisamide 100 mg, 25 mg, 50 mg capsule MO | 2 | |
| ZYPREXA RELPREVV 210 MG INTRAMUSCULAR SUSPENSION MO | 4 | PA,QL (4 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ZYPREXA RELPREVV 300 MG INTRAMUSCULAR SUSPENSION MO | 5 | PA,QL (2 per 28 days) |
| ZYPREXA RELPREVV 405 MG INTRAMUSCULAR SUSPENSION MO | 5 | PA,QL (1 per 28 days) |
| DEVICES | | |
| 1ST TIER UNIFINE PENTIPS 29 GAUGE X 1/2" NEEDLE; 1ST TIER UNIFINE PENTIPS 31 GAUGE X 1/4" NEEDLE; 1ST TIER UNIFINE PENTIPS 31 GAUGE X 3/16" NEEDLE; 1ST TIER UNIFINE PENTIPS 31 GAUGE X 5/16" NEEDLE; 1ST TIER UNIFINE PE MO | | |
| 1ST TIER UNIFINE PENTIPS PLUS 29 GAUGE X 1/2" NEEDLE; 1ST TIER UNIFINE PENTIPS PLUS 31 GAUGE X 1/4" NEEDLE; 1ST TIER UNIFINE PENTIPS PLUS 31 GAUGE X 3/16" NEEDLE; 1ST TIER UNIFINE PENTIPS PLUS 32 GAUGE X 5/32" NE MO | | |
| ADVOCATE PEN NEEDLES 29 GAUGE X 1/2"; ADVOCATE PEN NEEDLES 31 GAUGE X 3/16"; ADVOCATE PEN NEEDLES 31 GAUGE X 5/16" MO | 1 | |
| ADVOCATE SYRINGES 0.3 ML 29 X 1/2"; ADVOCATE SYRINGES 0.3 ML 30 X 5/16"; ADVOCATE SYRINGES 0.3 ML 31 X 5/16"; ADVOCATE SYRINGES 1 ML 29 X 1/2"; ADVOCATE SYRINGES 1 ML 30 X 5/16"; ADVOCATE SYRINGES 1 ML 31 X 5/16"; ADVOCATE S MO | | |
| ASSURE ID INSULIN SAFETY 0.5 ML 29 X 1/2" SYRINGE; ASSURE ID INSULIN SAFETY 1 ML 29 X 1/2" SYRINGE MO | 1 | |
| AUTOJECT 2 INJECTION DEVICE SUBCUTANEOUS INSULIN PEN MO | 1 | |
| AUTOPEN 1 TO 16 UNITS SUBCUTANEOUS MO | 1 | |
| AUTOPEN 1 TO 21 UNITS SUBCUTANEOUS MO | 1 | |
| AUTOPEN 2 TO 32 UNITS SUBCUTANEOUS MO | 1 | |
| AUTOPEN 2 TO 42 UNITS SUBCUTANEOUS MO | 1 | |
| BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" MO | 1 | |
| BD AUTOSHIELD PEN NEEDLE 29 GAUGE X 3/16"; BD AUTOSHIELD PEN NEEDLE 29 GAUGE X 5/16" MO | 1 | |
| BD ECLIPSE LUER-LOK 1 ML 30 X 1/2" SYRINGE MO | 1 | |
| BD INSULIN PEN NEEDLE UF MINI 31 GAUGE X 3/16" MO | 1 | |
| BD INSULIN PEN NEEDLE UF ORIGINAL 29 GAUGE X 1/2" MO | 1 | |
| BD INSULIN PEN NEEDLE UF SHORT 31 GAUGE X 5/16" MO | 1 | |
| BD INSULIN SYRINGE 1 ML 25 X 1"; BD INSULIN SYRINGE 1 ML 25 X 5/8"; BD INSULIN SYRINGE 1 ML 26 X 1/2"; BD INSULIN SYRINGE 1 ML 28 X 1/2" MO | 1 | |
| BD INSULIN SYRINGE HALF UNIT 0.3 ML 31 X 15/64"; BD INSULIN SYRINGE HALF UNIT 0.3 ML 31 X 5/16" MO | 1 | |
| BD INSULIN SYRINGE MICRO-FINE 0.3 ML 28; BD INSULIN SYRINGE MICRO-FINE 1 ML 28 X 1/2"; BD INSULIN SYRINGE MICRO-FINE 1/2 ML 28 X 1/2" MO | 1 | |
| BD INSULIN SYRINGE SAFETY-LOK 1 ML 29 X 1/2" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| BD INSULIN SYRINGE SLIP TIP 1 ML MO | 1 | |
| BD INSULIN SYRINGE ULT-FINE II 0.3 ML 31 X 5/16"; BD INSULIN SYRINGE ULT-FINE II 1 ML 31 X 5/16"; BD INSULIN SYRINGE ULT-FINE II 1/2 ML 31 X 5/16" MO | 1 | |
| BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 X 1/2"; BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 31 X 15/64"; BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 31 X 5/16"; BD INSULIN SYRINGE ULTRA-FINE 1 ML 29 X 1/2"; BD INSULIN SYRINGE MO | | |
| BD INTEGRA INSULIN SYRINGE 1 ML 29 X 1/2" MO | 1 | |
| BD LO-DOSE MICRO-FINE IV 0.3 ML 28 X 1/2" SYRINGE; BD LO-DOSE MICRO-FINE IV 1/2 ML 28 X 1/2" SYRINGE MO | 1 | |
| BD LO-DOSE ULTRA-FINE 0.3 ML 29 X 1/2" SYRINGE; BD LO-DOSE ULTRA-FINE 1/2 ML 29 X 1/2" SYRINGE MO | 1 | |
| BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 X 1/2"; BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 31 X 5/16"; BD SAFETYGLIDE INSULIN SYRINGE 1 ML 29 X 1/2"; BD SAFETYGLIDE INSULIN SYRINGE 1/2 ML 29 X 1/2"; BD SAFETYGLIDE I MO | | |
| BD SAFETYGLIDE SYRINGE 1 ML 27 X 5/8" MO | 1 | |
| BD ULTRA-FINE NANO PEN NEEDLES 32 GAUGE X 5/32" MO | 1 | |
| CAREFINE PEN NEEDLE 29 GAUGE X 1/2"; CAREFINE PEN NEEDLE 30 GAUGE X 5/16"; CAREFINE PEN NEEDLE 31 GAUGE X 1/4"; CAREFINE PEN NEEDLE 31 GAUGE X 5/16"; CAREFINE PEN NEEDLE 32 GAUGE X 1/4"; CAREFINE PEN NEEDLE 32 GAUGE X 3/16" MO | | |
| CLICKFINE 31 GAUGE X 1/4" NEEDLE; CLICKFINE 31 GAUGE X 5/16" NEEDLE; CLICKFINE 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| COMFORT EZ PEN NEEDLES 31 GAUGE X 1/4"; COMFORT EZ PEN NEEDLES 31 GAUGE X 3/16"; COMFORT EZ PEN NEEDLES 31 GAUGE X 5/16"; COMFORT EZ PEN NEEDLES 32 GAUGE X 1/4"; COMFORT EZ PEN NEEDLES 32 GAUGE X 3/16"; COMFORT EZ PEN N MO | | |
| COMFORT EZ SYRINGE 0.3 ML 29 X 1/2"; COMFORT EZ SYRINGE 0.3 ML 30 X 1/2"; COMFORT EZ SYRINGE 0.3 ML 30 X 5/16"; COMFORT EZ SYRINGE 0.3 ML 31 X 5/16"; COMFORT EZ SYRINGE 1 ML 28 X 1/2"; COMFORT EZ SYRINGE 1 ML 29 X 1/2"; COM MO | | |
| EASY COMFORT INSULIN SYRINGE 0.3 ML 30 X 5/16"; EASY COMFORT INSULIN SYRINGE 1 ML 30 X 1/2"; EASY COMFORT INSULIN SYRINGE 1 ML 30 X 5/16"; EASY COMFORT INSULIN SYRINGE 1/2 ML 30 X 1/2"; EASY COMFORT INSULIN SYRING MO | | |
| EASY COMFORT PEN NEEDLES 31 GAUGE X 1/4"; EASY COMFORT PEN NEEDLES 31 GAUGE X 3/16"; EASY COMFORT PEN NEEDLES 31 GAUGE X 5/16"; EASY COMFORT PEN NEEDLES 32 GAUGE X 5/32" MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| EASY TOUCH 29 GAUGE X 1/2" NEEDLE; EASY TOUCH 31 GAUGE X 1/4" NEEDLE; EASY TOUCH 31 GAUGE X 3/16" NEEDLE; EASY TOUCH 31 GAUGE X 5/16" NEEDLE; EASY TOUCH 32 GAUGE X 1/4" NEEDLE; EASY TOUCH 32 GAUGE X 3/16" NEEDLE; EASY TOUCH 32 GAUG MO | | |
| EASY TOUCH INSULIN SAFETY SYRINGE 0.5 ML 29 X 1/2"; EASY TOUCH INSULIN SAFETY SYRINGE 0.5 ML 30 X 5/16"; EASY TOUCH INSULIN SAFETY SYRINGE 1 ML 29 X 1/2"; EASY TOUCH INSULIN SAFETY SYRINGE 1 ML 30 X 1/2" MO | 1 | |
| EASY TOUCH INSULIN SYRINGE 0.3 ML 30 X 1/2"; EASY TOUCH INSULIN SYRINGE 0.3 ML 30 X 5/16"; EASY TOUCH INSULIN SYRINGE 0.3 ML 31 X 5/16"; EASY TOUCH INSULIN SYRINGE 1 ML 27 X 1/2"; EASY TOUCH INSULIN SYRINGE 1 ML 28 MO | | |
| EXEL INSULIN 0.3 ML 29 X 1/2" SYRINGE; EXEL INSULIN 1 ML 27 X 1/2" SYRINGE; EXEL INSULIN 1 ML 30 X 5/16" SYRINGE; EXEL INSULIN 1/2 ML 28 X 1/2" SYRINGE; EXEL INSULIN 1/2 ML 30 X 5/16" SYRINGE MO | 1 | |
| FREESTYLE PRECISION 1 ML 30 X 5/16" SYRINGE; FREESTYLE PRECISION 1 ML 31 X 5/16" SYRINGE; FREESTYLE PRECISION 1/2 ML 30 X 5/16" SYRINGE; FREESTYLE PRECISION 1/2 ML 31 X 5/16" SYRINGE MO | 1 | |
| HEALTHY ACCENTS UNIFINE PENTIP 29 GAUGE X 1/2" NEEDLE; HEALTHY ACCENTS UNIFINE PENTIP 31 GAUGE X 1/4" NEEDLE; HEALTHY ACCENTS UNIFINE PENTIP 31 GAUGE X 3/16" NEEDLE; HEALTHY ACCENTS UNIFINE PENTIP 31 GAUGE X 5/1 MO | | |
| HUMAPEN LUXURA HD SUBCUTANEOUS MO | 1 | |
| INCONTROL PEN NEEDLE 29 GAUGE X 1/2"; INCONTROL PEN NEEDLE 31 GAUGE X 1/4"; INCONTROL PEN NEEDLE 31 GAUGE X 3/16"; INCONTROL PEN NEEDLE 31 GAUGE X 5/16"; INCONTROL PEN NEEDLE 32 GAUGE X 5/32" MO | 1 | |
| EXEL INSULIN SYRN 27G-1/2 ML MO | 1 | |
| INSULIN SYRINGE 1 ML 28 X 1/2"; INSULIN SYRINGE 1 ML 29 X 1/2"; INSULIN SYRINGE 1 ML 30 X 5/16"; INSULIN SYRINGE 1/2 ML 28 X 1/2"; INSULIN SYRINGE 1/2 ML 29 X 1/2"; INSULIN SYRINGE 1/2 ML 30 X 5/16" MO | 1 | |
| INSULIN SYRINGE MICROFINE 0.3 ML 28 X 1/2"; INSULIN SYRINGE MICROFINE 1 ML 27 X 5/8"; INSULIN SYRINGE MICROFINE 1/2 ML 28 X 1/2" MO | 1 | |
| BD LUER-LOK SYRINGE 1 ML MO | 1 | |
| INSULIN SYRINGE ULTRAFINE 1/2 ML 29 X 1/2" MO | 1 | |
| BD INSULIN SYR 1 ML 25GX5/8"; BD INSULIN SYR 1 ML 28GX1/2"; EQL INSULIN 1 ML SYRINGE; INSULIN 1 ML SYRINGE; INSULIN 1/2 ML SYRINGE; INSULIN 3/10 ML SYRINGE; INSULIN SYRN 0.3 ML 30GX1/2"; INSULIN SYRN 0.3 ML 31GX MO | | |
| INSULIN SYRINGE U100 1 ML MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| INSUPEN 29 GAUGE X 1/2" NEEDLE; INSUPEN 30 GAUGE X 5/16" NEEDLE; INSUPEN 31 GAUGE X 1/4" NEEDLE; INSUPEN 31 GAUGE X 5/16" NEEDLE; INSUPEN 32 GAUGE X 1/4" NEEDLE; INSUPEN 32 GAUGE X 5/16" NEEDLE; INSUPEN 32 GAUGE X 5/32" NEEDLE; INSUPE MO | | |
| LITE TOUCH INSULIN PEN NEEDLES 29 GAUGE X 1/2"; LITE TOUCH INSULIN PEN NEEDLES 31 GAUGE X 1/4"; LITE TOUCH INSULIN PEN NEEDLES 31 GAUGE X 3/16"; LITE TOUCH INSULIN PEN NEEDLES 31 GAUGE X 5/16" MO | 1 | |
| LITE TOUCH INSULIN SYRINGE 0.3 ML 29 X 1/2"; LITE TOUCH INSULIN SYRINGE 0.3 ML 30 X 5/16"; LITE TOUCH INSULIN SYRINGE 0.3 ML 31 X 5/16"; LITE TOUCH INSULIN SYRINGE 1 ML 28; LITE TOUCH INSULIN SYRINGE 1 ML 29; LITE T MO | | |
| MAGELLAN INSULIN SAFETY SYRINGE 0.3 ML 29 X 1/2", 0.5 ML 29 X 1/2", 1 ML 29 X 1/2", 1 ML 30 X 5/16" MO | 1 | |
| MAGELLAN SYRINGE 0.3 ML 30 X 5/16", 0.5 ML 30 X 5/16" MO | 1 | |
| MAXI-COMFORT INSULIN SYRINGE 1 ML 28 X 1/2"; MAXI-COMFORT INSULIN SYRINGE 1/2 ML 28 X 1/2" MO | 1 | |
| MEDI-JECTOR VISION MO | 1 | |
| MINI ULTRA-THIN II 31 GAUGE X 3/16" NEEDLE MO | 1 | |
| MONOJECT INSULIN SAFETY SYRINGE 0.3 ML 0.3 ML, 0.3 ML 30 X 5/16", 1/2 ML 29 X 1/2", 1/2 ML 30 X 5/16"; MONOJECT INSULIN SAFETY SYRINGE 0.3 ML 29 X 1/2"; MONOJECT INSULIN SAFETY SYRINGE 29 X 1/2" MO | 1 | |
| MONOJECT INSULIN SYRINGE 0.3 ML 29 X 1/2"; MONOJECT INSULIN SYRINGE 0.3 ML 30 X 5/16"; MONOJECT INSULIN SYRINGE 0.3 ML 31 X 5/16"; MONOJECT INSULIN SYRINGE 1 ML; MONOJECT INSULIN SYRINGE 1 ML 25 X 5/8"; MONOJECT INSUL MO | | |
| MONOJECT SYRINGE 1/2 ML 28 MO | 1 | |
| MONOJECT ULTRA COMFORT INSULIN 1/2 ML 28 SYRINGE MO | 1 | |
| NOVOFINE 30 30 GAUGE X 1/3" NEEDLE MO | 1 | |
| NOVOFINE 32 32 GAUGE X 1/4" NEEDLE MO | 1 | |
| NOVOFINE AUTOCOVER 30 GAUGE X 1/3" NEEDLE MO | 1 | |
| NOVOFINE PLUS 32 GAUGE X 1/6" NEEDLE MO | 1 | |
| NOVOPEN 3 INSULIN DEVICE MO | 1 | |
| NOVOPEN 3 PENMATE DEVICE MO | 1 | |
| NOVOPEN ECHO SUBCUTANEOUS MO | 1 | |
| NOVOPEN JR INSULIN DEVICE MO | 1 | |
| NOVOTWIST 30 GAUGE X 1/3" NEEDLE; NOVOTWIST 32 X 1/5" NEEDLE MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| KROGER PEN NEEDLES 29G; PEN NEEDLE 29 29, 29 GAUGE 29 GAUGE, 30 GAUGE X 5/16", 31 GAUGE 31 GAUGE, 31 GAUGE 31 GAUGE, 31 GAUGE 31 GAUGE, 32 GAUGE 32 GAUGE; PEN NEEDLE 29 GAUGE X 1/2"; PEN NEEDLE 31 GAUGE X 1/4"; PEN NEEDLE 31 GAUGE MO | | |
| COMFORT POINT PEN NDL 31GX1/6"; LEADER PEN NEEDLES 12MM 29G; LEADER PEN NEEDLES 31G; PEN NEEDLE, DIABETIC 31; PEN NEEDLES 6MM 31G MO | 1 | |
| PENTIPS 31 GAUGE X 3/16" NEEDLE; PENTIPS 31 GAUGE X 5/16" NEEDLE; PENTIPS 32 GAUGE X 5/32" NEEDLE MO | 1 | |
| PRODIGY INSULIN SYRINGE 0.3 ML 31 X 5/16"; PRODIGY INSULIN SYRINGE 1 ML 28 X 1/2"; PRODIGY INSULIN SYRINGE 1/2 ML 31 X 5/16" MO | 1 | |
| RELION NEEDLES 31 GAUGE X 1/4" MO | 1 | |
| RELION PEN NEEDLES 32 GAUGE X 5/32" MO | 1 | |
| SAFESNAP INSULIN SYRINGE 0.3 ML 30 X 5/16"; SAFESNAP INSULIN SYRINGE 0.5 ML 29 X 1/2"; SAFESNAP INSULIN SYRINGE 0.5 ML 30 X 5/16"; SAFESNAP INSULIN SYRINGE 1 ML 28 X 1/2"; SAFESNAP INSULIN SYRINGE 1 ML 29 X 1/2" MO | 1 | |
| SURE COMFORT INSULIN SYRINGE U-100 1/2 ML 29 X 1/2" MO | 1 | |
| SURE COMFORT INSULIN SYRINGE 0.3 ML 29 X 1/2"; SURE COMFORT INSULIN SYRINGE 0.3 ML 30 X 1/2"; SURE COMFORT INSULIN SYRINGE 0.3 ML 30 X 5/16"; SURE COMFORT INSULIN SYRINGE 0.3 ML 31 X 5/16"; SURE COMFORT INSULIN SY MO | | |
| SURE COMFORT PEN NEEDLE 29 GAUGE X 1/2"; SURE COMFORT PEN NEEDLE 30 GAUGE X 5/16"; SURE COMFORT PEN NEEDLE 31 GAUGE X 3/16"; SURE COMFORT PEN NEEDLE 31 GAUGE X 5/16"; SURE COMFORT PEN NEEDLE 32 GAUGE X 1/4"; SURE COMFO MO | | |
| SURE-FINE PEN NEEDLES 29 GAUGE X 1/2"; SURE-FINE PEN NEEDLES 31 GAUGE X 3/16"; SURE-FINE PEN NEEDLES 31 GAUGE X 5/16" MO | 1 | |
| SURE-JECT INSULIN SYRINGE 0.3 ML 29 X 1/2"; SURE-JECT INSULIN SYRINGE 0.3 ML 30 X 5/16"; SURE-JECT INSULIN SYRINGE 0.3 ML 31 X 5/16"; SURE-JECT INSULIN SYRINGE 1 ML 28 X 1/2"; SURE-JECT INSULIN SYRINGE 1 ML 29 X 1/2" MO | | |
| TERUMO INSULIN SYRINGE 0.5CC/27G 1/2 ML 27 X 1/2" MO | 1 | |
| TERUMO INSULIN SYRINGE 0.3 ML 30 X 3/8"; TERUMO INSULIN SYRINGE 1 ML 27 X 1/2"; TERUMO INSULIN SYRINGE 1 ML 28 X 1/2"; TERUMO INSULIN SYRINGE 1 ML 29 X 1/2"; TERUMO INSULIN SYRINGE 1/2 ML 28 X 1/2"; TERUMO INSULIN SYRIN MO | | |
| THINPRO INSULIN SYRINGE 0.3 ML 29 X 1/2"; THINPRO INSULIN SYRINGE 0.3 ML 30 X 3/8"; THINPRO INSULIN SYRINGE 0.3 ML 31 X 3/8"; THINPRO INSULIN SYRINGE 0.5 ML 31 X 3/8"; THINPRO INSULIN SYRINGE 1 ML 28 X 1/2"; THINPRO IN MO | | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| TOPCARE CLICKFINE 31 GAUGE X 1/4" NEEDLE; TOPCARE CLICKFINE 31 GAUGE X 5/16" NEEDLE MO | 1 | |
| TOPCARE ULTRA COMFORT 0.3 ML 29 X 1/2" SYRINGE; TOPCARE ULTRA COMFORT 0.3 ML 30 X 5/16" SYRINGE; TOPCARE ULTRA COMFORT 0.3 ML 31 X 5/16" SYRINGE; TOPCARE ULTRA COMFORT 1 ML 29 X 1/2" SYRINGE; TOPCARE ULTRA COMFORT 1 ML 3 MO | | |
| TRUEPLUS INSULIN 0.3 ML 29 X 1/2" SYRINGE; TRUEPLUS INSULIN 0.3 ML 30 X 5/16" SYRINGE; TRUEPLUS INSULIN 0.3 ML 31 X 5/16" SYRINGE; TRUEPLUS INSULIN 1 ML 28 X 1/2" SYRINGE; TRUEPLUS INSULIN 1 ML 29 X 1/2" SYRINGE; TRUEPLUS INS MO | | |
| ULTICARE 0.3 ML 29 X 1/2" SYRINGE; ULTICARE 0.3 ML 30 X 1/2" SYRINGE; ULTICARE 0.3 ML 30 X 5/16" SYRINGE; ULTICARE 0.3 ML 31 X 5/16" SYRINGE; ULTICARE 1 ML 29 X 1/2" SYRINGE; ULTICARE 1 ML 30 X 1/2" SYRINGE; ULTICARE 1 ML 30 X 5/16" MO | | |
| ULTILET INSULIN SYRINGE 0.3 ML 29; ULTILET INSULIN SYRINGE 0.3 ML 29 X 1/2"; ULTILET INSULIN SYRINGE 0.3 ML 30 X 5/16"; ULTILET INSULIN SYRINGE 0.3 ML 31 X 5/16"; ULTILET INSULIN SYRINGE 1 ML 29; ULTILET INSULIN SYRING MO | | |
| ULTILET PEN NEEDLE 29 GAUGE; ULTILET PEN NEEDLE 32 GAUGE X 5/32" MO | 1 | |
| ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 29 X 1/2"; ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 30 X 5/16"; ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 31 X 5/16" MO | 1 | |
| ULTRA COMFORT INSULIN SYRINGE; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 X 1/2"; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 30; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 30 X 5/16"; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 31 X 5 MO | | |
| ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 X 5/16"; ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 31 X 5/16"; ULTRA-THIN II (SHORT) INSULIN SYRINGE 1 ML 30 X 5/16"; ULTRA-THIN II (SHORT) INSULIN SYRINGE 1 ML MO | | |
| ULTRA-THIN II (SHORT) PEN NDL 31 GAUGE X 5/16" NEEDLE MO | 1 | |
| ULTRA-THIN II INSULIN PEN NEEDLES 29 GAUGE X 1/2" MO | 1 | |
| ULTRA-THIN II INSULIN SYRINGE 0.3 ML 29 X 1/2"; ULTRA-THIN II INSULIN SYRINGE 1 ML 29 X 1/2"; ULTRA-THIN II INSULIN SYRINGE 1/2 ML 29 X 1/2" MO | 1 | |
| UNIFINE PENTIPS 29 GAUGE NEEDLE; UNIFINE PENTIPS 29 GAUGE X 1/2" NEEDLE; UNIFINE PENTIPS 29 GAUGE X 5/16" NEEDLE; UNIFINE PENTIPS 30 GAUGE X 5/16" NEEDLE; UNIFINE PENTIPS 31 GAUGE X 1/4" NEEDLE; UNIFINE PENTIPS 31 GAUGE X 3/16 MO | | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| UNIFINE PENTIPS PLUS 29 GAUGE X 1/2" NEEDLE; UNIFINE PENTIPS PLUS 31 GAUGE X 1/4" NEEDLE; UNIFINE PENTIPS PLUS 31 GAUGE X 3/16" NEEDLE; UNIFINE PENTIPS PLUS 31 GAUGE X 5/16" NEEDLE; UNIFINE PENTIPS PLUS 32 GAUGE X 5/32" N MO | | |
| VANISHPOINT SYRINGE 1 ML 29 X 1/2"; VANISHPOINT SYRINGE 1/2 ML 30 X 1/2" MO | 1 | |
| VGO 20 DEVICE MO | 4 | |
| VGO 30 DEVICE MO | 4 | |
| VGO 40 DEVICE MO | 4 | |
| DIAGNOSTIC AGENTS | | |
| enlon 10 mg/ml injection solution MO | 1 | |
| ELECTROLYTIC, CALORIC, AND WATER BALANCE | | |
| acetic acid 0.25% irrig soln; acetic acid 2% ear solution MO | 2 | |
| amiloride hcl 5 mg tablet MO | 3 | |
| amiloride hcl-hctz 5-50 mg tab MO | 2 | |
| amino acids 15 % intravenous solution MO | 4 | B vs D |
| AMINOSYN 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN 7 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN 8.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 15 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 7 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 8.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN II 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN M 3.5 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-HBC 7% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-PF 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-PF 7 % (SULFITE-FREE) INTRAVENOUS SOLUTION MO | 4 | B vs D |
| AMINOSYN-RF 5.2 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| ammonium chloride 5 meq/ml MO | 1 | |
| AMMONUL 10 %-10 % INTRAVENOUS SOLUTION MO | 5 | |
| bumetanide 0.5 mg, 1 mg, 2 mg tablet; bumetanide 2.5 mg/10 ml vial MO | 2 | |
| BUPHENYL 500 MG TABLET SP | 5 | |
| calcium acetate 667 mg gelcap; calcium acetate 667 mg tablet MO | 4 | |
| calcium chloride 10% syringe; calcium chloride 10% vial MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>calcium gluconate 10% vial</i> ^{MO} | 1 | |
| CARBAGLU 200 MG DISPERSIBLE TABLET ^{SP} | 5 | PA |
| <i>chlorothiazide 250 mg, 500 mg tablet</i> ^{MO} | 2 | |
| <i>chlorothiazide sod 500 mg vial</i> ^{MO} | 2 | |
| <i>chlorthalidone 25 mg, 50 mg tablet</i> ^{MO} | 2 | |
| CLINIMIX 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 5 % IN 25 % DEXTROSE SULFITE-FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 2.75 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 4.25 % IN 20 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 4.25 % IN 25 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX 5 % IN 20 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 2.75 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 2.75 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 4.25 % IN 25 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 5 % IN 20 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| CLINIMIX E 5 % IN 25 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>clinisol sf 15 % intravenous solution</i> ^{MO} | 4 | B vs D |
| <i>probenecid-colchicine tabs</i> ^{MO} | 3 | |
| <i>constulose 10 gram/15 ml oral solution</i> ^{MO} | 2 | |
| <i>dextrose 10%-0.45% nacl iv sol</i> ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| dextrose 2.5%-0.45% nacl iv MO | 2 | |
| dextrose 5%-0.9% nacl iv soln MO | 2 | |
| dextrose 5%-0.45% nacl iv soln MO | 2 | |
| dextrose 10%-0.2% nacl iv soln MO | 2 | |
| dextrose 10%-water iv solution MO | 2 | |
| dextrose 20%-water iv soln MO | 2 | |
| dextrose 25%-water syringe MO | 2 | |
| dextrose 30%-water iv soln MO | 2 | |
| dextrose 40%-water iv soln MO | 2 | |
| dextrose 5%-water iv soln MO | 2 | |
| dextrose 5%-lr iv solution MO | 2 | |
| dextrose 5%-0.2% nacl iv soln MO | 2 | |
| dextrose 5%-0.3% nacl iv soln MO | 2 | |
| dextrose 50%-water syringe; dextrose 50%-water vial MO | 2 | |
| dextrose 70%-water iv soln MO | 2 | |
| DIURIL 250 MG/5 ML ORAL SUSPENSION MO | 4 | |
| DYRENIUM 100 MG, 50 MG CAPSULE MO | 4 | |
| dextrose 5%-electrolyte 48 MO | 2 | |
| enulose 10 gram/15 ml oral solution MO | 2 | |
| ethacrynate sodium 50 mg vial MO | 4 | |
| FREAMINE HBC 6.9 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| FREAMINE III 10 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| furosemide 10 mg/ml syringe; furosemide 10 mg/ml, 10 mg/ml, 40 mg/5 ml soln; furosemide 10 mg/ml, 10 mg/ml, 40 mg/5 ml solution; furosemide 20 mg, 40 mg, 80 mg tablet; furosemide 40 mg/4 ml vial MO | 1 | |
| generlac 10 gram/15 ml oral solution MO | 2 | |
| glycine 1.5% irrigation MO | 4 | |
| GLYCINE UROLOGIC 1.5 % IRRIGATION SOLUTION MO | 4 | |
| GLYCOPHOS 1 MMOL/ML INTRAVENOUS SOLUTION MO | 1 | |
| HEPATAMINE 8% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| hydrochlorothiazide 12.5 mg cp; hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tab; hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tb MO | 1 | |
| HYPERLYTE CR 25 MEQ-20 MEQ-5 MEQ/20 ML INTRAVENOUS SOLUTION MO | 4 | |
| indapamide 1.25 mg, 2.5 mg tablet MO | 1 | |
| INTRALIPID 20 %, 30 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| IONOSOL-B IN D5W INTRAVENOUS SOLUTION MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| IONOSOL-MB IN D5W INTRAVENOUS SOLUTION ^{MO} | 4 | |
| ISOLYTE S PH 7.4 INTRAVENOUS SOLUTION ^{MO} | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS SOLUTION ^{MO} | 4 | |
| ISOLYTE-S INTRAVENOUS SOLUTION ^{MO} | 4 | |
| <i>k-sol 20 meq/15 ml, 40 meq/15 ml oral liquid</i> ^{MO} | 1 | |
| K-TAB 10 MEQ, 20 MEQ, 8 MEQ TABLET,EXTENDED RELEASE ^{MO} | 4 | |
| KABIVEN 3.31 %-9.8 %-3.9 % INTRAVENOUS EMULSION ^{MO} | 4 | B vs D |
| <i>kionex 15 gram/60 ml oral suspension</i> ^{MO} | 3 | |
| <i>kionex oral powder</i> ^{MO} | 4 | |
| KLOR-CON 10 MEQ TABLET,EXTENDED RELEASE ^{MO} | 2 | |
| KLOR-CON 8 MEQ TABLET,EXTENDED RELEASE ^{MO} | 2 | |
| <i>klor-con m10 meq tablet,extended release</i> ^{MO} | 2 | |
| KLOR-CON M15 MEQ TABLET,EXTENDED RELEASE ^{MO} | 2 | |
| <i>klor-con m20 meq tablet,extended release</i> ^{MO} | 2 | |
| <i>klor-con sprinkle 10 meq, 8 meq capsule,extended release</i> ^{MO} | 2 | |
| KRISTALOSE 10 GRAM, 20 GRAM ORAL PACKET ^{MO} | 4 | |
| <i>lactated ringers injection; lactated ringers irrigation</i> ^{MO} | 2 | |
| <i>lactulose 10 gm/15 ml solution; lactulose 20 gm/30 ml solution</i> ^{MO} | 2 | |
| LIPOSYN II 20 % INTRAVENOUS EMULSION ^{MO} | 4 | B vs D |
| LIPOSYN III 10 %, 20 % INTRAVENOUS EMULSION ^{MO} | 4 | B vs D |
| LITHOSTAT 250 MG TABLET ^{MO} | 4 | |
| <i>mannitol 10% iv solution</i> ^{MO} | 2 | |
| <i>mannitol 20% iv solution</i> ^{MO} | 2 | |
| <i>mannitol 25% vial</i> ^{MO} | 2 | |
| <i>mannitol 5% iv solution</i> ^{MO} | 2 | |
| <i>methyclothiazide 5 mg tablet</i> ^{MO} | 2 | |
| <i>metolazone 10 mg, 2.5 mg, 5 mg tablet</i> ^{MO} | 2 | |
| NEPHRAMINE 5.4 % INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| NEUT 4 % INTRAVENOUS SOLUTION ^{MO} | 4 | |
| NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS SOLUTION ^{MO} | 4 | |
| NORMOSOL-R INTRAVENOUS SOLUTION ^{MO} | 4 | |
| NORMOSOL-R IN 5 % DEXTROSE INTRAVENOUS SOLUTION ^{MO} | 4 | |
| NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION ^{MO} | 4 | |
| NUTRILIPID 20 % INTRAVENOUS EMULSION ^{MO} | 4 | B vs D |
| OSMITROL 10 % INTRAVENOUS SOLUTION ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| OSMITROL 15 % INTRAVENOUS SOLUTION MO | 4 | |
| OSMITROL 20 % INTRAVENOUS SOLUTION MO | 4 | |
| OSMITROL 5 % INTRAVENOUS SOLUTION MO | 4 | |
| PERIKABIVEN 2.36 %-6.8 %-3.5 % INTRAVENOUS EMULSION MO | 4 | B vs D |
| PHOSLYRA 667 MG (169 MG CALCIUM)/5 ML ORAL SOLUTION MO | 3 | |
| PHYSIOLYTE 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L IRRIGATION SOLUTION MO | 1 | |
| PHYSIOSOL IRRIGATION 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L SOLUTION MO | 1 | |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION MO | 4 | |
| PLASMA-LYTE A INTRAVENOUS SOLUTION MO | 4 | |
| PLASMA-LYTE-56 IN 5 % DEXTROSE INTRAVENOUS SOLUTION MO | 4 | |
| potassium acet 2 meq/ml, 4 meq/ml vial; potassium acet 40 meq/20 ml vial MO | 1 | |
| d5%-1/2ns-kcl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.45% nacl MO | 2 | |
| potassium cl 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml sol; potassium cl 10% (40 meq/30 ml; potassium cl 20% (20 meq/15 ml, 40 meq/15 ml; potassium cl 40 meq/20 ml conc; potassiu MO | | |
| kcl 20 meq-ns 1,000 ml iv soln; kcl 40 meq-ns 1,000 ml iv soln MO | 2 | |
| d5w-kcl 20 meq/l, 30 meq/l, 40 meq/l iv solution; kcl 20 meq in d5w solution; kcl 40 meq in d5w solution MO | 2 | |
| kcl 20 meq in d5w-lact ringer; kcl 40 meq in d5w-lact ringer MO | 2 | |
| potassium cl 20 meq-0.45% nacl MO | 2 | |
| d5%-1/4ns-kcl 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.2% nacl MO | 2 | |
| kcl 20 meq in d5w-0.3% nacl MO | 2 | |
| kcl 20 meq in d5w-ns; kcl 40 meq in d5w-nacl 0.9% MO | 2 | |
| potassium citrate er 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) tb; potassium citrate er 10 meq tb; potassium citrate er 5 meq tab MO | 3 | |
| potassium phosp 45 mmol/15 ml MO | 1 | |
| PREMASOL 10 % INTRAVENOUS SOLUTION MO | 1 | B vs D |
| PREMASOL 6 % INTRAVENOUS SOLUTION MO | 1 | B vs D |
| probenecid 500 mg tablet MO | 3 | |
| PROCALAMINE 3% INTRAVENOUS SOLUTION MO | 4 | B vs D |
| PROSOL 20 % INTRAVENOUS SOLUTION MO | 4 | B vs D |
| RENACIDIN 6.602 G-0.198 G/100 ML IRRIGATION SOLUTION MO | 4 | |
| REVELA 0.8 GRAM ORAL POWDER PACKET; REVELA 800 MG TABLET MO | 4 | PA,QL (540 per 30 days) |
| REVELA 2.4 GRAM ORAL POWDER PACKET MO | 4 | PA,QL (180 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| RESECTISOL 5 % URETHRAL SOLUTION ^{MO} | 4 | |
| <i>ringer's iv solution; ringers irrigation solution</i> ^{MO} | 1 | |
| SAMSCA 15 MG, 30 MG TABLET ^{SP} | 5 | QL (60 per 30 days) |
| <i>sevelamer carbonate 800 mg tab</i> ^{MO} | 3 | QL (540 per 30 days) |
| <i>sodium acetate 2 meq/ml, 4 meq/ml vial; sodium acetate 200 meq/100 ml</i> ^{MO} | 1 | |
| <i>sodium bicarb 4.2% abbjct; sodium bicarb 7.5% abboject; sodium bicarb 8.4% abboject; sodium bicarb 8.4% vial</i> ^{MO} | 2 | |
| <i>sodium bicarb 4.2% vial</i> ^{MO} | 4 | |
| <i>sodium chloride 0.9% irrig.; sodium chloride 2.5 meq/ml, 4 meq/ml vl; sodium cl 2.5 meq/ml, 4 meq/ml vial</i> ^{MO} | 2 | |
| <i>sodium chloride 10% vial; sodium chloride 3% vial</i> ^{MO} | 2 | B vs D |
| <i>saline 0.45% soln-excel con; sodium chloride 0.45% soln</i> ^{MO} | 2 | |
| <i>sodium chloride 0.9% solution; sodium chloride 0.9% solution; sodium chloride 0.9% vial</i> ^{MO} | 2 | |
| <i>sodium chloride 3% iv soln</i> ^{MO} | 2 | |
| <i>sodium chloride 5% iv soln</i> ^{MO} | 2 | |
| SODIUM EDECRIN 50 MG INTRAVENOUS SOLUTION ^{MO} | 4 | |
| <i>sodium lactate 5 meq/ml vial</i> ^{MO} | 1 | |
| <i>sodium phenylbutyrate powder</i> ^{SP} | 5 | |
| <i>sodium phosphate 3mm/ml vial</i> ^{MO} | 1 | |
| <i>sodium polystyrene sulfonate (sorbitol free) 15 gram/60 ml oral susp</i> ^{MO} | 3 | |
| <i>sps 15 gm/60 ml suspension</i> ^{MO} | 3 | |
| <i>sps 30 gm/120 ml enema; sps 50 gm/200 ml enema</i> ^{MO} | 4 | |
| <i>sorbitol-mannitol irrig</i> ^{MO} | 1 | |
| SPS 15 GRAM/60 ML ORAL SUSPENSION ^{MO} | 3 | |
| SPS 30 GRAM/120 ML ENEMA ^{MO} | 4 | |
| <i>toremide 10 mg, 100 mg, 20 mg, 5 mg tablet; toremide 20 mg/2 ml vial; toremide 50 mg/5 ml vial</i> ^{MO} | 2 | |
| TPN ELECTROLYTES 35 MEQ-20 MEQ-5 MEQ/20 ML INTRAVENOUS SOLUTION ^{MO} | 4 | |
| TRAVASOL 10 % INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| <i>triamterene-hctz 37.5-25 mg cp; triamterene-hctz 37.5-25 mg, 75-50 mg tab; triamterene-hctz 37.5-25 mg, 75-50 mg tb</i> ^{MO} | 1 | |
| <i>triamterene-hctz 50-25 mg cap</i> ^{MO} | 2 | |
| TROPHAMINE 10 % INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |
| TROPHAMINE 6% INTRAVENOUS SOLUTION ^{MO} | 4 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| VOLUVEN 6 % INTRAVENOUS SOLUTION ^{MO} | 4 | |
| sterile water for irrigation ^{MO} | 2 | |
| ENZYMES | | |
| ADAGEN 250 UNIT/ML INTRAMUSCULAR SOLUTION ^{MO} | 5 | |
| ELELYSO 200 UNIT INTRAVENOUS SOLUTION ^{MO} | 5 | PA,QL (350 per 30 days) |
| ELITEK 1.5 MG, 7.5 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| FABRAZYME 35 MG, 5 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| LUMIZYME 50 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| MYOZYME 50 MG INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| NAGLAZYME 5 MG/5 ML INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| SUCRAID 8,500 UNIT/ML ORAL SOLUTION ^{SP} | 5 | |
| VPRIV 400 UNIT INTRAVENOUS SOLUTION ^{MO} | 5 | PA |
| EYE, EAR, NOSE AND THROAT (EENT) PREPS. | | |
| acetazolamide 125 mg, 250 mg tablet ^{MO} | 2 | |
| acetazolamide er 500 mg cap ^{MO} | 4 | |
| acetazolamide sod 500 mg vial ^{MO} | 2 | |
| acetic acid 0.25% irrig soln; acetic acid 2% ear solution ^{MO} | 2 | |
| acetic acid-aluminum drops ^{MO} | 3 | |
| ak-poly-bac 500 unit-10,000 unit/gram eye ointment ^{MO} | 2 | |
| akorn balanced salt soln ^{MO} | 1 | |
| AKTEN (PF) 3.5 % EYE GEL ^{MO} | 4 | |
| ALOMIDE 0.1 % EYE DROPS ^{MO} | 4 | |
| ALPHAGAN P 0.1 %, 0.15 % EYE DROPS ^{MO} | 3 | |
| ALREX 0.2 % EYE DROPS,SUSPENSION ^{MO} | 4 | |
| apraclonidine hcl 0.5% drops ^{MO} | 4 | |
| atropine 0.05 mg/ml, 0.1 mg/ml syringe; atropine 0.4 mg/ml, 1 mg/ml vial; atropine 1% eye ointment ^{MO} | 2 | |
| AZASITE 1 % EYE DROPS ^{MO} | 3 | |
| azelastine 0.1% (137 mcg) spry ^{MO} | 3 | QL (30 per 25 days) |
| azelastine 0.15% nasal spray ^{MO} | 4 | QL (30 per 25 days) |
| azelastine hcl 0.05% drops ^{MO} | 3 | |
| AZOPT 1 % EYE DROPS,SUSPENSION ^{MO} | 3 | |
| bacitracin 500 unit/gm ophth ^{MO} | 3 | |
| bacitracin-polymyxin eye oint ^{MO} | 2 | |
| balanced salt intraocular solution ^{MO} | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| BEPREVE 1.5 % EYE DROPS MO | 4 | |
| BESIVANCE 0.6 % EYE DROPS,SUSPENSION MO | 3 | |
| BETADINE OPHTHALMIC PREP 5 % SOLUTION MO | 4 | |
| <i>betaxolol hcl 0.5% eye drop</i> MO | 3 | |
| BLEPH-10 10 % EYE DROPS MO | 4 | |
| BLEPHAMIDE 10 %-0.2 % EYE DROPS,SUSPENSION MO | 4 | |
| BLEPHAMIDE S.O.P. 10 %-0.2 % EYE OINTMENT MO | 2 | |
| <i>brimonidine 0.2% eye drop; brimonidine tartrate 0.15% drp</i> MO | 3 | |
| BSS PLUS INTRAOCULAR SOLUTION MO | 4 | |
| <i>carteolol hcl 1% eye drops</i> MO | 2 | |
| <i>chlorhexidine 0.12% rinse</i> MO | 1 | |
| CILOXAN 0.3 % EYE OINTMENT MO | 4 | |
| CIPRODEX 0.3 %-0.1 % EAR DROPS,SUSPENSION MO | 4 | |
| <i>ciprofloxacin 0.3% eye drop; ciprofloxacin hcl 100 mg, 250 mg, 500 mg, 750 mg tab</i> MO | 1 | |
| COLY-MYCIN S 3.3 MG-3 MG-10 MG-0.5 MG/ML EAR DROPS,SUSPENSION MO | 4 | |
| COMBIGAN 0.2 %-0.5 % EYE DROPS MO | 3 | |
| CORTISPORIN-TC 3.3 MG-3 MG-10 MG-0.5 MG/ML EAR DROPS,SUSPENSION MO | 4 | |
| <i>cyclopentolate 1% eye drops; cyclopentolate hcl 2% drops</i> MO | 2 | |
| CYSTARAN 0.44 % EYE DROPS SP | 5 | PA,QL (60 per 28 days) |
| <i>dexamethasone 0.1% eye drop; dexamethasone 10 mg/ml, 4 mg/ml vial</i> MO | 2 | |
| <i>diclofenac 0.1% eye drops; diclofenac sod ec 25 mg, 50 mg, 75 mg tab; diclofenac sod er 100 mg tab</i> MO | 2 | |
| <i>dorzolamide hcl 2% eye drops</i> MO | 2 | QL (10 per 30 days) |
| <i>dorzolamide-timolol eye drops</i> MO | 2 | QL (10 per 30 days) |
| <i>doxycycline hyclate 100 mg, 20 mg tab; doxycycline hyclate 100 mg, 50 mg cap</i> MO | 3 | |
| DUREZOL 0.05 % EYE DROPS MO | 3 | |
| DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY MO | 3 | QL (23 per 28 days) |
| EMADINE 0.05 % EYE DROPS MO | 4 | |
| <i>epinastine hcl 0.05% eye drops</i> MO | 3 | |
| <i>erythromycin 0.5% eye ointment</i> MO | 2 | |
| <i>flunisolide 0.025% spray</i> MO | 3 | QL (50 per 30 days) |
| <i>fluorometholone 0.1% drops</i> MO | 3 | |
| <i>flurbiprofen 0.03% eye drop</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| fluticasone prop 50 mcg spray ^{MO} | 2 | QL (16 per 30 days) |
| garamycin 0.3 % eye drops; garamycin 3 mg/gm eye ointment ^{MO} | 3 | |
| gatifloxacin 0.5% eye drops ^{MO} | 4 | QL (2.5 per 25 days) |
| gentak 0.3 % (3 mg/gram) eye ointment ^{MO} | 2 | |
| gentamicin 0.1% cream; gentamicin 0.1% ointment; gentamicin 0.3% eye drops; gentamicin 0.3% eye ointment ^{MO} | 2 | |
| hydrocortison-acetic acid soln ^{MO} | 4 | |
| ILEVRO 0.3 % EYE DROPS,SUSPENSION ^{MO} | 3 | |
| IOPIDINE 1 % EYE DROPS IN A DROPPERETTE ^{MO} | 4 | |
| ipratropium 0.03% spray ^{MO} | 2 | QL (30 per 30 days) |
| ipratropium 0.06% spray ^{MO} | 2 | QL (45 per 30 days) |
| ISOPTO CARPINE 1 %, 2 %, 4 % EYE DROPS ^{MO} | 4 | |
| ketorolac 0.4% ophth solution; ketorolac 0.5% ophth solution ^{MO} | 2 | |
| LACRISERT 5 MG EYE INSERTS ^{MO} | 4 | |
| latanoprost 0.005% eye drops ^{MO} | 2 | QL (2.5 per 25 days) |
| levobunolol 0.25% eye drops; levobunolol 0.5% eye drops ^{MO} | 2 | |
| levofloxacin 0.5% eye drops; levofloxacin 250 mg, 500 mg, 750 mg tablet ^{MO} | 2 | |
| lidocaine 2% viscous soln; lidocaine hcl 1% vial; lidocaine hcl 2% jelly; lidocaine hcl 2% vial; lidocaine hcl 4% solution ^{MO} | 2 | |
| lidocaine viscous 2 % mucosal solution ^{MO} | 2 | |
| LUMIGAN 0.01 % EYE DROPS ^{MO} | 3 | QL (2.5 per 25 days) |
| MAXIDEX 0.1 % EYE DROPS,SUSPENSION ^{MO} | 4 | |
| methazolamide 25 mg, 50 mg tablet ^{MO} | 4 | |
| metipranolol 0.3% eye drops ^{MO} | 2 | |
| MIOCHOL-E 1:100 (20 MG/2 ML) INTRAOCULAR KIT ^{MO} | 4 | |
| MIOSTAT 0.01 % INTRAOCULAR SOLUTION ^{MO} | 4 | |
| naphazoline 0.1% eye drops ^{MO} | 1 | |
| NASONEX 50 MCG/ACTUATION SPRAY ^{MO} | 3 | QL (34 per 30 days) |
| NATACYN 5 % EYE DROPS,SUSPENSION ^{MO} | 4 | |
| neo-polycin 3.5 mg-400 unit-10,000 unit/g eye ointment ^{MO} | 2 | |
| neo-polycin hc 3.5 mg-400-10,000 unit/g-1 % eye ointment ^{MO} | 3 | |
| neo-bacit-poly-hc eye ointment ^{MO} | 3 | |
| neomyc-bacit-polymix eye oint ^{MO} | 2 | |
| neomyc-polym-dexamet eye ointm; neomyc-polym-dexameth eye drop ^{MO} | 2 | |
| neomyc-polym-gramicid eye drop ^{MO} | 2 | |
| neomycin-poly-hc eye drops ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| neomycin-polymyxin-hc ear soln; neomycin-polymyxin-hc ear susp MO | 2 | |
| neosporin (neo-polym-gramicid) 1.75mg-10,000 unit-0.025mg/ml eye drops MO | 2 | |
| ofloxacin 0.3% ear drops; ofloxacin 0.3% eye drops; ofloxacin 200 mg, 300 mg, 400 mg tablet MO | 2 | |
| olopatadine 665 mcg nasal spry MO | 4 | QL (31 per 30 days) |
| OMNARIS 50 MCG NASAL SPRAY MO | 3 | QL (13 per 30 days) |
| paroex oral rinse 0.12 % mouthwash MO | 1 | |
| PATADAY 0.2 % EYE DROPS MO | 3 | |
| periogard 0.12 % mouthwash MO | 1 | |
| PHOSPHOLINE IODIDE 0.125 % EYE DROPS MO | 4 | |
| pilocarpine 1% eye drops; pilocarpine 2% eye drops; pilocarpine 4% eye drops MO | 3 | |
| polycin 500 unit-10,000 unit/gram eye ointment MO | 2 | |
| polymyxin b-tmp eye drops MO | 1 | |
| PRED-G 0.3 %-1 % EYE DROPS,SUSPENSION MO | 4 | |
| PRED-G S.O.P. 0.3 %-0.6 % EYE OINTMENT MO | 4 | |
| prednisolone 5 mg/5 ml soln; prednisolone sod 1% eye drop; prednisolone sod ph 25 mg/5 ml MO | 3 | |
| proparacaine 0.5% eye drops MO | 1 | |
| QNASL 40 MCG/ACTUATION NASAL AEROSOL SPRAY MO | 4 | QL (4.9 per 30 days) |
| QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY MO | 4 | QL (8.7 per 30 days) |
| RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE MO | 3 | QL (60 per 30 days) |
| sulfacetamide 10% eye drops; sulfacetamide 10% eye ointment MO | 2 | |
| sulf-pred 10-0.23% eye drops MO | 2 | |
| timolol 0.25% eye drops; timolol 0.5% eye drops; timolol maleate 10 mg, 20 mg, 5 mg tablet MO | 2 | |
| timolol 0.25% gel-solution; timolol 0.5% gel-solution MO | 3 | |
| tobramycin 0.3% eye drops MO | 2 | |
| tobramycin-dexameth ophth susp MO | 4 | |
| TOBREX 0.3 % EYE OINTMENT MO | 4 | |
| TRAVATAN Z 0.004 % EYE DROPS MO | 3 | QL (2.5 per 25 days) |
| trifluridine 1% eye drops MO | 4 | |
| tropicamide 0.5% eye drops; tropicamide 1% eye drops MO | 1 | |
| TYZINE 0.05 % NASAL DROPS MO | 4 | |
| VERAMYST 27.5 MCG/ACTUATION NASAL SPRAY,SUSPENSION MO | 4 | QL (10 per 30 days) |
| VEXOL 1 % EYE DROPS,SUSPENSION MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| VIGAMOX 0.5 % EYE DROPS MO | 4 | |
| ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER MO | 3 | QL (6.1 per 28 days) |
| ZIRGAN 0.15 % EYE GEL MO | 4 | QL (5 per 30 days) |
| GASTROINTESTINAL DRUGS | | |
| <i>alosetron hcl 0.5 mg, 1 mg tablet</i> MO | 5 | QL (60 per 30 days) |
| AMITIZA 24 MCG, 8 MCG CAPSULE MO | 3 | |
| APRISO 0.375 GRAM CAPSULE,EXTENDED RELEASE MO | 3 | QL (120 per 30 days) |
| <i>balsalazide disodium 750 mg cp</i> MO | 4 | |
| CANASA 1,000 MG RECTAL SUPPOSITORY MO | 3 | QL (30 per 30 days) |
| CARAFATE 1 GRAM TABLET; CARAFATE 100 MG/ML ORAL SUSPENSION MO | 4 | |
| CHENODAL 250 MG TABLET SP | 5 | PA |
| <i>cimetidine 200 mg, 300 mg, 400 mg, 800 mg tablet</i> MO | 2 | |
| <i>cimetidine 300 mg/5 ml soln</i> MO | 2 | |
| <i>compro 25 mg rectal suppository</i> MO | 3 | |
| CREON 12,000-38,000-60,000 UNIT CAPSULE,DELAYED RELEASE; CREON 24,000-76,000-120,000 UNIT CAPSULE,DELAYED RELEASE; CREON 3,000-9,500-15,000 UNIT CAPSULE,DELAYED RELEASE; CREON 36,000-114,000-180,000 UNIT CAPSULE,DELAYED RELEASE; CREON 6 MO | | |
| DEXILANT 30 MG, 60 MG CAPSULE, DELAYED RELEASE MO | 4 | QL (30 per 30 days) |
| <i>dimenhydrinate 50 mg/ml vial</i> MO | 1 | |
| <i>diphenoxylat-atrop 2.5-0.025/5; diphenoxylate-atrop 2.5-0.025</i> MO | 2 | |
| <i>dronabinol 10 mg capsule</i> MO | 5 | B vs D,QL (120 per 30 days) |
| <i>dronabinol 2.5 mg, 5 mg capsule</i> MO | 4 | B vs D,QL (120 per 30 days) |
| EMEND 125 MG (1)-80 MG (2) CAPSULES IN A DOSE PACK MO | 4 | B vs D,QL (6 per 28 days) |
| EMEND 125 MG, 40 MG CAPSULE MO | 4 | B vs D,QL (2 per 28 days) |
| EMEND 150 MG INTRAVENOUS SOLUTION MO | 4 | PA,QL (2 per 28 days) |
| EMEND 80 MG CAPSULE MO | 4 | B vs D,QL (4 per 28 days) |
| <i>esomeprazole mag dr 20 mg, 40 mg cap</i> MO | 3 | QL (30 per 30 days) |
| <i>famotidine 20 mg, 40 mg tablet; famotidine 40 mg/4 ml vial</i> MO | 2 | |
| <i>famotidine 40 mg/5 ml susp</i> MO | 3 | |
| <i>famotidine 20 mg/2 ml vial</i> MO | 2 | |
| <i>famotidine 20 mg piggyback</i> MO | 2 | |
| GATTEX 30-VIAL 5 MG SUBCUTANEOUS KIT SP | 5 | PA,QL (30 per 30 days) |
| GATTEX ONE-VIAL 5 MG SUBCUTANEOUS KIT SP | 5 | PA,QL (30 per 30 days) |
| <i>gavilyte-c 240 gram-22.72 gram-6.72 gram-5.84 gram oral solution</i> MO | 2 | |
| <i>gavilyte-g 236 gram-22.74 gram-6.74 gram-5.86 gram oral solution</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>gavilyte-n 420 gram oral solution</i> ^{MO} | 2 | |
| <i>granisetron hcl 0.1 mg/ml vial; granisetron hcl 1 mg/ml vial</i> ^{MO} | 4 | |
| <i>granisetron hcl 1 mg tablet</i> ^{MO} | 3 | B vs D,QL (28 per 28 days) |
| <i>granisetron hcl 4 mg/4 ml vial</i> ^{MO} | 4 | QL (4 per 28 days) |
| <i>granisol 2 mg/10 ml solution</i> ^{MO} | 2 | B vs D,QL (150 per 28 days) |
| <i>lansoprazole dr 15 mg capsule</i> ^{MO} | 3 | QL (60 per 30 days) |
| <i>lansoprazole dr 30 mg capsule</i> ^{MO} | 3 | QL (30 per 30 days) |
| LIALDA 1.2 GRAM TABLET,DELAYED RELEASE ^{MO} | 3 | QL (120 per 30 days) |
| LINZESS 145 MCG, 290 MCG CAPSULE ^{MO} | 3 | QL (30 per 30 days) |
| <i>loperamide 2 mg capsule</i> ^{MO} | 2 | |
| LOTRONEX 0.5 MG, 1 MG TABLET ^{MO} | 5 | QL (60 per 30 days) |
| <i>meclizine 12.5 mg, 25 mg tablet</i> ^{MO} | 2 | |
| <i>mesalamine 4 gm/60 ml enema</i> ^{MO} | 4 | QL (1800 per 30 days) |
| <i>mesalamine 4 gm/60 ml kit</i> ^{MO} | 4 | |
| <i>metoclopramide 10 mg, 5 mg tablet</i> ^{MO} | 1 | |
| <i>metoclopramide 10 mg/2 ml syr; metoclopramide 10 mg/2 ml vial; metoclopramide 5 mg/5 ml, 5 mg/ml soln</i> ^{MO} | 2 | |
| <i>misoprostol 100 mcg, 200 mcg tablet</i> ^{MO} | 3 | |
| <i>nizatidine 15 mg/ml solution; nizatidine 150 mg, 300 mg capsule</i> ^{MO} | 3 | |
| <i>omeprazole dr 10 mg, 20 mg capsule</i> ^{MO} | 2 | QL (60 per 30 days) |
| <i>omeprazole dr 40 mg capsule</i> ^{MO} | 2 | QL (30 per 30 days) |
| <i>ondansetron odt 4 mg, 8 mg tablet</i> ^{MO} | 2 | B vs D,QL (90 per 30 days) |
| <i>ondansetron 4 mg/5 ml solution</i> ^{MO} | 4 | B vs D,QL (450 per 30 days) |
| <i>ondansetron 40 mg/20 ml vial</i> ^{MO} | 2 | |
| <i>ondansetron hcl 24 mg tablet</i> ^{MO} | 2 | B vs D,QL (30 per 30 days) |
| <i>ondansetron hcl 4 mg, 8 mg tablet</i> ^{MO} | 2 | B vs D,QL (90 per 30 days) |
| <i>ondansetron 4 mg/2 ml isecure; ondansetron hcl 4 mg/2 ml vial</i> ^{MO} | 2 | |
| <i>pantoprazole sod dr 20 mg, 40 mg tab</i> ^{MO} | 1 | QL (60 per 30 days) |
| <i>pantoprazole sodium 40 mg vial</i> ^{MO} | 4 | |
| <i>paregoric liquid</i> ^{MO} | 4 | |
| <i>peg 3350 electrolyte soln; peg-3350 and electrolytes soln</i> ^{MO} | 2 | |
| <i>peg-3350 with flavor packs 420 gram oral solution</i> ^{MO} | 2 | |
| <i>peg-3350 solution</i> ^{MO} | 2 | |
| PENTASA 250 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | QL (150 per 30 days) |
| PENTASA 500 MG CAPSULE,EXTENDED RELEASE ^{MO} | 4 | QL (300 per 30 days) |
| <i>polyethylene glycol 3350 powd</i> ^{MO} | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| <i>prochlorperazine 25 mg supp</i> ^{MO} | 3 | |
| <i>prochlorperazine 5 mg/ml vial</i> ^{MO} | 2 | |
| <i>prochlorperazine 10 mg, 5 mg tab; prochlorperazine 10 mg, 5 mg tablet</i> ^{MO} | 1 | B vs D |
| PROTONIX 40 MG INTRAVENOUS SOLUTION ^{MO} | 4 | |
| <i>ranitidine 1,000 mg/40 ml vial; ranitidine 15 mg/ml syrup; ranitidine 150 mg, 300 mg tablet; ranitidine hcl 50 mg/2 ml vial</i> ^{MO} | 2 | |
| <i>ranitidine 150 mg, 300 mg capsule</i> ^{MO} | 3 | |
| RELISTOR 12 MG/0.6 ML KIT; RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION; RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE ^{SP} | 5 | PA,QL (36 per 28 days) |
| RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE ^{SP} | 5 | PA,QL (12 per 30 days) |
| SANCUSO 3.1 MG/24 HOUR TRANSDERMAL PATCH ^{MO} | 4 | QL (4 per 30 days) |
| <i>sucrafate 1 gm tablet</i> ^{MO} | 2 | |
| SUPREP BOWEL PREP KIT 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLUTION ^{MO} | 3 | |
| TRANSDERM-SCOP 1.5 MG TRANSDERMAL PATCH (1 MG OVER 3 DAYS) ^{MO} | 4 | PA,QL (4 per 12 days) |
| <i>trilyte with flavor packets 420 gram oral solution</i> ^{MO} | 2 | |
| <i>trimethobenzamide 300 mg cap</i> ^{MO} | 4 | PA |
| <i>ursodiol 250 mg, 500 mg tablet</i> ^{MO} | 4 | |
| GOLD COMPOUNDS | | |
| RIDAURA 3 MG CAPSULE ^{MO} | 5 | |
| HEAVY METAL ANTAGONISTS | | |
| BAL IN OIL 100 MG/ML INTRAMUSCULAR SOLUTION ^{MO} | 4 | |
| <i>calcium disodium versenate 200 mg/ml injection solution</i> ^{MO} | 1 | |
| CHEMET 100 MG CAPSULE ^{MO} | 4 | |
| CUPRIMINE 250 MG CAPSULE ^{MO} | 5 | |
| <i>deferoxamine 2 gram, 500 mg vial</i> ^{MO} | 3 | |
| DEPEN TITRATABS 250 MG TABLET ^{MO} | 4 | |
| EXJADE 125 MG, 250 MG, 500 MG DISPERSIBLE TABLET ^{SP} | 5 | PA |
| SYPRINE 250 MG CAPSULE ^{MO} | 4 | |
| HORMONES AND SYNTHETIC SUBSTITUTES | | |
| <i>a-hydrocort 100 mg solution for injection</i> ^{HI,MO} | 1 | |
| <i>acarbose 100 mg, 25 mg, 50 mg tablet</i> ^{MO} | 3 | |
| ALORA 0.025 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH ^{MO} | 4 | PA,QL (8 per 28 days) |
| <i>altavera (28) 0.15 mg-0.03 mg tablet</i> ^{MO} | 4 | |
| <i>alyacen 1/35 (28) 1 mg-35 mcg tablet</i> ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| alyacen 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet MO | 4 | |
| amethia 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack MO | 4 | QL (91 per 90 days) |
| amethia lo 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack MO | 4 | QL (91 per 90 days) |
| amethyst 90 mcg-20 mcg tablet MO | 4 | |
| ANADROL-50 50 MG TABLET MO | 5 | |
| ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) TRANSDERMAL GEL PACKET MO | 3 | QL (37.5 per 30 days) |
| ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) TRANSDERMAL GEL PACKET MO | 3 | QL (150 per 30 days) |
| ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GEL PUMP MO | 3 | QL (176 per 30 days) |
| androxy 10 mg tablet MO | 4 | |
| APIDRA 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 4 | |
| APIDRA SOLOSTAR 100 UNIT/ML SUBCUTANEOUS INSULIN PEN MO | 4 | |
| apri 0.15 mg-0.03 mg tablet MO | 4 | |
| aranelle (28) 0.5 mg/1 mg/0.5 mg-35 mcg tablet MO | 4 | |
| ARISTOSPAN INTRA-ARTICULAR 20 MG/ML SUSPENSION FOR INJECTION MO | 4 | |
| ARISTOSPAN INTRALESIONAL 5 MG/ML SUSPENSION FOR INJECTION MO | 4 | |
| ashlyna 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack MO | 4 | QL (91 per 90 days) |
| aubra 0.1 mg-20 mcg tablet MO | 4 | |
| AVANDIA 2 MG, 4 MG TABLET MO | 4 | QL (60 per 30 days) |
| AVANDIA 8 MG TABLET MO | 4 | QL (30 per 30 days) |
| aviane 0.1 mg-20 mcg tablet MO | 4 | |
| AYGESTIN 5 MG TABLET MO | 4 | |
| azurette (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| balziva (28) 0.4 mg-35 mcg tablet MO | 4 | |
| betamethasone ac-sp 6 mg/ml vl MO | 2 | |
| BREVICON (28) 0.5 MG-35 MCG TABLET MO | 4 | |
| briellyn 0.4 mg-35 mcg tablet MO | 4 | |
| budesonide ec capsule MO | 5 | |
| calcitonin-salmon 200 units sp MO | 3 | QL (3.7 per 28 days) |
| camila 0.35 mg tablet MO | 4 | |
| CAMRESE 0.15 MG-30 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |
| CAMRESE LO 0.10 MG-20 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |
| caziant (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet MO | 4 | |
| chateal 0.15 mg-0.03 mg tablet MO | 4 | |
| chorionic gonad 10,000 unit vl MO | 4 | PA |
| cortisone 25 mg tablet MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>cryselle (28) 0.3 mg-30 mcg tablet</i> MO | 4 | |
| <i>cyclafem 1/35 (28) 1 mg-35 mcg tablet</i> MO | 4 | |
| <i>cyclafem 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> MO | 4 | |
| CYCLESSA (28) 0.1 MG/0.125 MG/0.15 MG-25 MCG TABLET MO | 4 | |
| <i>cyred 0.15 mg-0.03 mg tablet</i> MO | 4 | |
| CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET MO | 4 | |
| <i>danazol 100 mg, 200 mg, 50 mg capsule</i> MO | 4 | |
| <i>dasetta 1/35 (28) 1 mg-35 mcg tablet</i> MO | 4 | |
| <i>dasetta 7/7/7 (28) 0.5 mg(7)/0.75 mg(7)/1 mg(7)-35 mcg tablet</i> MO | 4 | |
| <i>daysee 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> MO | 4 | QL (91 per 90 days) |
| <i>deblitane 0.35 mg tablet</i> MO | 4 | |
| DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML INTRAMUSCULAR OIL MO | 4 | PA |
| <i>delyla (28) 0.1 mg-20 mcg tablet</i> MO | 4 | |
| DEPO-ESTRADIOL 5 MG/ML INTRAMUSCULAR OIL MO | 2 | PA |
| DEPO-PROVERA 400 MG/ML INTRAMUSCULAR SOLUTION MO | 4 | |
| DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SUBCUTANEOUS SYRINGE MO | 4 | QL (0.65 per 90 days) |
| <i>desmopressin 0.1 mg/ml sol; desmopressin ac 0.1 mg/ml (refrigerate), 4 mcg/ml ampul; desmopressin acetate 0.1 mg, 0.2 mg tb</i> MO | 4 | |
| <i>desmopressin 10 mcg/0.1 ml spr</i> MO | 3 | |
| <i>desogestr-eth estrad eth estra</i> MO | 4 | |
| DESOGEN 0.15 MG-0.03 MG TABLET MO | 4 | |
| <i>desogestrel-ethinyl estrad tab</i> MO | 4 | |
| <i>dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg tablet; dexamethasone 0.5 mg/5 ml elx; dexamethasone 0.5 mg/5 ml liq</i> MO | 2 | |
| DEXAMETHASONE INTENSOL 1 MG/ML DROPS (CONCENTRATE) MO | 3 | |
| <i>dexamethasone 0.1% eye drop; dexamethasone 10 mg/ml, 4 mg/ml vial</i> MO | 2 | |
| DEXPAK 10 DAY 1.5 MG (35 TABS) TABLETS IN A DOSE PACK MO | 4 | |
| DEXPAK 13 DAY 1.5 MG (51 TABS) TABLETS IN A DOSE PACK MO | 4 | |
| DEXPAK 6 DAY 1.5 MG (21 TABS) TABLETS IN A DOSE PACK MO | 4 | |
| <i>drospirenone-ee 3-0.02 mg, 3-0.03 mg tab; drospirenone-eth estradiol tab</i> MO | 4 | |
| DUAVEE 0.45 MG-20 MG TABLET MO | 4 | PA,QL (30 per 30 days) |
| EGRIFTA 1 MG, 2 MG SUBCUTANEOUS SOLUTION SP | 5 | PA,QL (60 per 30 days) |
| <i>elinest 0.3 mg-30 mcg tablet</i> MO | 4 | |
| ELLA 30 MG TABLET MO | 3 | QL (1 per 30 days) |
| <i>emoquette 0.15 mg-0.03 mg tablet</i> MO | 4 | |
| ENDOMETRIN 100 MG VAGINAL INSERTS MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| enpresse 50-30 (6)/75-40(5)/125-30(10) tablet MO | 4 | |
| enskyce 0.15 mg-0.03 mg tablet MO | 4 | |
| errin 0.35 mg tablet MO | 4 | |
| ESTRACE 0.01% (0.1 MG/GRAM) VAGINAL CREAM MO | 4 | |
| estradiol 0.025 mg patch; estradiol 0.0375 mg patch; estradiol 0.05 mg patch; estradiol 0.075 mg patch; estradiol 0.1 mg patch MO | 4 | PA,QL (8 per 28 days) |
| estradiol 0.025 mg/day patch; estradiol 0.0375 mg/day patch; estradiol 0.05 mg/day patch; estradiol 0.06 mg/day patch; estradiol 0.075 mg/day patch; estradiol 0.1 mg/day patch MO | 3 | PA,QL (4 per 28 days) |
| estradiol 0.5 mg, 1 mg, 2 mg tablet MO | 2 | PA |
| estradiol 10 mg/ml, 20 mg/ml, 40 mg/ml vial; estradiol valerate 10 mg/ml, 20 mg/ml, 40 mg/ml vial MO | 4 | PA |
| ESTRING 2 MG VAGINAL MO | 4 | QL (1 per 90 days) |
| ESTROSTEP FE-28 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET MO | 4 | |
| falmina (28) 0.1 mg-20 mcg tablet MO | 4 | |
| FEMCON FE 0.4 MG-35 MCG (21)/75 MG (7) CHEWABLE TABLET MO | 4 | |
| FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR VAGINAL MO | 4 | QL (1 per 90 days) |
| fludrocortisone 0.1 mg tablet MO | 2 | |
| FORTEO 20 MCG/DOSE (600 MCG/2.4 ML) SUBCUTANEOUS PEN INJECTOR SP | 4 | ST,QL (2.4 per 28 days) |
| FORTICAL 200 UNIT/ACTUATION NASAL SPRAY MO | 4 | QL (3.7 per 28 days) |
| GIANVI (28) 3 MG-20 MCG TABLET MO | 4 | |
| gildagia 0.4 mg-35 mcg tablet MO | 4 | |
| gildess 1 mg-20 mcg tablet; gildess 1.5 mg-30 mcg tablet MO | 4 | |
| gildess 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| gildess fe 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| glimepiride 1 mg, 2 mg, 4 mg tablet MO | 1 | |
| glipizide 10 mg, 5 mg tablet MO | 1 | |
| glipizide er 10 mg, 2.5 mg, 5 mg tablet; glipizide xl 10 mg, 2.5 mg, 5 mg tablet MO | 2 | |
| glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg MO | 2 | |
| GLUCAGEN HYPOKIT 1 MG INJECTION MO | 4 | |
| GLUCAGON EMERGENCY KIT (HUMAN-RECOMB) 1 MG INJECTION MO | 3 | |
| GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE MO | 4 | QL (60 per 30 days) |
| GLUMETZA 500 MG TABLET,EXTENDED RELEASE MO | 4 | QL (120 per 30 days) |
| GLYSET 100 MG, 25 MG, 50 MG TABLET MO | 4 | |
| GLYXAMBI 10 MG-5 MG TABLET; GLYXAMBI 25 MG-5 MG TABLET MO | 3 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| <i>heather 0.35 mg tablet</i> MO | 4 | |
| HUMALOG 100 UNIT/ML SUBCUTANEOUS CARTRIDGE; HUMALOG 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| HUMALOG KWIKPEN 100 UNIT/ML, 200 UNIT/ML (3 ML) SUBCUTANEOUS MO | 3 | |
| HUMALOG MIX 50-50 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| HUMALOG MIX 50-50 KWIKPEN 100 UNIT/ML SUBCUTANEOUS PEN MO | 3 | |
| HUMALOG MIX 75-25 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| HUMALOG MIX 75-25 KWIKPEN 100 UNIT/ML SUBCUTANEOUS INSULIN PEN MO | 3 | |
| HUMULIN 70/30 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| HUMULIN 70/30 KWIKPEN 100 UNIT/ML (70-30) SUBCUTANEOUS MO | 3 | |
| HUMULIN 70-30 PEN MO | 3 | |
| HUMULIN N 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| HUMULIN N KWIKPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS MO | 3 | |
| HUMULIN N 100 UNITS/ML PEN MO | 3 | |
| HUMULIN R 100 UNIT/ML INJECTION SOLUTION MO | 3 | |
| HUMULIN R U-500 "CONCENTRATED" INSULIN 500 UNIT/ML SUBCUTANEOUS SOLN MO | 3 | |
| <i>hydrocortisone 1% cream; hydrocortisone 1% ointment; hydrocortisone 10 mg, 20 mg, 5 mg tablet; hydrocortisone 2.5% cream; hydrocortisone 2.5% lotion; hydrocortisone 2.5% ointment</i> MO | 2 | |
| INCRELEX 10 MG/ML SUBCUTANEOUS SOLUTION SP | 5 | PA |
| <i>introvale 0.15 mg-30 mcg tablets,3 month dose pack</i> MO | 4 | QL (91 per 90 days) |
| INVOKAMET 150 MG-1,000 MG TABLET; INVOKAMET 150 MG-500 MG TABLET; INVOKAMET 50 MG-1,000 MG TABLET; INVOKAMET 50 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| INVOKANA 100 MG, 300 MG TABLET MO | 3 | QL (30 per 30 days) |
| JANUMET 50 MG-1,000 MG TABLET; JANUMET 50 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE MO | 3 | QL (30 per 30 days) |
| JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE; JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE MO | 3 | QL (60 per 30 days) |
| JANUVIA 100 MG, 25 MG, 50 MG TABLET MO | 3 | QL (30 per 30 days) |
| JARDIANCE 10 MG, 25 MG TABLET MO | 3 | QL (30 per 30 days) |
| <i>jencycla 0.35 mg tablet</i> MO | 4 | |
| JENTADUETO 2.5 MG-1,000 MG TABLET; JENTADUETO 2.5 MG-500 MG TABLET; JENTADUETO 2.5 MG-850 MG TABLET MO | 3 | QL (60 per 30 days) |
| JOLESSA 0.15 MG-30 MCG TABLETS,3 MONTH DOSE PACK MO | 4 | QL (91 per 90 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| JOLIVETTE 0.35 MG TABLET MO | 4 | |
| junel 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| junel 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO | 4 | |
| junel fe 24 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| JUVISYNC 100-10 MG, 100-20 MG, 100-40 MG, 50-10 MG, 50-20 MG, 50-40 MG TABLET MO | 3 | QL (30 per 30 days) |
| kariva (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| KAZANO 12.5 MG-1,000 MG TABLET; KAZANO 12.5 MG-500 MG TABLET MO | 4 | QL (60 per 30 days) |
| kelnor 1/35 (28) 1 mg-35 mcg tablet MO | 4 | |
| kimidess (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE MO | 4 | QL (60 per 30 days) |
| KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE; KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE MO | 4 | QL (30 per 30 days) |
| KORLYM 300 MG TABLET SP | 5 | PA,QL (120 per 30 days) |
| kurvelo 0.15 mg-0.03 mg tablet MO | 4 | |
| levono-e estrad 0.10-0.02-0.01 MO | 4 | QL (91 per 90 days) |
| levono-e estrad 0.15-0.03-0.01 MO | 4 | |
| LANTUS 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| LANTUS SOLOSTAR 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO | 3 | |
| larin 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| larin 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| larin 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| larin fe 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| LEENA 28 0.5 MG/1 MG/0.5 MG-35 MCG TABLET MO | 4 | |
| lessina 0.1 mg-20 mcg tablet MO | 4 | |
| LEVEMIR 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| LEVEMIR FLEXPEN 100 UNITS/ML MO | 3 | |
| LEVEMIR FLEXTOUCH 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO | 3 | |
| levonest (28) 50-30 (6)/75-40(5)/125-30(10) tablet MO | 4 | |
| levonorgestrel 0.75 mg, 1.5 mg tablet MO | 4 | |
| levonor-eth estrad 0.09-0.02 mg; levonor-eth estrad 0.1-0.02 mg; levonor-eth estrad 0.15-0.03 MO | 4 | |
| levonor-eth estrad 0.15-0.03 MO | 4 | QL (91 per 90 days) |
| levora-28 0.15 mg-0.03 mg tablet MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg tablet; levothyroxine 100 mcg, 200 mcg, 500 mcg vial MO | 1 | |
| LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| liothyronine sod 10 mcg/ml vl MO | 2 | |
| liothyronine sod 25 mcg, 5 mcg, 50 mcg tab MO | 3 | |
| loestrin 1.5/30 (21) 1.5 mg-30 mcg tablet MO | 4 | |
| loestrin 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| loestrin fe 1.5/30 (28-day) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO | 4 | |
| LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET MO | 4 | |
| lomedica 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO | 4 | |
| loryna (28) 3 mg-20 mcg tablet MO | 3 | |
| low-ogestrel (28) 0.3 mg-30 mcg tablet MO | 4 | |
| lutera (28) 0.1 mg-20 mcg tablet MO | 4 | |
| lyza 0.35 mg tablet MO | 4 | |
| marlissa 0.15 mg-0.03 mg tablet MO | 4 | |
| MEDROL 2 MG TABLET MO | 4 | |
| medroxyprogesterone 10 mg, 2.5 mg, 5 mg tab MO | 2 | |
| medroxyprogesterone 150 mg/ml; medroxyprogesterone 150 mg/ml MO | 2 | QL (1 per 90 days) |
| MENEST 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG TABLET MO | 4 | PA |
| MENOSTAR 14 MCG/24 HR TRANSDERMAL PATCH MO | 4 | PA,QL (8 per 28 days) |
| metformin hcl 1,000 mg, 500 mg, 850 mg tablet MO | 1 | |
| metformin hcl er 500 mg tablet MO | 1 | QL (120 per 30 days) |
| metformin hcl er 750 mg tablet MO | 1 | QL (60 per 30 days) |
| methimazole 10 mg, 5 mg tablet MO | 2 | |
| METHITEST 10 MG TABLET MO | 4 | |
| methylprednisolone 16 mg, 32 mg, 4 mg, 4 mg, 8 mg dosepk; methylprednisolone 16 mg, 32 mg, 4 mg, 4 mg, 8 mg tab; methylprednisolone 16 mg, 32 mg, 4 mg, 4 mg, 8 mg tablet MO | 2 | B vs D |
| methylprednisolone 40 mg/ml, 80 mg/ml vl HI,MO | 2 | |
| methylprednisolone 125 mg, 40 mg vial HI,MO | 4 | |
| methylprednisolone ss 1 gm vl MO | 4 | |
| MIACALCIN 200 UNIT/ML INJECTION SOLUTION MO | 4 | |
| MICROGESTIN 1.5/30 (21) 1.5 MG-30 MCG TABLET MO | 4 | |
| microgestin 1/20 (21) 1 mg-20 mcg tablet MO | 4 | |
| MICROGESTIN FE 1.5/30 (28) 1.5 MG-30 MCG (21)/75 MG (7) TABLET MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| MICROGESTIN FE 1/20 (28) 1 MG-20 MCG (21)/75 MG (7) TABLET MO | 4 | |
| <i>mimvey 1 mg-0.5 mg tablet MO</i> | 4 | PA |
| <i>mircette (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO</i> | 4 | |
| MODICON (28) 0.5 MG-35 MCG TABLET MO | 4 | |
| <i>mono-lynyah 0.25 mg-35 mcg tablet MO</i> | 4 | |
| MONONESSA (28) 0.25 MG-35 MCG TABLET MO | 4 | |
| <i>my way 1.5 mg tablet MO</i> | 4 | |
| MYALEPT 5 MG/ML (FINAL CONCENTRATION) SUBCUTANEOUS SOLUTION SP | 5 | PA,QL (60 per 30 days) |
| <i>myzilra 50-30 (6)/75-40(5)/125-30(10) tablet MO</i> | 4 | |
| NATAZIA 3 MG/2 MG-2 MG/2 MG-3 MG/1 MG TABLET MO | 4 | |
| <i>nateglinide 120 mg, 60 mg tablet MO</i> | 3 | |
| NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE SUBCUTANEOUS CARTRIDGE SP | 5 | PA,QL (2 per 28 days) |
| <i>necon 0.5/35 (28) 0.5 mg-35 mcg tablet MO</i> | 4 | |
| <i>necon 1/35 (28) 1 mg-35 mcg tablet MO</i> | 4 | |
| NECON 1/50 (28) 1 MG-50 MCG TABLET MO | 4 | |
| <i>necon 10/11 (28) 0.5 mg-35 mcg(10)/1 mg-35 mcg(11) tablet MO</i> | 4 | |
| NECON 7/7/7 (28) 0.5 MG/0.75 MG/1 MG-35 MCG TABLET MO | 4 | |
| NESINA 12.5 MG, 25 MG, 6.25 MG TABLET MO | 4 | QL (30 per 30 days) |
| <i>next choice one dose 1.5 mg tablet MO</i> | 4 | |
| <i>nikki (28) 3 mg-20 mcg tablet MO</i> | 4 | |
| NOR-QD 0.35 MG TABLET MO | 4 | |
| NORA-BE 0.35 MG TABLET MO | 4 | |
| <i>norethindrone 0.35 mg tablet MO</i> | 4 | |
| <i>norethind-eth estrad 1-0.02 mg MO</i> | 4 | |
| <i>norethindrone 5 mg tablet MO</i> | 3 | |
| <i>norethin-estrad-ferr 1-0.02 mg MO</i> | 4 | |
| <i>norg-ee 0.18-0.215-0.25/0.035; norg-ethin estra 0.25-0.035 mg MO</i> | 4 | |
| NORINYL 1+35 (28) 1 MG-35 MCG TABLET MO | 4 | |
| NORINYL 1+50 (28) 1 MG-50 MCG TABLET MO | 4 | |
| <i>norlyroc 0.35 mg tablet MO</i> | 4 | |
| <i>nortrel 0.5/35 (28) 0.5 mg-35 mcg tablet MO</i> | 4 | |
| <i>nortrel 1/35 (21) 1 mg-35 mcg tablet MO</i> | 4 | |
| <i>nortrel 1/35 (28) 1 mg-35 mcg tablet MO</i> | 4 | |
| <i>nortrel 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet MO</i> | 4 | |
| NOVOLIN 70/30 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| NOVOLIN N 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| NOVOLIN R 100 UNIT/ML INJECTION SOLUTION MO | 3 | |
| NOVOLOG 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| NOVOLOG FLEXPEN 100 UNIT/ML SUBCUTANEOUS MO | 3 | |
| NOVOLOG MIX 70-30 100 UNIT/ML SUBCUTANEOUS SOLUTION MO | 3 | |
| NOVOLOG MIX 70-30 FLEXPEN 100 UNIT/ML SUBCUTANEOUS PEN MO | 3 | |
| NOVOLOG PENFILL 100 UNIT/ML SUBCUTANEOUS CARTRIDGE MO | 3 | |
| NUVARING 0.12 MG -0.015 MG/24 HR VAGINAL MO | 4 | QL (1 per 28 days) |
| OCELLA 3 MG-0.03 MG TABLET MO | 4 | |
| octreotide 1,000 mcg/5 ml vial; octreotide acet 100 mcg/ml, 200 mcg/ml, 50 mcg/ml amp; octreotide acet 100 mcg/ml, 200 mcg/ml, 50 mcg/ml vl; octreotide acet 50 mcg/ml syr; octreotide acet 500 mcg/ml syr SP | 4 | PA |
| octreotide 1,000 mcg/ml, 500 mcg/ml vial; octreotide acet 1,000 mcg/ml, 500 mcg/ml vl; octreotide acet 100 mcg/ml syr SP | 5 | PA |
| ogestrel (28) 0.5 mg-50 mcg tablet MO | 4 | |
| OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS CARTRIDGE; OMNITROPE 5.8 MG SUBCUTANEOUS SOLUTION SP | 5 | PA |
| ONGLYZA 2.5 MG, 5 MG TABLET MO | 4 | QL (30 per 30 days) |
| orapred 15 mg/5 ml solution MO | 4 | |
| orsythia 0.1 mg-20 mcg tablet MO | 4 | |
| ORTHO EVRA 150 MCG-35 MCG/24 HR TRANSDERMAL PATCH MO | 4 | QL (3 per 28 days) |
| ORTHO MICRONOR 0.35 MG TABLET MO | 4 | |
| ORTHO-CEPT (28) 0.15 MG-0.03 MG TABLET MO | 4 | |
| ORTHO-CYCLLEN (28) 0.25 MG-35 MCG TABLET MO | 4 | |
| ORTHO-NOVUM 1/35 (28) 1 MG-35 MCG TABLET MO | 4 | |
| ORTHO-NOVUM 7/7/7 (28) 0.5 MG/0.75 MG/1 MG-35 MCG TABLET MO | 4 | |
| OSENI 12.5 MG-15 MG TABLET; OSENI 12.5 MG-30 MG TABLET; OSENI 12.5 MG-45 MG TABLET; OSENI 25 MG-15 MG TABLET; OSENI 25 MG-30 MG TABLET; OSENI 25 MG-45 MG TABLET MO | 4 | QL (30 per 30 days) |
| ovcon-35 (28) 0.4 mg-35 mcg tablet MO | 4 | |
| oxandrolone 10 mg tablet MO | 5 | PA,QL (60 per 30 days) |
| oxandrolone 2.5 mg tablet MO | 3 | PA,QL (120 per 30 days) |
| PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) ORAL SOLUTION MO | 4 | |
| philith 0.4 mg-35 mcg tablet MO | 4 | |
| pimtrea (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| pioglitazone hcl 15 mg, 30 mg, 45 mg tablet MO | 2 | QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| pioglitazone-glimepiride 30-2; pioglitazone-glimepiride 30-4 ^{MO} | 4 | QL (30 per 30 days) |
| pioglitazone-metformin 15-500; pioglitazone-metformin 15-850 ^{MO} | 4 | QL (90 per 30 days) |
| pirmella 0.5/0.75/1 mg-35 mcg tablet; pirmella 1 mg-35 mcg tablet ^{MO} | 4 | |
| portia 0.15 mg-0.03 mg tablet ^{MO} | 4 | |
| prednisolone 15 mg/5 ml syrup ^{MO} | 2 | |
| prednisolone 15 mg/5 ml soln ^{MO} | 2 | |
| prednisolone 5 mg/5 ml soln; prednisolone sod 1% eye drop; prednisolone sod ph 25 mg/5 ml ^{MO} | 3 | |
| prednisone 1 mg, 10 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 5 mg, 50 mg tab dose pack; prednisone 1 mg, 10 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 5 mg, 50 mg tablet; prednisone 5 mg/5 ml solution ^{MO} | 1 | B vs D |
| PREDNISONE INTENSOL 5 MG/ML ORAL CONCENTRATE ^{MO} | 3 | B vs D |
| PREMARIN 0.625 MG/GRAM VAGINAL CREAM ^{MO} | 3 | |
| previfem 0.25 mg-35 mcg tablet ^{MO} | 4 | |
| progesterone oil 50 mg/ml v1 ^{MO} | 3 | |
| progesterone in oil 50 mg/ml intramuscular ^{MO} | 3 | |
| progesterone 100 mg, 200 mg capsule ^{MO} | 3 | |
| PROGLYCEM 50 MG/ML ORAL SUSPENSION ^{MO} | 4 | |
| propylthiouracil 50 mg tablet ^{MO} | 3 | |
| PROVERA 10 MG, 2.5 MG, 5 MG TABLET ^{MO} | 4 | |
| QUARTETTE 0.15 MG-20 MCG/0.15 MG-25 MCG TABLETS,3 MONTH DOSE PACK ^{MO} | 4 | QL (91 per 90 days) |
| quasense 0.15 mg-30 mcg tablets,3 month dose pack ^{MO} | 4 | QL (91 per 90 days) |
| raloxifene hcl 60 mg tablet ^{MO} | 3 | QL (30 per 30 days) |
| reclipsen (28) 0.15 mg-0.03 mg tablet ^{MO} | 4 | |
| repaglinide 0.5 mg, 1 mg, 2 mg tablet ^{MO} | 4 | |
| SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG INTRAMUSCULAR KIT; SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG INTRAMUSCULAR SUSP,EXTENDED RELEASE ^{MO} | 5 | PA |
| SEROSTIM 4 MG, 5 MG, 6 MG SUBCUTANEOUS SOLUTION ^{SP} | 5 | PA |
| sharobel 0.35 mg tablet ^{MO} | 4 | |
| SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SUBCUTANEOUS SOLUTION ^{SP} | 5 | PA,QL (60 per 30 days) |
| SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG INTRAVENOUS SOLUTION ^{MO} | 4 | |
| SOLU-MEDROL (PF) 1,000 MG/8 ML, 500 MG/4 ML INTRAVENOUS SOLUTION ^{MO} | 4 | |
| SOLU-MEDROL (PF) 125 MG/2 ML, 40 MG/ML SOLUTION FOR INJECTION ^{HI,MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| SOMATULINE DEPOT 120 MG/0.5 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (0.5 per 28 days) |
| SOMATULINE DEPOT 60 MG/0.2 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (0.2 per 28 days) |
| SOMATULINE DEPOT 90 MG/0.3 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (0.3 per 28 days) |
| SOMAVERT 10 MG, 15 MG, 20 MG SUBCUTANEOUS SOLUTION SP | 5 | PA,QL (60 per 30 days) |
| SOMAVERT 25 MG, 30 MG SUBCUTANEOUS SOLUTION SP | 5 | PA,QL (30 per 30 days) |
| <i>sprintec (28) 0.25 mg-35 mcg tablet</i> MO | 4 | |
| <i>sronyx 0.1 mg-20 mcg tablet</i> MO | 4 | |
| STIMATE 150 MCG/SPRAY (0.1 ML) NASAL SPRAY MO | 4 | |
| STRIANT 30 MG BUCCAL SYSTEM,SUSTAINED RELEASE MO | 4 | |
| <i>syeda 3 mg-0.03 mg tablet</i> MO | 4 | |
| SYMLINPEN 120 2,700 MCG/2.7 ML SUBCUTANEOUS PEN INJECTOR MO | 4 | QL (10.8 per 30 days) |
| SYMLINPEN 60 1,500 MCG/1.5 ML SUBCUTANEOUS PEN INJECTOR MO | 4 | QL (10.5 per 30 days) |
| SYNAREL 2 MG/ML NASAL SPRAY SP | 5 | |
| SYNJARDY 12.5 MG-1,000 MG TABLET; SYNJARDY 12.5 MG-500 MG TABLET; SYNJARDY 5 MG-1,000 MG TABLET; SYNJARDY 5 MG-500 MG TABLET MO | 3 | QL (60 per 30 days) |
| SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 3 | |
| <i>tarina fe 1 mg-20 mcg (21)/75 mg (7) tablet</i> MO | 4 | |
| <i>testosteron cyp 1,000 mg/10 ml; testosterone cyp 100 mg/ml, 200 mg/ml</i> MO | 3 | |
| <i>testosteron enan 1,000 mg/5 ml</i> MO | 3 | |
| TESTRED 10 MG CAPSULE MO | 5 | |
| THYROLAR-1 12.5 MCG-50 MCG TABLET MO | 2 | |
| THYROLAR-1/2 6.25 MCG-25 MCG TABLET MO | 2 | |
| THYROLAR-1/4 3.1 MCG-12.5 MCG TABLET MO | 2 | |
| THYROLAR-2 25 MCG-100 MCG TABLET MO | 2 | |
| THYROLAR-3 37.5 MCG-150 MCG TABLET MO | 2 | |
| <i>tilia fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet</i> MO | 4 | |
| <i>tolazamide 250 mg, 500 mg tablet</i> MO | 4 | |
| <i>tolbutamide 500 mg tablet</i> MO | 4 | |
| TOUJEO SOLOSTAR 300 UNIT/ML (1.5 ML) SUBCUTANEOUS INSULIN PEN MO | 3 | |
| TRADJENTA 5 MG TABLET MO | 3 | QL (30 per 30 days) |
| <i>tri-legest fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet</i> MO | 4 | |
| <i>tri-linyah (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet</i> MO | 4 | |
| TRI-NORINYL (28) 0.5 MG/1 MG/0.5 MG-35 MCG TABLET MO | 4 | |
| <i>tri-previfem (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet</i> MO | 4 | |
| <i>tri-sprintec (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet</i> MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| triamcinolone 0.147 mg/g spray; triamcinolone acet 40mg/ml vL; triamcinolone acet 50mg/5ml vL MO | 4 | |
| TRINESSA (28) 0.18 MG(7)/0.215 MG(7)/0.25 MG(7)-35 MCG TABLET MO | 4 | |
| trivora (28) 50-30 (6)/75-40(5)/125-30(10) tablet MO | 4 | |
| TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (2 per 28 days) |
| UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO | 2 | |
| VAGIFEM 10 MCG VAGINAL TABLET MO | 4 | |
| velivet triphasic regimen (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet MO | 4 | |
| VERIPRED 20 20 MG/5 ML ORAL SOLUTION MO | 4 | |
| vestura (28) 3 mg-20 mcg tablet MO | 2 | |
| VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (9 per 30 days) |
| VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO | 3 | QL (9 per 30 days) |
| viorele (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO | 4 | |
| VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH MO | 4 | PA,QL (8 per 28 days) |
| vyfemla (28) 0.4 mg-35 mcg tablet MO | 4 | |
| wera (28) 0.5 mg-35 mcg tablet MO | 4 | |
| WYMZYA FE 0.4 MG-35 MCG (21)/75 MG (7) CHEWABLE TABLET MO | 4 | |
| xulane 150 mcg-35 mcg/24 hr transdermal patch MO | 4 | QL (3 per 28 days) |
| YASMIN (28) 3 MG-0.03 MG TABLET MO | 4 | |
| YAZ (28) 3 MG-20 MCG TABLET MO | 4 | |
| zarah 3 mg-0.03 mg tablet MO | 3 | |
| zenchent (28) 0.4 mg-35 mcg tablet MO | 4 | |
| zenchent fe 0.4 mg-35 mcg (21)/75 mg (7) chewable tablet MO | 4 | |
| zeosa 0.4 mg-35 mcg (21)/75 mg (7) chewable tablet MO | 4 | |
| ZORBTIVE 8.8 MG SUBCUTANEOUS SOLUTION SP | 5 | PA |
| zovia 1/35e (28) 1 mg-35 mcg tablet MO | 4 | |
| zovia 1/50e (28) 1 mg-50 mcg tablet MO | 4 | |
| LOCAL ANESTHETICS (PARENTERAL) | | |
| bupivacaine 0.25% vial MO | 1 | |
| bupivacaine 0.25% ampul; bupivacaine 0.5% ampul; bupivacaine 0.75% vial MO | 1 | |
| lidocaine 5% in d7.5w ampul MO | 1 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| lidocaine hcl 1% ampul; lidocaine hcl 1% syringe; lidocaine hcl 1.5% ampul; lidocaine hcl 2% luer-jet; lidocaine hcl 2% vial; lidocaine hcl 4% ampul MO | 2 | |
| lidocaine 2% viscous soln; lidocaine hcl 1% vial; lidocaine hcl 2% jelly; lidocaine hcl 2% vial; lidocaine hcl 4% solution MO | 2 | |
| lidocaine 0.5%-epi 1:200,000; lidocaine 1%-epi 1:100,000; lidocaine 2%-epi 1:100,000 MO | 2 | |
| lidocaine 1.5%-epi 1:200,000; lidocaine 2%-epi 1:200,000 MO | 2 | |
| lidocaine 2% - epi 1:100,000 MO | 2 | |
| lidocaine 2% - epi 1:50,000 MO | 1 | |
| mepivacaine hcl 3% cartridge MO | 1 | |
| polocaine 1 % (10 mg/ml), 2 % injection solution MO | 1 | |
| polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) injection solution MO | 1 | |
| ropivacaine 0.2% 40 mg/20 ml; ropivacaine 0.5% 150 mg/30 ml; ropivacaine 0.75% 150 mg/20 ml; ropivacaine 1% 200 mg/20 ml v MO | 4 | |
| MISCELLANEOUS THERAPEUTIC AGENTS | | |
| acetylcysteine 6 gram/30 ml v MO | 4 | |
| ACTIMMUNE 100 MCG (2 MILLION UNIT)/0.5 ML SUBCUTANEOUS SOLUTION SP | 5 | PA |
| alendronate sodium 10 mg, 40 mg, 5 mg tab; alendronate sodium 10 mg, 40 mg, 5 mg tablet MO | 1 | QL (30 per 30 days) |
| alendronate sodium 35 mg, 70 mg tab MO | 1 | QL (4 per 28 days) |
| allopurinol 100 mg, 300 mg tablet MO | 1 | |
| ALOPRIM 500 MG INTRAVENOUS SOLUTION MO | 4 | |
| amifostine 500 mg vial MO | 5 | B vs D |
| AMPYRA 10 MG TABLET,EXTENDED RELEASE SP | 5 | PA,QL (60 per 30 days) |
| ARCALYST 220 MG SUBCUTANEOUS SOLUTION SP | 5 | PA |
| ATELVIA 35 MG TABLET,DELAYED RELEASE MO | 4 | QL (4 per 28 days) |
| ATGAM 50 MG/ML INTRAVENOUS HI,MO | 3 | PA |
| AUBAGIO 14 MG, 7 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| AVODART 0.5 MG CAPSULE MO | 4 | PA,QL (30 per 30 days) |
| AVONEX 30 MCG/0.5 ML, 30 MCG/0.5 ML INTRAMUSCULAR PEN INJECTOR; AVONEX 30 MCG/0.5 ML, 30 MCG/0.5 ML INTRAMUSCULAR PEN KIT; AVONEX 30 MCG/0.5 ML, 30 MCG/0.5 ML INTRAMUSCULAR SYRINGE; AVONEX 30 MCG/0.5 ML, 30 MCG/0.5 ML INTRAMUSCULAR SYR MO | | |
| AVONEX (WITH ALBUMIN) 30 MCG INTRAMUSCULAR KIT SP | 5 | PA,QL (4 per 28 days) |
| AZASAN 100 MG, 75 MG TABLET MO | 4 | B vs D |
| azathioprine 50 mg tablet MO | 2 | B vs D |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| BENLYSTA 120 MG, 400 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (30 per 28 days) |
| BETASERON 0.3 MG SUBCUTANEOUS KIT; BETASERON 0.3 MG SUBCUTANEOUS SOLUTION SP | 5 | PA,QL (15 per 30 days) |
| BINOSTO 70 MG EFFERVESCENT TABLET MO | 4 | QL (4 per 28 days) |
| <i>calcium folinate (leucovorin) 10 mg/ml injection solution</i> MO | 2 | |
| CARNITOR SUGAR-FREE 100 MG/ML ORAL SOLUTION MO | 4 | |
| CELLCEPT 200 MG/ML ORAL SUSPENSION; CELLCEPT 500 MG TABLET MO | 5 | B vs D |
| CELLCEPT 250 MG CAPSULE MO | 4 | B vs D |
| CELLCEPT INTRAVENOUS 500 MG INTRAVENOUS SOLUTION MO | 4 | B vs D |
| CINRYZE 500 UNIT (5 ML) INTRAVENOUS SOLUTION MO | 5 | PA,QL (100 per 30 days) |
| <i>colchicine 0.6 mg tablet</i> MO | 3 | QL (120 per 30 days) |
| COLCRYS 0.6 MG TABLET MO | 3 | QL (120 per 30 days) |
| COPAXONE 20 MG/ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (30 per 30 days) |
| COPAXONE 40 MG/ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (12 per 28 days) |
| <i>cyclosporine 100 mg, 25 mg capsule; cyclosporine 50 mg/ml ampul</i> MO | 4 | B vs D |
| <i>cyclosporine modified 100 mg, 25 mg, 50 mg</i> MO | 4 | B vs D |
| CYSTADANE 1 GRAM/1.7 ML ORAL POWDER SP | 5 | |
| CYSTAGON 150 MG, 50 MG CAPSULE MO | 4 | |
| DEMSEER 250 MG CAPSULE MO | 5 | |
| <i>dexrazoxane 250 mg, 500 mg vial</i> MO | 4 | B vs D |
| <i>disulfiram 250 mg, 500 mg tablet</i> MO | 4 | |
| ELMIRON 100 MG CAPSULE MO | 4 | |
| ENBREL 25 MG (1 ML) SUBCUTANEOUS SOLUTION; ENBREL 50 MG/ML (0.98 ML) SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (8 per 28 days) |
| ENBREL 25 MG/0.5 ML (0.51 ML) SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (4.08 per 28 days) |
| ENBREL SURECLICK 50 MG/ML (0.98 ML) SUBCUTANEOUS PEN INJECTOR SP | 5 | PA,QL (8 per 28 days) |
| <i>etidronate disodium 200 mg, 400 mg tab</i> MO | 4 | |
| <i>finasteride 5 mg tablet</i> MO | 2 | QL (30 per 30 days) |
| FIRAZYR 30 MG/3 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (9 per 30 days) |
| <i>fluoritab 0.125 mg fluoride(0.275)/drop oral drops; fluoritab 0.5 mg fluoride (1.1 mg) chewable tablet</i> MO | 1 | |
| FLUORITAB 1 MG FLUORIDE (2.2 MG) CHEWABLE TABLET MO | 4 | |
| <i>fomepizole 1.5 gm/1.5 ml vial</i> MO | 1 | |
| FUSILEV 50 MG INTRAVENOUS SOLUTION MO | 4 | PA |
| <i>gengraf 100 mg, 25 mg capsule; gengraf 100 mg/ml oral solution</i> MO | 4 | B vs D |
| GILENYA 0.5 MG CAPSULE SP | 5 | PA,QL (30 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| HUMIRA 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT SP | 5 | PA,QL (0.4 per 28 days) |
| HUMIRA 20 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT SP | 5 | PA,QL (2.4 per 28 days) |
| HUMIRA 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT SP | 5 | PA,QL (4.8 per 28 days) |
| HUMIRA CROHN'S DISEASE STARTER PACK 40 MG/0.8 ML SUBCUTANEOUS PEN KIT SP | 5 | PA,QL (4.8 per 28 days) |
| HUMIRA PEDIATRIC CROHN'S START PCK 40 MG/0.8 ML SUBCUTANEOUS SYRIN KIT SP | 5 | PA,QL (4.8 per 28 days) |
| HUMIRA PEN 40 MG/0.8 ML SUBCUTANEOUS SP | 5 | PA,QL (4.8 per 28 days) |
| HUMIRA PSORIASIS STARTER PACK 40 MG/0.8 ML SUBCUTANEOUS PEN KIT SP | 5 | PA,QL (4.8 per 28 days) |
| <i>ibandronate 3 mg/3 ml syringe; ibandronate 3 mg/3 ml vial</i> MO | 4 | PA,QL (3 per 90 days) |
| <i>ibandronate sodium 150 mg tab</i> MO | 3 | QL (1 per 28 days) |
| IMURAN 50 MG TABLET MO | 4 | B vs D |
| JALYN 0.5 MG-0.4 MG CAPSULE, EXTENDED RELEASE MO | 4 | PA,QL (30 per 30 days) |
| KUVAN 100 MG SOLUBLE TABLET; KUVAN 100 MG, 500 MG ORAL POWDER PACKET SP | 5 | PA |
| <i>leflunomide 10 mg, 20 mg tablet</i> MO | 2 | QL (30 per 30 days) |
| <i>leucovorin cal 100 mg, 200 mg, 350 mg, 50 mg, 500 mg, 500 mg/50 ml vl; leucovorin calcium 100 mg, 200 mg, 350 mg, 50 mg, 500 mg, 500 mg/50 ml vial; leucovorin calcium 100 mg, 200 mg, 350 mg, 50 mg, 500 mg, 500 mg/50 ml vl</i> MO | | |
| <i>leucovorin calcium 10 mg, 15 mg, 25 mg, 5 mg tab</i> MO | 2 | |
| <i>levocarnitine 200 mg/ml vial; levocarnitine 330 mg tablet</i> MO | 3 | |
| <i>levocarnitine 100 mg/ml soln</i> MO | 3 | |
| <i>levoleucovorin 175 mg/17.5 ml</i> MO | 5 | PA |
| <i>ludent fluoride 0.25 mg fluorid (0.55 mg), 0.5 mg fluoride (1.1 mg), 1 mg fluoride (2.2 mg) chewable tablet; ludent fluoride 0.25 mg fluoride (0.55 mg) chewable tablet</i> MO | 1 | |
| <i>mesna 1 gram/10 ml vial</i> MO | 4 | B vs D |
| MESNEX 400 MG TABLET SP | 4 | |
| <i>mycophenolate 200 mg/ml susp</i> MO | 4 | B vs D |
| <i>mycophenolate 250 mg capsule; mycophenolate 500 mg tablet</i> MO | 3 | B vs D |
| <i>mycophenolic acid dr 180 mg, 360 mg tb</i> MO | 4 | B vs D |
| MYFORTIC 180 MG, 360 MG TABLET, DELAYED RELEASE MO | 4 | B vs D |
| NULOJIX 250 MG INTRAVENOUS SOLUTION MO | 5 | PA,QL (200 per 30 days) |
| ORFADIN 10 MG, 2 MG, 5 MG CAPSULE SP | 5 | |
| <i>pamidronate 30 mg/10 ml vial; pamidronate 60 mg/10 ml vial; pamidronate 90 mg/10 ml vial</i> MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE; PROGRAF 5 MG/ML INTRAVENOUS SOLUTION MO | 4 | B vs D |
| PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE MO | 4 | QL (1 per 180 days) |
| RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET; RAPAMUNE 1 MG/ML ORAL SOLUTION MO | 4 | B vs D |
| REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (6 per 28 days) |
| REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR SP | 5 | PA,QL (6 per 28 days) |
| REBIF REBIDOSE 8.8 MCG/0.2 ML-22 MCG/0.5 ML (6) SUBCUTANEOUS PEN INJ. SP | 5 | PA,QL (4.2 per 28 days) |
| REBIF TITRATION PACK 8.8 MCG/0.2 ML-22 MCG/0.5 ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (4.2 per 28 days) |
| REMICADE 100 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| <i>risedronate sod dr 35 mg, 35 mg tab; risedronate sodium 35 mg, 35 mg tab</i> MO | 4 | QL (4 per 28 days) |
| <i>risedronate sodium 150 mg tab</i> MO | 4 | QL (1 per 30 days) |
| <i>risedronate sodium 30 mg, 5 mg tab; risedronate sodium 30 mg, 5 mg tablet</i> MO | 4 | QL (30 per 30 days) |
| SANDIMMUNE 100 MG/ML ORAL SOLUTION MO | 4 | B vs D |
| SENSIPAR 30 MG TABLET MO | 3 | QL (60 per 30 days) |
| SENSIPAR 60 MG TABLET MO | 5 | QL (60 per 30 days) |
| SENSIPAR 90 MG TABLET MO | 5 | QL (120 per 30 days) |
| SIMPONI 100 MG/ML SUBCUTANEOUS PEN INJECTOR; SIMPONI 100 MG/ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (3 per 30 days) |
| SIMULECT 10 MG, 20 MG INTRAVENOUS SOLUTION MO | 5 | B vs D |
| <i>sirolimus 0.5 mg, 1 mg, 2 mg tablet</i> MO | 4 | B vs D |
| <i>fluoride 0.25 mg tablet chew; fluoride 0.5 mg tablet chew; fluoride 1 mg tablet chewable; sodium fluoride 0.5 mg/ml drop</i> MO | 1 | |
| <i>sodium nitrite 300 mg/10 ml vl</i> MO | 1 | |
| <i>sodium thiosulfat 12.5 g/50 ml</i> MO | 1 | |
| <i>stannous fluor 0.63% rinse</i> MO | 2 | |
| <i>tacrolimus 0.5 mg, 1 mg, 5 mg capsule</i> MO | 3 | B vs D |
| TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE, DELAYED RELEASE; TECFIDERA 120 MG (14)-240 MG (46) CAPSULE, DELAYED RELEASE SP | 5 | PA,QL (60 per 30 days) |
| TECFIDERA 120 MG CAPSULE, DELAYED RELEASE SP | 5 | PA,QL (14 per 30 days) |
| THALOMID 100 MG, 200 MG, 50 MG CAPSULE SP | 5 | PA,QL (30 per 30 days) |
| THALOMID 150 MG CAPSULE SP | 5 | PA,QL (60 per 30 days) |
| THIOLA 100 MG TABLET MO | 5 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| THYMOGLOBULIN 25 MG INTRAVENOUS SOLUTION MO | 3 | B vs D |
| TYBOST 150 MG TABLET MO | 4 | QL (30 per 30 days) |
| TYSABRI 300 MG/15 ML INTRAVENOUS SOLUTION MO | 5 | PA |
| ULORIC 40 MG, 80 MG TABLET MO | 3 | ST,QL (30 per 30 days) |
| XGEVA 120 MG/1.7 ML (70 MG/ML) SUBCUTANEOUS SOLUTION MO | 5 | PA,QL (1.7 per 28 days) |
| ZAVESCA 100 MG CAPSULE SP | 5 | QL (90 per 30 days) |
| zoledronic acid 4 mg vial MO | 5 | PA,QL (15 per 21 days) |
| zoledronic acid 4 mg/5 ml vial MO | 4 | PA,QL (15 per 21 days) |
| zoledronic acid 4 mg/100 ml MO | 4 | PA,QL (300 per 21 days) |
| zoledronic acid 5 mg/100 ml MO | 4 | PA,QL (100 per 365 days) |
| ZORTRESS 0.25 MG, 0.75 MG TABLET MO | 4 | B vs D,QL (60 per 30 days) |
| ZORTRESS 0.5 MG TABLET MO | 4 | B vs D,QL (120 per 30 days) |
| OXYTOCICS | | |
| CERVIDIL 10 MG VAGINAL INSERT,CONTROLLED RELEASE MO | 4 | |
| HEMABATE 250 MCG/ML INTRAMUSCULAR SOLUTION MO | 4 | |
| methylergonovine 0.2 mg tablet MO | 4 | |
| methylergonovine 0.2 mg/ml amp MO | 3 | |
| PREPIDIL 0.5 MG/3 G VAGINAL GEL MO | 4 | |
| PHARMACEUTICAL AIDS | | |
| BAND-AID GAUZE PADS 2" X 2" BANDAGE MO | 1 | |
| BORDERED GAUZE 2" X 2" BANDAGE MO | 1 | |
| CURITY GAUZE 2" X 2" BANDAGE MO | 1 | |
| DERMACEA 2" X 2" BANDAGE MO | 1 | |
| GAUZE PADS 2"X2" MO | 1 | |
| GAUZE PAD 2" X 2" BANDAGE MO | 1 | |
| STERILE GAUZE PAD 2" X 2" BANDAGE MO | 1 | |
| RESPIRATORY TRACT AGENTS | | |
| acetylcysteine 10% vial; acetylcysteine 20% vial MO | 2 | B vs D |
| ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET SP | 5 | PA,QL (90 per 30 days) |
| ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION MO | 3 | QL (60 per 30 days) |
| ADVAIR HFA 115 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 230 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 45 MCG-21 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (12 per 30 days) |
| ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION AEROSOL INHALER MO | 4 | QL (18.3 per 28 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| ARALAST NP 1,000 MG, 500 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (13 per 30 days) |
| ASMANEX TWISTHALER 110 MCG (30 DOSES), 110 MCG (7 DOSES), 220 MCG (120 DOSES), 220 MCG (14 DOSES), 220 MCG (30 DOSES), 220 MCG (60 DOSES) BREATH ACTIVATED MO | 3 | QL (1 per 30 days) |
| BREO ELLIPTA 100 MCG-25 MCG/DOSE POWDER FOR INHALATION; BREO ELLIPTA 200 MCG-25 MCG/DOSE POWDER FOR INHALATION MO | 3 | QL (60 per 30 days) |
| <i>budesonide 0.25 mg/2 ml, 0.5 mg/2 ml susp</i> MO | 4 | B vs D |
| <i>cromolyn 100 mg/5 ml oral conc</i> MO | 5 | |
| <i>cromolyn 20 mg/2 ml neb soln</i> MO | 2 | B vs D |
| <i>cromolyn 4% eye drops</i> MO | 2 | |
| DALIRESP 500 MCG TABLET MO | 3 | QL (30 per 30 days) |
| DULERA 100 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER; DULERA 200 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER MO | 4 | QL (13 per 30 days) |
| <i>epoprostenol sodium 0.5 mg, 1.5 mg v1</i> MO | 5 | PA |
| FLOVENT DISKUS 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION MO | 3 | QL (60 per 30 days) |
| FLOVENT HFA 110 MCG/ACTUATION, 220 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (24 per 30 days) |
| FLOVENT HFA 44 MCG/ACTUATION AEROSOL INHALER MO | 3 | QL (10.6 per 30 days) |
| GLASSIA 1 GRAM/50 ML (2 %) INTRAVENOUS SOLUTION MO | 5 | PA |
| KALYDECO 150 MG TABLET SP | 5 | PA,QL (60 per 30 days) |
| KALYDECO 50 MG, 75 MG ORAL GRANULES IN PACKET SP | 5 | PA,QL (56 per 28 days) |
| LETAIRIS 10 MG, 5 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| <i>montelukast sod 10 mg tablet; montelukast sod 4 mg, 5 mg tab chew</i> MO | 2 | QL (30 per 30 days) |
| <i>montelukast sod 4 mg granules</i> MO | 4 | QL (30 per 30 days) |
| OFEV 100 MG, 150 MG CAPSULE SP | 5 | PA,QL (60 per 30 days) |
| OPSUMIT 10 MG TABLET SP | 5 | PA,QL (30 per 30 days) |
| PULMOZYME 1 MG/ML SOLUTION FOR INHALATION SP | 5 | B vs D,QL (150 per 30 days) |
| QVAR 40 MCG/ACTUATION METERED AEROSOL ORAL INHALER MO | 3 | QL (34.8 per 30 days) |
| QVAR 80 MCG/ACTUATION METERED AEROSOL ORAL INHALER MO | 3 | QL (17.4 per 30 days) |
| REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML INJECTION SOLUTION MO | 5 | PA |
| SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER; SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER MO | 3 | QL (11 per 30 days) |
| TRACLEER 125 MG, 62.5 MG TABLET SP | 5 | PA,QL (60 per 30 days) |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| VELETRI 0.5 MG, 1.5 MG INTRAVENOUS SOLUTION MO | 5 | PA |
| VENTAVIS 10 MCG/ML, 20 MCG/ML SOLUTION FOR NEBULIZATION SP | 5 | PA,QL (270 per 30 days) |
| XOLAIR 150 MG SUBCUTANEOUS SOLUTION MO | 5 | PA,QL (7.2 per 28 days) |
| <i>zafirlukast 10 mg, 20 mg tablet</i> MO | 4 | QL (60 per 30 days) |
| SERUMS, TOXOIDS, AND VACCINES | | |
| ACTHIB (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| ADACEL (TDAP ADOLESCENT/ADULT)(PF) 2 LF-(5-3-5MCG)-5 LF/0.5 ML IM SUSP; ADACEL (TDAP ADOLESN/ADULT)(PF)2 LF-(2.5-5-3-5)-5 LF/0.5 ML IM SYRINGE MO | 4 | |
| <i>bcg vaccine (tice strain) vial</i> MO | 4 | |
| BEXSERO (PF) 50MCG-50MCG-50MCG-25MCG/0.5ML INTRAMUSCULAR SYRINGE MO | 4 | |
| BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SUSPENSION; BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| CERVARIX VACCINE (PF) 20 MCG-20 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| COMVAX (PF) 5 MCG-7.5 MCG-125 MCG/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| CYTOGAM 50 MG/ML INTRAVENOUS SOLUTION MO | 5 | PA,QL (1050 per 30 days) |
| DAPTACEL (DTAP PEDIATRIC) (PF) 15 LF UNIT-10 MCG-5 LF/0.5 ML IM SUSP MO | 4 | |
| ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SUSPENSION; ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SYRINGE MO | 4 | B vs D |
| ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML INTRAMUSCULAR SUSPENSION; ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | B vs D |
| GAMUNEX 10% VIAL MO | 5 | PA |
| GAMUNEX-C 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION MO | 5 | PA |
| GARDASIL (PF) 20MCG-40MCG-40MCG-20MCG/0.5ML INTRAMUSCULAR SUSPENSION; GARDASIL (PF) 20MCG-40MCG-40MCG-20MCG/0.5ML INTRAMUSCULAR SYRINGE MO | 4 | QL (1.5 per 365 days) |
| GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SUSPENSION; GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | QL (1.5 per 365 days) |
| HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SUSPENSION; HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| HYPERTET S/D (PF) 250 UNIT INTRAMUSCULAR SYRINGE MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| IMOVAX RABIES VACCINE (PF) 2.5 UNIT INTRAMUSCULAR SOLUTION MO | 3 | B vs D |
| INFANRIX (DTAP) (PF) 25 LF UNIT-58 MCG-10 LF/0.5ML INTRAMUSCULAR SUSP; INFANRIX (DTAP)(PF) 25 LF UNIT-58MCG-10 LF/0.5ML INTRAMUSCULAR SYRINGE MO | 4 | |
| IPOL 40 UNIT-8 UNIT-32 UNIT/0.5 ML SUSPENSION FOR INJECTION MO | 4 | |
| IXIARO (PF) 6 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SUSPENSION; KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML SUBCUTANEOUS SOLUTION MO | 4 | |
| MENACTRA (PF) 4 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| MENHIBRIX (PF) 5 MCG-2.5 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| MENOMUNE - A/C/Y/W-135 50 MCG SUBCUTANEOUS SOLUTION MO | 4 | |
| MENOMUNE - A/C/Y/W-135 (PF) 50 MCG SUBCUTANEOUS SOLUTION MO | 4 | |
| MENVEO A-C-Y-W-135-DIP (PF) 10 MCG-5 MCG/0.5 ML INTRAMUSCULAR KIT MO | 4 | |
| MENVEO MENA COMPONENT (PF) 10 MCG/0.5 ML (FINAL) IM SOLUTION MO | 4 | |
| MENVEO MENCYW-135 COMPONENT (PF) 5 MCG X 3/0.5 ML (FINAL) IM SOLUTION MO | 4 | |
| PEDIARIX (PF) 10MCG-25LF-25MCG-10LF-40-8-32 INTRAMUSCULAR SYRINGE MO | 4 | |
| PEDVAX HIB (PF) 7.5 MCG/0.5 ML INTRAMUSCULAR SOLUTION MO | 4 | |
| PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF/0.5 ML INTRAMUSCULAR KIT MO | 4 | |
| PROQUAD (PF) 10EXP3-4.3-3-3.99TCID50/0.5ML SUBCUTANEOUS SUSPENSION MO | 4 | |
| QUADRACEL (PF) 15 LF-48 MCG-5 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION MO | 4 | |
| RABAVERT (PF) 2.5 UNIT INTRAMUSCULAR SUSPENSION MO | 3 | B vs D |
| RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SUSPENSION; RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | B vs D |
| RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML INJECTION SYRINGE MO | 4 | |
| ROTARIX 10EXP6 CCID50/ML SUSPENSION MO | 4 | |
| ROTATEQ VACCINE 2 ML ORAL SUSPENSION MO | 4 | |
| TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION; TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| <i>tetanus toxoid adsorbed vial</i> MO | 4 | B vs D |
| <i>diphtheria-tetanus toxoids-ped</i> MO | 4 | |
| <i>tetanus diphtheria toxoids</i> MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| THERACYS 81 MG INTRAVESICAL SUSPENSION MO | 4 | B vs D |
| TRUMENBA 120 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| TWINRIX (PF) 720 ELISA UNIT-20 MCG/ML INTRAMUSCULAR SUSPENSION; TWINRIX (PF) 720 ELISA UNIT-20 MCG/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SOLUTION; TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SYRINGE MO | 4 | |
| VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SUSPENSION; VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SYRINGE MO | 4 | |
| VARIVAX (PF) 1,350 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION MO | 3 | |
| VARIZIG 125 UNIT INTRAMUSCULAR POWDER FOR SOLUTION MO | 5 | PA,QL (10 per 30 days) |
| VARIZIG 125 UNIT/1.2 ML INTRAMUSCULAR SOLUTION MO | 5 | PA,QL (12 per 30 days) |
| WINRHO SDF 1,500 UNIT/1.3 ML, 15,000 UNIT/13 ML, 2,500 UNIT/2.2 ML, 5,000 UNIT/4.4 ML INJECTION SOLUTION MO | 5 | B vs D |
| YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION MO | 4 | |
| ZOSTAVAX (PF) 19,400 UNIT/0.65 ML SUBCUTANEOUS SUSPENSION MO | 3 | QL (0.65 per 365 days) |
| SKIN AND MUCOUS MEMBRANE AGENTS | | |
| 8-MOP 10 MG CAPSULE MO | 4 | |
| <i>acitretin 10 mg, 17.5 mg, 25 mg capsule</i> MO | 5 | |
| <i>acyclovir 5% ointment</i> MO | 4 | PA |
| <i>adapalene 0.1% cream; adapalene 0.1% gel</i> MO | 4 | |
| AKNE-MYCIN 2% OINTMENT MO | 4 | |
| ALA-CORT 1 % TOPICAL CREAM MO | 2 | |
| <i>alclometasone dipr 0.05% oint; alclometasone dipro 0.05% crm</i> MO | 3 | |
| ALCOHOL PADS MO | 1 | |
| ALCOHOL PREP PADS MO | 1 | |
| ALCOHOL PREP SWABS MO | 1 | |
| ALCOHOL 70% SWABS MO | 1 | |
| ALCOHOL WIPES MO | 1 | |
| ALTABAX 1 % TOPICAL OINTMENT MO | 4 | |
| <i>amcinonide 0.1% cream; amcinonide 0.1% lotion; amcinonide 0.1% ointment</i> MO | 4 | |
| <i>ammonium lactate 12% cream; ammonium lactate 12% lotion</i> MO | 2 | |
| <i>amnesteem 10 mg, 20 mg, 40 mg capsule</i> MO | 4 | |
| ANUSOL-HC 2.5 % RECTAL CREAM MO | 4 | |
| <i>apexicon e 0.05 % topical cream</i> MO | 4 | |
| AVC VAGINAL 15 % CREAM MO | 2 | |
| AZELEX 20 % TOPICAL CREAM MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| BD ALCOHOL SWABS MO | 1 | |
| betamethasone dp 0.05% crm; betamethasone dp 0.05% lot; betamethasone dp 0.05% oint MO | 3 | |
| betamethasone va 0.1% cream; betamethasone va 0.1% lotion; betamethasone valer 0.1% ointm MO | 2 | |
| betamethasone dp aug 0.05% crm; betamethasone dp aug 0.05% gel; betamethasone dp aug 0.05% lot; betamethasone dp aug 0.05% oin MO | 3 | |
| calcipotriene 0.005% cream MO | 4 | QL (120 per 30 days) |
| calcipotriene 0.005% ointment MO | 4 | |
| calcipotriene 0.005% solution MO | 4 | QL (60 per 30 days) |
| calcipotriene-betameth dp oint MO | 5 | |
| CAPEX 0.01 % SHAMPOO MO | 4 | |
| CENTANY 2 % TOPICAL OINTMENT MO | 4 | |
| CENTANY AT 2 % OINTMENT TOPICAL KIT MO | 3 | |
| ciclodan 0.77 % topical cream; ciclodan 8 % topical solution MO | 3 | |
| ciclopirox 0.77% cream; ciclopirox 8% solution MO | 3 | |
| ciclopirox 0.77% gel; ciclopirox 0.77% topical susp; ciclopirox 1% shampoo MO | 4 | |
| claravis 10 mg, 20 mg, 30 mg, 40 mg capsule MO | 4 | |
| CLEOCIN 100 MG VAGINAL SUPPOSITORY MO | 4 | |
| clindamycin 150 mg/ml addvan; clindamycin 2% vaginal cream; clindamycin ph 1% gel; clindamycin ph 1% solution; clindamycin ph 600 mg/4 ml vl; clindamycin phos 1% pledget; clindamycin phosp 1% lotion MO | 3 | |
| clindamycin-benzoyl perox gel MO | 4 | |
| CLINDESSE 2 % VAGINAL CREAM,EXTENDED RELEASE MO | 4 | |
| clobetasol 0.05% cream MO | 4 | |
| clobetasol 0.05% gel; clobetasol 0.05% ointment; clobetasol 0.05% solution MO | 3 | |
| clobetasol emollient 0.05% crm MO | 3 | |
| clocortolone pivalate 0.1% crm MO | 4 | |
| clotrimazole 1% cream; clotrimazole 1% solution; clotrimazole 10 mg troche MO | 2 | |
| clotrimazole-betamethasone crm; clotrimazole-betamethasone lot MO | 3 | |
| CNL 8 NAIL 8 % TOPICAL KIT MO | 4 | |
| colocort 100 mg/60 ml enema MO | 4 | |
| CONDYLOX 0.5 % TOPICAL GEL; CONDYLOX 0.5 % TOPICAL SOLUTION MO | 4 | |
| cormax 0.05 % topical solution MO | 4 | |
| CORTIFOAM 10 % (80 MG) RECTAL MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| CORTISPORIN 1 % TOPICAL OINTMENT; CORTISPORIN 3.5 MG/G-10,000 UNIT/G-0.5 % TOPICAL CREAM MO | 4 | |
| COSENTYX 150 MG/ML SUBCUTANEOUS SYRINGE SP | 5 | PA,QL (2 per 28 days) |
| COSENTYX (2 SYRINGES) 300 MG (150 MG/ML) SUBCUTANEOUS SP | 5 | PA,QL (2 per 28 days) |
| COSENTYX PEN 150 MG/ML SUBCUTANEOUS SP | 5 | PA,QL (2 per 28 days) |
| COSENTYX PEN (2 PENS) 300 MG (150 MG/ML) SUBCUTANEOUS SP | 5 | PA,QL (2 per 28 days) |
| CURITY ALCOHOL SWABS MO | 1 | |
| DENAVIR 1 % TOPICAL CREAM MO | 4 | |
| DESONATE 0.05 % TOPICAL GEL MO | 4 | |
| <i>desonide 0.05% cream; desonide 0.05% lotion; desonide 0.05% ointment</i> MO | 4 | |
| <i>desoximetasone 0.05% cream; desoximetasone 0.05% gel; desoximetasone 0.05% ointment; desoximetasone 0.25% cream; desoximetasone 0.25% ointment</i> MO | 4 | |
| <i>diflorasone 0.05% cream; diflorasone 0.05% ointment</i> MO | 4 | |
| EASY TOUCH ALCOHOL PREP PADS MO | 1 | |
| <i>econazole nitrate 1% cream</i> MO | 3 | |
| ELIDEL 1 % TOPICAL CREAM MO | 4 | |
| EPIDUO 0.1 %-2.5 % TOPICAL GEL; EPIDUO 0.1 %-2.5 % TOPICAL GEL WITH PUMP MO | 4 | |
| EPIDUO FORTE 0.3 %-2.5 % TOPICAL GEL WITH PUMP MO | 4 | |
| <i>ery pads 2 % topical swab</i> MO | 3 | |
| <i>erythromycin 2% gel</i> MO | 2 | |
| <i>erythromycin 2% pledgets; erythromycin 2% solution</i> MO | 3 | |
| <i>erythromycin-benzoyl gel</i> MO | 3 | |
| EURAX 10 % LOTION; EURAX 10 % TOPICAL CREAM MO | 4 | |
| EXELDERM 1 % TOPICAL CREAM; EXELDERM 1 % TOPICAL SOLUTION MO | 4 | |
| <i>fluocinolone 0.01% body oil; fluocinolone 0.01% solution</i> MO | 4 | |
| <i>fluocinolone 0.01% cream; fluocinolone 0.025% cream; fluocinolone 0.025% ointment</i> MO | 3 | |
| <i>fluocinolone 0.01% scalp oil</i> MO | 3 | |
| <i>fluocinonide 0.05% cream; fluocinonide 0.05% gel; fluocinonide 0.05% ointment</i> MO | 3 | |
| <i>fluocinonide 0.05% solution</i> MO | 4 | |
| <i>fluocinonide-e 0.05 % topical cream</i> MO | 3 | |
| <i>fluorouracil 0.5% cream; fluorouracil 2% topical soln; fluorouracil 5% cream; fluorouracil 5% top solution</i> MO | 4 | |
| <i>fluticasone prop 0.005% oint; fluticasone prop 0.05% cream</i> MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| gentamicin 0.1% cream; gentamicin 0.1% ointment; gentamicin 0.3% eye drops; gentamicin 0.3% eye ointment MO | 2 | |
| gynazole-1 2 % vaginal cream MO | 4 | |
| halobetasol prop 0.05% cream; halobetasol prop 0.05% ointment MO | 4 | |
| HALOG 0.1 % TOPICAL CREAM; HALOG 0.1 % TOPICAL OINTMENT MO | 4 | |
| HALONATE COMBO PACK MO | 4 | |
| halonate pac combo pack MO | 3 | |
| hydrocortisone 1% cream; hydrocortisone 1% ointment; hydrocortisone 10 mg, 20 mg, 5 mg tablet; hydrocortisone 2.5% cream; hydrocortisone 2.5% lotion; hydrocortisone 2.5% ointment MO | 2 | |
| hydrocortisone 100 mg/60 ml MO | 3 | |
| hydrocort buty 0.1% lipo cream MO | 4 | |
| hydrocortisone 0.1% soln; hydrocortisone buty 0.1% cream; hydrocortisone butyr 0.1% oint MO | 3 | |
| hydrocortisone val 0.2% cream; hydrocortisone val 0.2% ointment MO | 4 | |
| hydrocortisone 1% absorbase MO | 1 | |
| imiquimod 5% cream packet MO | 4 | QL (12 per 30 days) |
| IV PREP WIPES MEDICATED MO | 1 | |
| KENALOG 0.147 MG/GRAM TOPICAL AEROSOL MO | 4 | |
| KEPIVANCE 6.25 MG INTRAVENOUS SOLUTION MO | 5 | |
| ketoconazole 2% cream; ketoconazole 2% shampoo; ketoconazole 200 mg tablet MO | 2 | |
| ketoconazole 2% foam MO | 4 | |
| ketodan 2% foam MO | 4 | |
| KLARON 10 % TOPICAL SUSPENSION MO | 4 | |
| LAC-HYDRIN 12% CREAM; LAC-HYDRIN 12% LOTION MO | 4 | |
| LEVULAN 20 % TOPICAL SOLUTION MO | 4 | |
| lidocaine 5% ointment MO | 4 | |
| lidocaine 5% patch MO | 4 | PA,QL (90 per 30 days) |
| lidocaine-prilocaine cream MO | 3 | |
| lindane 1% lotion; lindane 1% shampoo MO | 4 | |
| mafenide acetate 50 gm powd pk MO | 4 | |
| malathion 0.5% lotion MO | 4 | |
| MENTAX 1 % TOPICAL CREAM MO | 4 | |
| methoxsalen 10 mg capsule MO | 5 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| metronidazole 0.75% cream; metronidazole 0.75% lotion; metronidazole 375 mg capsule; metronidazole topical 0.75% gl; metronidazole topical 1% gel; metronidazole topical 1% gel MO | 4 | |
| metronidazole 250 mg, 500 mg tablet; metronidazole vaginal 0.75% gl MO | 2 | |
| miconazole-3 200 mg vaginal suppository MO | 3 | |
| mometasone furoate 0.1% cream; mometasone furoate 0.1% oint; mometasone furoate 0.1% soln MO | 2 | |
| mupirocin 2% ointment MO | 2 | |
| mupirocin 2% cream MO | 4 | |
| myorisan 10 mg, 20 mg, 30 mg, 40 mg capsule MO | 4 | |
| naftifine hcl 1% cream MO | 3 | |
| NAFTIN 1 %, 2 % TOPICAL CREAM; NAFTIN 1 %, 2 % TOPICAL GEL MO | 3 | |
| neomy-polymyxin b 40 mg/ml amp MO | 3 | |
| nyamyc 100,000 unit/gram topical powder MO | 2 | |
| nystatin 100,000 unit/gm cream; nystatin 100,000 unit/gm powd; nystatin 100,000 units/gm oint; nystatin 100,000 units/ml susp; nystatin 500,000 unit oral tab MO | 2 | |
| nystatin-triamcinolone cream; nystatin-triamcinolone ointm MO | 4 | |
| nystop 100,000 unit/gram topical powder MO | 2 | |
| oralone 0.1 % dental paste MO | 1 | |
| OXISTAT 1 % LOTION; OXISTAT 1 % TOPICAL CREAM MO | 4 | |
| OXSORALEN 1 % LOTION MO | 4 | |
| PANDEL 0.1 % TOPICAL CREAM MO | 4 | |
| PANRETIN 0.1 % TOPICAL GEL SP | 5 | |
| pedi-dri topical powder MO | 2 | |
| permethrin 5% cream MO | 3 | |
| PICATO 0.015 % TOPICAL GEL MO | 4 | QL (3 per 30 days) |
| PICATO 0.05 % TOPICAL GEL MO | 4 | QL (2 per 30 days) |
| podofilox 0.5% topical soln MO | 4 | |
| prednicarbate 0.1% cream; prednicarbate 0.1% ointment MO | 3 | |
| procto-pak 1 % rectal cream MO | 2 | |
| PROCTOSOL HC 2.5 % RECTAL CREAM MO | 2 | |
| proctozone-hc 2.5 % rectal cream MO | 3 | |
| psorcon 0.05 % topical cream MO | 4 | |
| RECTIV 0.4 % (W/W) OINTMENT MO | 4 | QL (30 per 30 days) |
| REGANEX 0.01 % TOPICAL GEL MO | 5 | |
| RIMSO-50 50 % INTRAVESICAL SOLUTION MO | 2 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|---|------|-------------------------------------|
| SANTYL 250 UNIT/GRAM TOPICAL OINTMENT MO | 4 | |
| selenium sulfide 2.5% lotion MO | 2 | |
| silver sulfadiazine 1% cream MO | 2 | |
| SORIATANE 10 MG, 17.5 MG, 25 MG CAPSULE MO | 5 | |
| SSD 1 % TOPICAL CREAM MO | 2 | |
| sulfacetamide sod 10% top susp MO | 2 | |
| SULFAMYLON 50 GRAM TOPICAL PACKET; SULFAMYLON 85 MG/G TOPICAL CREAM MO | 4 | |
| SURE COMFORT ALCOHOL PREP PADS MO | 1 | |
| SURE-PREP ALCOHOL PREP PADS MO | 1 | |
| SYNERA 70 MG-70 MG PATCH MO | 4 | |
| TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION MO | 3 | QL (420 per 30 days) |
| TARGRETIN 1 % TOPICAL GEL SP | 5 | PA |
| TAZORAC 0.05 %, 0.1 % TOPICAL CREAM; TAZORAC 0.05 %, 0.1 % TOPICAL GEL MO | 4 | PA |
| terconazole 0.4% cream; terconazole 0.8% cream; terconazole 80 mg suppository MO | 2 | |
| THERMAZENE 1 % TOPICAL CREAM MO | 2 | |
| tretinoin 0.01% gel; tretinoin 0.025% cream; tretinoin 0.025% gel; tretinoin 0.05% cream; tretinoin 0.1% cream MO | 3 | PA |
| triamcinolone 0.025% cream; triamcinolone 0.025% oint; triamcinolone 0.1% cream; triamcinolone 0.1% ointment; triamcinolone 0.5% cream; triamcinolone 0.5% ointment MO | 2 | |
| triamcinolone 0.025% lotion; triamcinolone 0.1% lotion; triamcinolone 0.1% paste MO | 3 | |
| triamcinolone 0.147 mg/g spray; triamcinolone acet 40mg/ml vl; triamcinolone acet 50mg/5ml vl MO | 4 | |
| triderm 0.1 % topical cream MO | 2 | |
| u-cort 1 %-10 % topical cream MO | 2 | |
| ULTILET ALCOHOL SWAB MO | 1 | |
| UVADEX 20 MCG/ML INJECTION SOLUTION MO | 4 | B vs D |
| VALCHLOR 0.016 % TOPICAL GEL SP | 5 | PA,QL (60 per 28 days) |
| VANAZOLE 0.75 % VAGINAL GEL MO | 3 | |
| VELTIN 1.2 %-0.025 % TOPICAL GEL MO | 4 | |
| VEREGEN 15 % TOPICAL OINTMENT MO | 5 | |
| WEBCOL TOPICAL PADS MO | 1 | |
| WESTCORT 0.2% OINTMENT MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| zenatane 10 mg, 20 mg, 30 mg, 40 mg capsule ^{MO} | 4 | |
| ZOVIRAX 5 % TOPICAL CREAM ^{MO} | 5 | PA |
| ZYCLARA TOPICAL CREAM PUMP ^{MO} | 4 | QL (15 per 30 days) |
| ZYCLARA 3.75 % TOPICAL CREAM PACKET ^{MO} | 4 | |
| SMOOTH MUSCLE RELAXANTS | | |
| aminophylline 250 mg/10 ml, 500 mg/20 ml vial ^{MO} | 2 | |
| ELIXOPHYLLIN 80 MG/15 ML ORAL ELIXIR ^{MO} | 2 | |
| flavoxate hcl 100 mg tablet ^{MO} | 3 | |
| LUFYLLIN 200 MG TABLET ^{MO} | 4 | |
| MYRBETRIQ 25 MG, 50 MG TABLET,EXTENDED RELEASE ^{MO} | 4 | QL (30 per 30 days) |
| oxybutynin 5 mg tablet; oxybutynin 5 mg/5 ml syrup ^{MO} | 2 | |
| oxybutynin cl er 10 mg, 15 mg, 5 mg tablet ^{MO} | 3 | QL (60 per 30 days) |
| theophylline 80 mg/15 ml soln; theophylline 80 mg/15 ml soln ^{MO} | 4 | |
| theophylline er 100 mg, 200 mg, 300 mg, 450 mg tab; theophylline er 100 mg, 200 mg, 300 mg, 450 mg tablet; theophylline er 400 mg, 600 mg tablet ^{MO} | 2 | |
| theophylline 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 400 mg/500 ml, 800 mg/250 ml, 800 mg/500 ml d5w ^{MO} | 2 | |
| tolterodine tart er 2 mg, 4 mg cap ^{MO} | 2 | QL (30 per 30 days) |
| tolterodine tartrate 1 mg, 2 mg tab ^{MO} | 3 | QL (60 per 30 days) |
| TOVIAZ 4 MG, 8 MG TABLET,EXTENDED RELEASE ^{MO} | 3 | QL (30 per 30 days) |
| tropium chloride 20 mg tablet ^{MO} | 4 | |
| tropium chloride er 60 mg cap ^{MO} | 4 | QL (30 per 30 days) |
| VESICARE 10 MG, 5 MG TABLET ^{MO} | 4 | QL (30 per 30 days) |
| VITAMINS | | |
| bal-care dha 27 mg-1 mg-430 mg tablet&capsule,delayed release ^{MO} | 4 | |
| c-nate dha 28 mg-1 mg-200 mg capsule ^{MO} | 4 | |
| calcitriol 0.25 mcg, 0.5 mcg capsule; calcitriol 1 mcg/ml ampul ^{MO} | 2 | |
| calcitriol 1 mcg/ml solution ^{MO} | 3 | |
| cavan-ec sod dha vitamins ^{MO} | 4 | |
| CITRANATAL 90 DHA PACK ^{MO} | 4 | |
| CITRANATAL ASSURE COMBO PACK ^{MO} | 4 | |
| CITRANATAL DHA PACK ^{MO} | 4 | |
| CITRANATAL RX TABLET ^{MO} | 4 | |
| complete natal dha 29 mg-1 mg-250 mg oral pack ^{MO} | 4 | |
| completenate 29 mg-1 mg chewable tablet ^{MO} | 4 | |
| CONCEPT DHA 35 MG-1 MG-200 MG CAPSULE ^{MO} | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| CONCEPT OB 85 MG-1 MG CAPSULE MO | 4 | |
| dexpanthenol 250 mg/ml vial MO | 1 | |
| doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg cap; doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg capsule MO | 4 | |
| doxercalciferol 4 mcg/2 ml vl MO | 3 | |
| elite-ob 50 mg-1.25 mg tablet MO | 4 | |
| folivane-ob 85 mg-1 mg capsule MO | 4 | |
| folivane-prx dha nf capsule MO | 4 | |
| GESTICARE DHA COMBO PACK MO | 4 | |
| HECTOROL 2 MCG/ML (1 ML) INTRAVENOUS SOLUTION MO | 3 | |
| inatal advance 90 mg-1 mg-50 mg tablet MO | 4 | |
| inatal ultra 90 mg-1 mg-50 mg tablet MO | 4 | |
| multi-vitamin with fluoride 0.25 mg, 0.5 mg, 1 mg chewable tablet MO | 4 | |
| multivitamin with fluoride 0.5 mg chewable tablet MO | 4 | |
| multivitamins with fluoride 0.25 mg, 0.5 mg, 1 mg chewable tablet MO | 4 | |
| MVC-FLUORIDE 0.25 MG, 0.5 MG, 1 MG CHEWABLE TABLET MO | 4 | |
| O-CAL PRENATAL 15 MG-1 MG TABLET MO | 4 | |
| paire ob plus dha 22 mg-6 mg-1 mg-200 mg oral pack MO | 4 | |
| paricalcitol 1 mcg, 2 mcg capsule; paricalcitol 10 mcg/2 ml vial; paricalcitol 2 mcg/ml, 5 mcg/ml vial MO | 3 | |
| paricalcitol 4 mcg capsule MO | 4 | |
| prv ob+dha 27 mg-1 mg-50 mg-250 mg oral pack MO | 4 | |
| pr natal 400 29 mg-1 mg-400 mg oral pack MO | 4 | |
| pr natal 400 ec 29 mg-1 mg-400 mg tablet&capsule, delayed release MO | 4 | |
| pr natal 430 29 mg-1 mg-430 mg oral pack MO | 4 | |
| pr natal 430 ec 29 mg-1 mg-430 mg tablet&capsule, delayed release MO | 4 | |
| PRENATA 29 MG IRON-1 MG CHEWABLE TABLET MO | 4 | |
| PRENATABS FA 29 MG-1 MG TABLET MO | 4 | |
| prenatal plus (calcium carbonate) 27 mg iron-1 mg tablet MO | 4 | |
| prenatal plus iron tablet MO | 4 | |
| PRENATE DHA 28 MG IRON-1 MG-300 MG CAPSULE MO | 4 | |
| PRENATE ELITE 26 MG IRON-1 MG TABLET MO | 4 | |
| PRENATE ESSENTIAL 29 MG IRON-1 MG-300 MG CAPSULE MO | 4 | |
| preplus 27 mg iron-1 mg tablet MO | 4 | |
| PREQUE 10 15 MG IRON-0.5 MG-25 MG TABLET MO | 4 | |
| relnate dha 28 mg-1 mg-200 mg capsule MO | 4 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

| DRUG NAME | TIER | UTILIZATION MANAGEMENT REQUIREMENTS |
|--|------|-------------------------------------|
| se-natal 19 29 mg iron-1 mg chewable tablet MO | 4 | |
| se-natal 19 (with docusate) 29 mg iron-1 mg-25 mg tablet MO | 4 | |
| se-tan dha 30 mg-1 mg-310.1 mg capsule MO | 4 | |
| setonet prenatal vitamin MO | 4 | |
| SETONET-EC PRENATAL VITAMINS MO | 4 | |
| taron-bc 20 mg iron-1 mg-25 mg/25 mg tablets MO | 4 | |
| taron-c dha 35 mg-1 mg-200 mg capsule MO | 4 | |
| taron-prex prenatal-dha 30 mg iron-1.2 mg-55 mg-265mg capsule MO | 4 | |
| thrivite-19 29 mg iron-1 mg-25 mg tablet MO | 4 | |
| tri-vit with fluoride & iron 0.25 mg-10 mg/ml oral drops MO | 1 | |
| tri-vitamin with fluoride 0.5 mg fluoride (1.1 mg)/ml oral drops MO | 1 | |
| triadvance 90 mg-1 mg-50 mg tablet MO | 4 | |
| trinatal gt 90 mg-1 mg-50 mg tablet MO | 4 | |
| trinatal rx 1 60 mg iron-1 mg tablet MO | 4 | |
| trinatal ultra tablet MO | 4 | |
| triveen-duo dha 29 mg-1 mg-400 mg oral pack MO | 4 | |
| triveen-prx rnf 26 mg-1.2 mg-55 mg-300 mg capsule MO | 4 | |
| ultimate ob dha combo pack MO | 4 | |
| ultimatecare one 27 mg-1 mg-330 mg capsule MO | 4 | |
| ultimatecare one nf 27 mg-1 mg-50 mg-500 mg capsule MO | 4 | |
| vena-bal dha 27 mg-1 mg-430 mg tablet&capsule,delayed release MO | 4 | |
| virt-c dha 35 mg-1 mg-200 mg capsule MO | 4 | |
| virt-care one 27 mg-1 mg-330 mg capsule MO | 4 | |
| zatean-ch 27 mg-1 mg-50 mg-250 mg capsule MO | 4 | |
| ZEMPLAR 2 MCG/ML, 5 MCG/ML INTRAVENOUS SOLUTION MO | 3 | |

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D

Index

A

- a-hydrocort... 71
- abacavir... 10
- abacavir-lamivudine-zidovudine... 10
- ABELCET... 10
- ABILIFY DISCMELT... 39
- ABILIFY MAINTENA... 39
- ABILIFY... 39
- ABRAXANE... 21
- acamprosate... 39
- acarbose... 71
- acebutolol... 32
- acetaminophen-codeine... 39
- acetasol hc... 65
- acetazolamide sodium... 65
- acetazolamide... 65
- acetic acid... 59, 65
- acetic acid-aluminum acetate... 65
- acetylcysteine... 83, 87
- acitretin... 91
- ACTHIB (PF)... 89
- ACTIMMUNE... 83
- acyclovir sodium... 10
- acyclovir... 10, 91
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 89
- ADAGEN... 65
- ADALAT CC... 32
- adapalene... 91
- ADCIRCA... 32
- adefovir... 10
- ADEMPAS... 87
- adenosine... 32
- adriamycin pfs... 21
- adriamycin... 21
- ADVAIR DISKUS... 87
- ADVAIR HFA... 87
- ADVOCATE PEN NEEDLES... 53
- ADVOCATE SYRINGES... 53
- afeditab cr... 32
- AFINITOR DISPERZ... 21
- AFINITOR... 21
- AGGRENEX... 32
- ak-poly-bac... 65
- AKNE-MYCIN... 91
- akorn balanced salt... 65
- AKTEN (PF)... 65
- ALA-CORT... 91
- ALBENZA... 10
- albuterol sulfate... 27
- alclometasone... 91
- ALCOHOL PADS... 91
- ALCOHOL PREP PADS... 91
- ALCOHOL PREP SWABS... 91
- ALCOHOL SWABS... 91
- ALCOHOL WIPES... 91
- alendronate... 83
- alfuzosin... 27
- ALIMTA... 21
- ALINIA... 10
- ALKERAN... 21
- allopurinol... 83
- ALOMIDE... 65
- ALOPRIM... 83
- ALORA... 71
- alosetron... 69
- ALPHAGAN P... 65
- alprazolam... 39
- ALREX... 65
- ALSUMA... 39
- ALTABAX... 91
- altavera (28)... 71
- ALVESCO... 87
- alyacen 1/35 (28)... 71
- alyacen 7/7/7 (28)... 72
- amantadine hcl... 39
- AMBISOME... 10
- amcinonide... 91
- amethia lo... 72
- amethia... 72
- amethyst... 72
- amifostine crystalline... 83
- amikacin... 10
- amiloride... 59
- amiloride-hydrochlorothiazide... 59
- amino acids 15 %... 59
- aminocaproic acid... 30
- aminophylline... 97
- AMINOSYN II 10 %... 59
- AMINOSYN II 15 %... 59
- AMINOSYN II 7 %... 59
- AMINOSYN II 8.5 %... 59

| | | |
|--------------------------------------|----------------------------------|-------------------------------------|
| AMINOSYN II 8.5 %-ELECTROLYTES... 59 | AMPYRA... 83 | ATELVIA... 83 |
| AMINOSYN M 3.5 %... 59 | AMTURNIDE... 33 | atenolol... 33 |
| AMINOSYN 10 %... 59 | ANADROL-50... 72 | atenolol-chlorthalidone... 33 |
| AMINOSYN 7 % WITH ELECTROLYTES... 59 | anagrelide... 30 | ATGAM... 83 |
| AMINOSYN 8.5 %... 59 | anastrozole... 21 | atorvastatin... 33 |
| AMINOSYN 8.5 %-ELECTROLYTES... 59 | ANDROGEL... 72 | atovaquone... 10 |
| AMINOSYN-HBC 7%... 59 | androxy... 72 | atovaquone-proguanil... 10 |
| AMINOSYN-PF 10 %... 59 | ANORO ELLIPTA... 27 | ATRIPLA... 10 |
| AMINOSYN-PF 7 % (SULFITE-FREE)... 59 | ANUSOL-HC... 91 | atropine... 27, 65 |
| AMINOSYN-RF 5.2 %... 59 | apexicon e... 91 | ATROVENT HFA... 28 |
| amiodarone... 32 | APIDRA SOLOSTAR... 72 | AUBAGIO... 83 |
| AMITIZA... 69 | APIDRA... 72 | aubra... 72 |
| amitriptyline... 39 | APOKYN... 40 | AUTOJECT 2 INJECTION DEVICE... 53 |
| amlodipine... 32 | apraclonidine... 65 | AUTOPEN 1 TO 16 UNITS... 53 |
| amlodipine-atorvastatin... 32 | apri... 72 | AUTOPEN 1 TO 21 UNITS... 53 |
| amlodipine-benazepril... 32, 33 | APRISO... 69 | AUTOPEN 2 TO 32 UNITS... 53 |
| amlodipine-valsartan... 33 | APTIOM... 40 | AUTOPEN 2 TO 42 UNITS... 53 |
| amlodipine-valsartan-hcthiazid... 33 | APTIVUS... 10 | AVANDIA... 72 |
| ammonium chloride... 59 | ARALAST NP... 88 | AVASTIN... 21 |
| ammonium lactate... 91 | aranelle (28)... 72 | AVC VAGINAL... 91 |
| AMMONUL... 59 | ARCALYST... 83 | AVELOX IN NA CL (ISO-OSMOTIC)... 11 |
| amnestem... 91 | ARCAPTA NEOHALER... 27 | aviane... 72 |
| amoxapine... 39 | argatroban... 30 | AVODART... 83 |
| amoxicillin... 10 | aripiprazole... 40 | AVONEX (WITH ALBUMIN)... 83 |
| amoxicillin-pot clavulanate... 10 | ARISTOSPAN INTRA-ARTICULAR... 72 | AVONEX... 83 |
| amphetamine salt combo... 39, 40 | ARISTOSPAN INTRALESIONAL... 72 | AYGESTIN... 72 |
| amphotericin b... 10 | ARRANON... 21 | azacitidine... 21 |
| ampicillin sodium... 10 | ARZERRA... 21 | AZASAN... 83 |
| ampicillin... 10 | ashlyna... 72 | AZASITE... 65 |
| ampicillin-sulbactam... 10 | ASMANEX HFA... 88 | azathioprine... 83 |
| | ASMANEX TWISTHALER... 88 | azelastine... 65 |
| | aspirin-dipyridamole... 33 | AZELEX... 91 |
| | ASSURE ID INSULIN SAFETY... 53 | |

AZILECT... 40
azithromycin... 11
AZOPT... 65
AZOR... 33
aztreonam... 11
azurette (28)... 72

B

baciim... 11
bacitracin... 11, 65
bacitracin-polymyxin b... 65
baclofen... 28
BAL IN OIL... 71
bal-care dha... 97
balanced salt... 65
balsalazide... 69
balziva (28)... 72
BAND-AID GAUZE PADS... 87
BANZEL... 40
BARACLUDE... 11
bcg vaccine, live (pf)... 89
BD ALCOHOL SWABS... 92
BD AUTOSHIELD DUO PEN NEEDLE... 53
BD AUTOSHIELD PEN NEEDLE... 53
BD ECLIPSE LUER-LOK... 53
BD INSULIN PEN NEEDLE UF MINI... 53
BD INSULIN PEN NEEDLE UF ORIG... 53
BD INSULIN PEN NEEDLE UF SHORT... 53
BD INSULIN SYRINGE HALF UNIT... 53
BD INSULIN SYRINGE MICRO-FINE... 53
BD INSULIN SYRINGE SAFETY-LOK... 53
BD INSULIN SYRINGE SLIP TIP... 54
BD INSULIN SYRINGE ULT-FINE II... 54
BD INSULIN SYRINGE ULTRA-FINE... 54
BD INSULIN SYRINGE... 53
BD INTEGRA INSULIN SYRINGE... 54
BD LO-DOSE MICRO-FINE IV... 54
BD LO-DOSE ULTRA-FINE... 54
BD SAFETYGLIDE INSULIN SYRINGE... 54
BD SAFETYGLIDE SYRINGE... 54
BD ULTRA-FINE NANO PEN NEEDLES... 54
BELEODAQ... 21
benazepril... 33
benazepril-hydrochlorothiazide... 33
BENICAR HCT... 33
BENICAR... 33
BENLYSTA... 84
benztropine... 40
BEPREVE... 66
BESIVANCE... 66
BETADINE OPHTHALMIC PREP... 66
betamethasone acet,sod phos... 72
betamethasone dipropionate... 92
betamethasone valerate... 92
betamethasone, augmented... 92
BETASERON... 84
betaxolol... 66
bethanechol chloride... 28
BETHKIS... 11
bexarotene... 21
BEXSERO (PF)... 89
bicalutamide... 21
BICILLIN C-R... 11
BICILLIN L-A... 11
BICNU... 21
BIDIL... 33
BILTRICIDE... 11
BINOSTO... 84
bisoprolol fumarate... 33
bisoprolol-hydrochlorothiazide... 33
bleomycin... 21
BLEPH-10... 66
BLEPHAMIDE S.O.P... 66
BLEPHAMIDE... 66
BOOSTRIX TDAP... 89
BORDERED GAUZE... 87
BOSULIF... 21
BREO ELLIPTA... 88
BREVIBLOC IN NAACL (ISO-OSM)... 33
BREVICON (28)... 72
briellyn... 72
BRILINTA... 30
brimonidine... 66
BRINTELLIX... 40
bromocriptine... 40
BSS PLUS... 66
budeprion sr... 40
budesonide... 72, 88
bumetanide... 59
BUPHENYL... 59
bupivacaine (pf)... 82
bupivacaine... 82

BUPRENEX... 40
 buprenorphine hcl... 40
 buproban... 40
 bupropion hcl... 40
 buspirone... 40
 BUSULFEX... 21
 butalbital-acetaminophen... 40
 butalbital-acetaminophen-caff... 40
 butalbital-aspirin-caffeine... 40
 BUTISOL... 40
 butorphanol tartrate... 40
 BYSTOLIC... 33

C

c-nate dha... 97
 CAFERGOT... 28
 caffeine citrated... 40
 caffeine-sodium benzoate... 40
 calcipotriene... 92
 calcipotriene-betamethasone... 92
 calcitonin (salmon)... 72
 calcitriol... 97
 calcium acetate... 59
 calcium chloride... 59
 calcium disodium versenate... 71
 calcium folinate (leucovorin)... 84
 calcium gluconate... 60
 camila... 72
 CAMPTOSAR... 21
 CAMRESE LO... 72
 CAMRESE... 72
 CANASA... 69
 CANCIDAS... 11
 candesartan... 33
 candesartan-hydrochlorothiazid... 33
 CANTIL... 28
 CAPASTAT... 11
 CAPEX... 92
 CAPITAL WITH CODEINE... 41
 CAPRELSA... 21
 captopril... 33
 captopril-hydrochlorothiazide... 33
 CARAFATE... 69
 CARBAGLU... 60
 carbamazepine... 41
 CARBATROL... 41
 carbidopa-levodopa... 41
 carboplatin... 22
 CARDENE SR... 33
 CAREFINE PEN NEEDLE... 54
 CARNITOR SUGAR-FREE... 84
 carteolol... 66
 cartia xt... 33
 carvedilol... 34
 cavan-ec sod dha... 97
 CAYSTON... 11
 caziant (28)... 72
 cefaclor... 11
 cefadroxil... 11
 cefazolin in dextrose (iso-os)... 11
 cefazolin... 11
 cefdinir... 11
 cefepime in dextrose 5 %... 11
 cefepime in dextrose,iso-osm... 11
 cefepime... 11
 cefotaxime... 11, 12
 cefotetan in dextrose, iso-osm... 12
 cefotetan... 12
 cefoxitin in dextrose, iso-osm... 12
 cefoxitin... 12
 cefpodoxime... 12
 cefprozil... 12
 ceftazidime in d5w... 12
 ceftazidime... 12
 ceftibuten... 12
 ceftriaxone in dextrose,iso-os... 12
 ceftriaxone... 12
 cefuroxime axetil... 12
 cefuroxime sodium... 12
 cefuroxime-dextrose (iso-osm)... 12
 celecoxib... 41
 CELLCEPT INTRAVENOUS... 84
 CELLCEPT... 84
 CELONTIN... 41
 CENTANY AT... 92
 CENTANY... 92
 cephalixin... 12
 CERVARIX VACCINE (PF)... 89
 CERVIDIL... 87
 cetirizine... 20
 CHANTIX CONTINUING MONTH BOX... 28
 CHANTIX STARTING MONTH BOX... 28
 CHANTIX... 28
 chateal... 72
 CHEMET... 71
 CHENODAL... 69
 chloramphenicol sod succinate... 12

| | | |
|---|---|---|
| chlorhexidine gluconate... 66 | clarithromycin... 12 | CLINIMIX 5%-D20W(SULFITE-FREE)... 60 |
| chloroquine phosphate... 12 | clemastine... 21 | CLINIMIX 5%/D15W SULFITE FREE... 60 |
| chlorothiazide sodium... 60 | CLEOCIN... 92 | CLINIMIX 5%/D25W SULFITE-FREE... 60 |
| chlorothiazide... 60 | CLICKFINE... 54 | clinisol sf 15 %... 60 |
| chlorpromazine... 41 | clindamycin hcl... 12 | clobetasol... 92 |
| chlorthalidone... 60 | clindamycin in 5 % dextrose... 12 | clobetasol-emollient... 92 |
| cholestyramine (with sugar)... 34 | clindamycin palmitate hcl... 13 | clocortolone pivalate... 92 |
| cholestyramine light... 34 | clindamycin pediatric... 13 | CLOLAR... 22 |
| chorionic gonadotropin, human... 72 | clindamycin phosphate... 13, 92 | clomipramine... 41 |
| ciclodan... 92 | clindamycin-benzoyl peroxide... 92 | clonazepam... 41 |
| ciclopirox... 92 | CLINDESSE... 92 | clonidine hcl... 34 |
| cidofovir... 12 | CLINIMIX E 2.75%/D10W SUL FREE... 60 | clonidine... 34 |
| cilostazol... 30 | CLINIMIX E 2.75%/D5W SULF FREE... 60 | clopidogrel... 30 |
| CILOXAN... 66 | CLINIMIX E 4.25%/D10W SUL FREE... 60 | clorazepate dipotassium... 41 |
| cimetidine hcl... 69 | CLINIMIX E 4.25%/D25W SUL FREE... 60 | clorpres... 34 |
| cimetidine... 69 | CLINIMIX E 4.25%/D5W SULF FREE... 60 | clotrimazole... 92 |
| CINRYZE... 84 | CLINIMIX E 5%/D15W SULFIT FREE... 60 | clotrimazole-betamethasone... 92 |
| CIPRODEX... 66 | CLINIMIX E 5%/D20W SULFIT FREE... 60 | clozapine... 41 |
| ciprofloxacin (mixture)... 12 | CLINIMIX E 5%/D25W SULFIT FREE... 60 | CNL 8 NAIL... 92 |
| ciprofloxacin hcl... 12, 66 | CLINIMIX 2.75%/D5W SULFIT FREE... 60 | COARTEM... 13 |
| ciprofloxacin in 5 % dextrose... 12 | CLINIMIX 4.25%-D20W SULF-FREE... 60 | codeine sulfate... 41 |
| ciprofloxacin lactate... 12 | CLINIMIX 4.25%-D25W SULF-FREE... 60 | colchicine... 84 |
| cisplatin... 22 | CLINIMIX 4.25%/D10W SULF FREE... 60 | colchicine-probenecid... 60 |
| citalopram... 41 | CLINIMIX 4.25%/D5W SULFIT FREE... 60 | COLCRYS... 84 |
| CITRANATAL ASSURE... 97 | CLINIMIX 4.25%-D20W SULF-FREE... 60 | colestipol... 34 |
| CITRANATAL DHA (NEW FORMULA)... 97 | CLINIMIX 4.25%-D25W SULF-FREE... 60 | colistin (colistimethate na)... 13 |
| CITRANATAL RX (NEW FORMULA)... 97 | CLINIMIX 4.25%/D10W SULF FREE... 60 | colocort... 92 |
| CITRANATAL 90 DHA (NEW FORMULA... 97 | CLINIMIX 4.25%/D5W SULFIT FREE... 60 | COLY-MYCIN S... 66 |
| cladribine... 22 | | COMBIGAN... 66 |
| claravis... 92 | | COMBIVENT RESPIMAT... 28 |
| | | COMETRIQ... 22 |

| | | |
|------------------------------|--------------------------------------|--|
| COMFORT EZ PEN NEEDLES... 54 | CURITY ALCOHOL SWABS... 93 | daunorubicin... 22 |
| COMFORT EZ SYRINGE... 54 | CURITY GAUZE... 87 | DAUNOXOME... 22 |
| COMPLERA... 13 | cyclafem 1/35 (28)... 73 | daysee... 73 |
| complete natal dha... 97 | cyclafem 7/7/7 (28)... 73 | DAYTRANA... 41 |
| completenate... 97 | CYCLESSA (28)... 73 | deblitane... 73 |
| compro... 69 | cyclopentolate... 66 | decitabine... 22 |
| COMVAX (PF)... 89 | cyclophosphamide... 22 | deferoxamine... 71 |
| CONCEPT DHA... 97 | cycloserine... 13 | DELESTROGEN... 73 |
| CONCEPT OB... 98 | CYCLOSET... 41 | delyla (28)... 73 |
| CONDYLOX... 92 | cyclosporine modified... 84 | demeclocycline... 13 |
| constulose... 60 | cyclosporine... 84 | DEM SER... 84 |
| COPAXONE... 84 | CYKLOKAPRON... 30 | DENAVIR... 93 |
| COREG CR... 34 | cyproheptadine... 21 | DEPACON... 41 |
| CORLOPAM... 34 | CYRAMZA... 22 | DEPEN TITRATABS... 71 |
| cormax... 92 | cyred... 73 | DEPO-ESTRADIOL... 73 |
| CORTIFOAM... 92 | CYSTADANE... 84 | DEPO-PROVERA... 73 |
| cortisone... 72 | CYSTAGON... 84 | DEPO-SUBQ PROVERA 104... 73 |
| CORTISPORIN... 93 | CYSTARAN... 66 | DEPOCYT (PF)... 22 |
| CORTISPORIN-TC... 66 | cytarabine (pf)... 22 | DERMACEA... 87 |
| COSENTYX (2 SYRINGES)... 93 | cytarabine... 22 | desipramine... 41 |
| COSENTYX PEN (2 PENS)... 93 | CYTOGAM... 89 | desmopressin... 73 |
| COSENTYX PEN... 93 | CYTOMEL... 73 | desog-e.estradiol/e.estradiol... 73 |
| COSENTYX... 93 | D | DESOGEN... 73 |
| COSMEGEN... 22 | dacarbazine... 22 | desogestrel-ethinyl estradiol... 73 |
| COUMADIN... 30 | DALIRESP... 88 | DESONATE... 93 |
| CREON... 69 | danazol... 73 | desonide... 93 |
| CRESEMBA... 13 | dantrolene... 28 | desoximetasone... 93 |
| CRESTOR... 34 | dapsone... 13 | DEXAMETHASONE INTENSOL... 73 |
| CRIXIVAN... 13 | DAPTACEL (DTAP PEDIATRIC) (PF)... 89 | dexamethasone sodium phosphate... 66, 73 |
| cromolyn... 88 | DARAPRIM... 13 | dexamethasone... 73 |
| cryselle (28)... 73 | dasetta 1/35 (28)... 73 | DEXILANT... 69 |
| CUBICIN... 13 | dasetta 7/7/7 (28)... 73 | dexmethylphenidate... 41 |
| CUPRIMINE... 71 | | |

DEXPAK 10 DAY... 73
 DEXPAK 13 DAY... 73
 DEXPAK 6 DAY... 73
 dexpanthenol... 98
 dexrazoxane hcl... 84
 dextroamphetamine... 41, 42
 dextroamphetamine-amphetamine... 42
 dextrose 10 % and 0.2 % nacl... 61
 dextrose 10 % in water (d10w)... 61
 dextrose 20 % in water (d20w)... 61
 dextrose 25 % in water (d25w)... 61
 dextrose 30 % in water (d30w)... 61
 dextrose 40 % in water (d40w)... 61
 dextrose 5 % in water (d5w)... 61
 dextrose 5 %-lactated ringers... 61
 dextrose 5%-0.2 % sod chloride... 61
 dextrose 5%-0.3 % sod.chloride... 61
 dextrose 50 % in water (d50w)... 61
 dextrose 70 % in water (d70w)... 61
 diazepam intensol... 42
 diazepam... 42
 diclofenac potassium... 42
 diclofenac sodium... 42, 66
 dicloxacillin... 13
 dicyclomine... 28
 didanosine... 13
 diflorasone... 93
 diflunisal... 42
 digitek... 34
 digox... 34
 digoxin... 34
 dihydroergotamine... 28
 dilantin extended... 42
 DILANTIN INFATABS... 42
 dilantin... 42
 DILANTIN-125... 42
 DILATRATE-SR... 34
 dilt-cd... 34
 dilt-xr... 34
 diltiazem hcl... 34
 diltzac er... 34
 dimenhydrinate... 69
 diphenhydramine hcl... 21
 diphenoxylate-atropine... 69
 disopyramide phosphate... 34
 disulfiram... 84
 DIURIL... 61
 divalproex... 42
 dobutamine in d5w... 28
 dobutamine... 28
 DOCEFREZ... 22
 docetaxel... 22
 donepezil... 28
 dopamine in 5 % dextrose... 28
 dopamine... 28
 DORIBAX... 13
 dorzolamide... 66
 dorzolamide-timolol... 66
 doxazosin... 34
 doxepin... 42
 doxercalciferol... 98
 doxorubicin... 22
 doxorubicin, peg-liposomal... 22
 doxy-100... 13
 doxycycline hyclate... 13, 66
 doxycycline monohydrate... 13
 dronabinol... 69
 droperidol... 42
 drospirenone-ethinyl estradiol... 73
 DROXIA... 22
 DUAVEE... 73
 DULERA... 88
 duloxetine... 42
 DUONEB... 28
 DURAMORPH (PF)... 42
 DUREZOL... 66
 DYMISTA... 66
 DYRENIUM... 61
 d10 % & 0.45 % sodium chloride... 60
 d2.5 %-0.45 % sodium chloride... 61
 d5 % and 0.9 % sodium chloride... 61
 d5 %-0.45 % sodium chloride... 61

E

E.E.S. 400... 13
 EASY COMFORT INSULIN SYRINGE... 54
 EASY COMFORT PEN NEEDLES... 54
 EASY TOUCH ALCOHOL PREP PADS... 93
 EASY TOUCH INSULIN SAFETY SYR... 55
 EASY TOUCH INSULIN SYRINGE... 55
 EASY TOUCH... 55
 econazole... 93
 EDARBI... 35
 EDARBYCLOR... 35

| | | |
|-------------------------------------|-------------------------------------|-------------------------------------|
| EDURANT... 13 | enskyce... 74 | escitalopram oxalate... 43 |
| EFFIENT... 30 | entacapone... 42 | esmolol... 35 |
| EGRIFTA... 73 | entecavir... 13 | esomeprazole magnesium... 69 |
| electrolyte-48 in d5w... 61 | enulose... 61 | ESTRACE... 74 |
| ELELYSO... 65 | EPIDUO FORTE... 93 | estradiol valerate... 74 |
| ELIDEL... 93 | EPIDUO... 93 | estradiol... 74 |
| ELIGARD... 22 | epinastine... 66 | ESTRING... 74 |
| elinest... 73 | epinephrine... 28 | ESTROSTEP FE-28... 74 |
| ELIQUIS... 30 | EPIPEN JR 2-PAK... 28 | eszopiclone... 43 |
| elite-ob... 98 | EPIPEN 2-PAK... 28 | ethacrynate sodium... 61 |
| ELITEK... 65 | epirubicin... 22 | ethambutol... 14 |
| ELIXOPHYLLIN... 97 | epitol... 42 | ethosuximide... 43 |
| ELLA... 73 | EPIVIR HBV... 13 | etidronate disodium... 84 |
| ELLEENCE... 22 | eplerenone... 35 | etodolac... 43 |
| ELMIRON... 84 | EPOGEN... 30 | ETOPOPHOS... 23 |
| EMADINE... 66 | epoprostenol (glycine)... 88 | etoposide... 23 |
| EMCYT... 22 | EPZICOM... 14 | EURAX... 93 |
| EMEND... 69 | EQUETRO... 42 | EVOTAZ... 14 |
| emoquette... 73 | ERAXIS(WATER DILUENT)... 14 | EXEL INSULIN... 55 |
| EMSAM... 42 | ERBITUX... 22 | EXELDERM... 93 |
| EMTRIVA... 13 | ERGOMAR... 28 | EXELON... 28 |
| enalapril maleate... 35 | ERIVEDGE... 23 | exemestane... 23 |
| enalapril-hydrochlorothiazide... 35 | errin... 74 | EXJADE... 71 |
| enalaprilat... 35 | ERWINAZE... 23 | F |
| ENBREL SURECLICK... 84 | ery pads... 93 | FABRAZYME... 65 |
| ENBREL... 84 | ERY-TAB... 14 | falmina (28)... 74 |
| endocet... 42 | ERYTHROCIN (AS STEARATE)... 14 | famciclovir... 14 |
| ENDOMETRIN... 73 | ERYTHROCIN... 14 | famotidine (pf)... 69 |
| ENGERIX-B (PF)... 89 | erythromycin ethylsuccinate... 14 | famotidine (pf)-nacl (iso-os)... 69 |
| ENGERIX-B PEDIATRIC (PF)... 89 | erythromycin with ethanol... 93 | famotidine... 69 |
| enlon... 59 | erythromycin... 14, 66 | FANAPT... 43 |
| enoxaparin... 30 | erythromycin-benzoyl peroxide... 93 | FARESTON... 23 |
| enpresse... 74 | erythromycin-sulfisoxazole... 14 | FARYDAK... 23 |

| | | |
|---|--------------------------------------|-------------------------------------|
| FASLODEX... 23 | flunisolide... 66 | FUSILEV... 84 |
| FAZACLO... 43 | fluocinolone... 93 | FUZEON... 14 |
| felbamate... 43 | fluocinolone-shower cap... 93 | FYCOMPA... 44 |
| felodipine... 35 | fluocinonide... 93 | G |
| FEMCON FE... 74 | fluocinonide-e... 93 | gabapentin... 44 |
| FEMRING... 74 | fluoritab... 84 | galantamine... 28, 29 |
| fenofibrate micronized... 35 | fluorometholone... 66 | GAMUNEX... 89 |
| fenofibrate nanocrystallized... 35 | fluorouracil... 23, 93 | GAMUNEX-C... 89 |
| fenofibrate... 35 | fluoxetine... 43 | ganciclovir sodium... 14 |
| fenofibric acid (choline)... 35 | fluphenazine decanoate... 43 | garamycin... 67 |
| fenopropfen... 43 | fluphenazine hcl... 43 | GARDASIL (PF)... 89 |
| fentanyl citrate (pf)... 43 | flurbiprofen sodium... 66 | GARDASIL 9 (PF)... 89 |
| fentanyl citrate... 43 | flurbiprofen... 44 | gatifloxacin... 67 |
| fentanyl... 43 | flutamide... 23 | GATTEX ONE-VIAL... 69 |
| FETZIMA... 43 | fluticasone... 67, 93 | GATTEX 30-VIAL... 69 |
| finasteride... 84 | fluvoxamine... 44 | GAUZE BANDAGE... 87 |
| FIRAZYR... 84 | folivane-ob... 98 | GAUZE PAD... 87 |
| FIRMAGON KIT W DILUENT SYRINGE... 23 | folivane-prx dha nf... 98 | gavilyte-c... 69 |
| FIRMAGON... 23 | FOLOTYN... 23 | gavilyte-g... 69 |
| flavoxate... 97 | fomepizole... 84 | gavilyte-n... 70 |
| flecainide... 35 | fondaparinux... 30 | GAZYVA... 23 |
| FLECTOR... 43 | FORADIL AEROLIZER... 28 | gemcitabine... 23 |
| FLOVENT DISKUS... 88 | FORTEO... 74 | gemfibrozil... 35 |
| FLOVENT HFA... 88 | FORTICAL... 74 | generlac... 61 |
| floxuridine... 23 | foscarnet... 14 | gengraf... 84 |
| fluconazole in dextrose(iso-o)... 14 | fosinopril... 35 | gentak... 67 |
| fluconazole in nacl (iso-osm)... 14 | fosinopril-hydrochlorothiazide... 35 | gentamicin in nacl (iso-osm)... 14 |
| fluconazole... 14 | fosphenytoin... 44 | gentamicin sulfate (ped) (pf)... 14 |
| flucytosine... 14 | FRAGMIN... 31 | gentamicin sulfate (pf)... 14 |
| fludarabine... 23 | FREAMINE HBC 6.9 %... 61 | gentamicin... 14, 67, 94 |
| fludrocortisone... 74 | FREAMINE III 10 %... 61 | GEODON... 44 |
| flumazenil... 43 | FREESTYLE PRECISION... 55 | GESTICARE DHA... 98 |
| | furosemide... 61 | GIANVI (28)... 74 |

| | | |
|--------------------------------------|--------------------------------------|--------------------------------------|
| gildagia... 74 | halobetasol propionate... 94 | HUMIRA PEN... 85 |
| gildess fe... 74 | HALOG... 94 | HUMIRA PSORIASIS STARTER PACK... 85 |
| gildess 24 fe... 74 | halonate pac... 94 | HUMIRA... 85 |
| gildess... 74 | HALONATE... 94 | HUMULIN N KWIKPEN... 75 |
| GILENYA... 84 | haloperidol decanoate... 44 | HUMULIN N PEN... 75 |
| GILOTRIF... 23 | haloperidol lactate... 44 | HUMULIN N... 75 |
| GLASSIA... 88 | haloperidol... 44 | HUMULIN R U-500 "CONCENTRATED"... 75 |
| GLEEVEC... 23 | HARVONI... 14 | HUMULIN R... 75 |
| GLEOSTINE... 23 | HAVRIX (PF)... 89 | HUMULIN 70/30 KWIKPEN... 75 |
| glimepiride... 74 | HEALTHY ACCENTS UNIFINE PENTIP... 55 | HUMULIN 70/30 PEN... 75 |
| glipizide... 74 | heather... 75 | HUMULIN 70/30... 75 |
| glipizide-metformin... 74 | HECTOROL... 98 | HYCAMTIN... 23 |
| GLUCAGEN HYPOKIT... 74 | HEMABATE... 87 | hydralazine... 35 |
| GLUCAGON EMERGENCY KIT (HUMAN)... 74 | heparin (porcine) in nacl (pf)... 31 | hydrochlorothiazide... 61 |
| GLUMETZA... 74 | heparin (porcine) in 5 % dex... 31 | hydrocodone-acetaminophen... 44 |
| GLYCINE UROLOGIC... 61 | heparin (porcine)... 31 | hydrocodone-ibuprofen... 44 |
| glycine... 61 | heparin(porcine) in 0.45% nacl... 31 | hydrocortisone butyr-emollient... 94 |
| GLYCOPHOS... 61 | heparin, porcine (pf)... 31 | hydrocortisone butyrate... 94 |
| glycopyrrolate... 29 | HEPATAMINE 8%... 61 | hydrocortisone valerate... 94 |
| GLYSET... 74 | HERCEPTIN... 23 | hydrocortisone... 75, 94 |
| GLYXAMBI... 74 | HETLIOZ... 44 | hydrocortisone-acetic acid... 67 |
| granisetron (pf)... 70 | HEXALEN... 23 | hydrocortisone-min oil-wht pet... 94 |
| granisetron hcl... 70 | HUMALOG KWIKPEN... 75 | hydromorphone (pf)... 44 |
| granisol... 70 | HUMALOG MIX 50-50 KWIKPEN... 75 | hydromorphone... 44 |
| GRANIX... 31 | HUMALOG MIX 50-50... 75 | hydroxychloroquine... 14 |
| griseofulvin microsize... 14 | HUMALOG MIX 75-25 KWIKPEN... 75 | hydroxyurea... 23 |
| griseofulvin ultramicronsize... 14 | HUMALOG MIX 75-25... 75 | HYPERLYTE CR... 61 |
| guanfacine... 35 | HUMALOG... 75 | HYPERTET S/D (PF)... 89 |
| guanidine... 29 | HUMAPEN LUXURA HD... 55 | |
| gynazole-1... 94 | HUMIRA CROHN'S DIS START PCK... 85 | I |
| | HUMIRA PED CROHN'S STARTER PK... 85 | ibandronate... 85 |
| H | | IBRANCE... 23 |
| HALAVEN... 23 | | |

| | | |
|-------------------------------------|--------------------------------------|----------------------------|
| ibuprofen... 44 | INSUPEN... 56 | itraconazole... 15 |
| ibuprofen-oxycodone... 44 | INTELENCE... 15 | IV PREP WIPES... 94 |
| ibutilide fumarate... 35 | INTRALIPID... 61 | ivermectin... 15 |
| ICLUSIG... 23, 24 | INTRON A... 15 | IXEMPRA... 24 |
| IDAMYCIN PFS... 24 | introvale... 75 | IXIARO (PF)... 90 |
| idarubicin... 24 | INVANZ... 15 | J |
| ifosfamide... 24 | INVEGA SUSTENNA... 45 | JAKAFI... 24 |
| ILEVRO... 67 | INVEGA... 45 | JALYN... 85 |
| IMBRUVICA... 24 | INVIRASE... 15 | jantoven... 31 |
| imipenem-cilastatin... 14 | INVOKAMET... 75 | JANUMET XR... 75 |
| imipramine hcl... 44 | INVOKANA... 75 | JANUMET... 75 |
| imipramine pamoate... 45 | IONOSOL-B IN D5W... 61 | JANUVIA... 75 |
| imiquimod... 94 | IONOSOL-MB IN D5W... 62 | JARDIANCE... 75 |
| IMOVAX RABIES VACCINE (PF)... 90 | IOPIDINE... 67 | jencycla... 75 |
| IMURAN... 85 | IPOL... 90 | JENTADUETO... 75 |
| inatal advance... 98 | ipratropium bromide... 29, 67 | JEVTANA... 24 |
| inatal ultra... 98 | ipratropium-albuterol... 29 | JOLESSA... 75 |
| INCONTROL PEN NEEDLE... 55 | irbesartan... 35 | JOLIVETTE... 76 |
| INCRELEX... 75 | irbesartan-hydrochlorothiazide... 35 | junel fe 1.5/30 (28)... 76 |
| indapamide... 61 | IRENKA... 45 | junel fe 1/20 (28)... 76 |
| INFANRIX (DTAP) (PF)... 90 | IRESSA... 24 | junel fe 24... 76 |
| INFERGEN... 15 | irinotecan... 24 | junel 1.5/30 (21)... 76 |
| INFUMORPH P/F... 45 | ISENTRESS... 15 | junel 1/20 (21)... 76 |
| INLYTA... 24 | ISOLYTE S PH 7.4... 62 | JUVISYNC... 76 |
| INS SYRINGE/NEEDLE 0.5CC/27G... 55 | ISOLYTE-P IN 5 % DEXTROSE... 62 | K |
| INSULIN SYRINGE MICROFINE... 55 | ISOLYTE-S... 62 | k-sol... 62 |
| INSULIN SYRINGE NEEDLELESS... 55 | isoniazid... 15 | K-TAB... 62 |
| INSULIN SYRINGE ULTRAFINE... 55 | ISOPTO CARPINE... 67 | KABIVEN... 62 |
| INSULIN SYRINGE... 55 | isosorbide dinitrate... 35 | KADCYLA... 24 |
| INSULIN SYRINGE-NEEDLE U-100... 55 | isosorbide mononitrate... 35 | KALETRA... 15 |
| INSULIN SYRINGES (DISPOSABLE)... 55 | isradipine... 35 | KALYDECO... 88 |
| | ISTODAX... 24 | kariva (28)... 76 |
| | ISUPREL... 29 | KAZANO... 76 |

kelnor 1/35 (28)... 76
 KENALOG... 94
 KEPIVANCE... 94
 KETEK... 15
 ketoconazole... 15, 94
 ketodan... 94
 ketoprofen... 45
 ketorolac... 67
 KEYTRUDA... 24
 kimidess (28)... 76
 KINRIX (PF)... 90
 kionex... 62
 KLARON... 94
 klor-con m10... 62
 KLOR-CON M15... 62
 klor-con m20... 62
 klor-con sprinkle... 62
 KLOR-CON 10... 62
 KLOR-CON 8... 62
 KOMBIGLYZE XR... 76
 KORLYM... 76
 KRISTALOSE... 62
 kurvelo... 76
 KUVAN... 85
 KYNAMRO... 35

L

l norgest/e.estradiol-e.estrad... 76
 labetalol... 35
 LAC-HYDRIN... 94
 LACRISERT... 67
 lactated ringers... 62
 lactulose... 62
 LAMICTAL ODT STARTER (BLUE)... 45
 LAMICTAL ODT STARTER (GREEN)... 45
 LAMICTAL ODT STARTER (ORANGE)... 45
 LAMICTAL ODT... 45
 LAMICTAL STARTER (BLUE) KIT... 45
 LAMICTAL STARTER (GREEN) KIT... 45
 LAMICTAL STARTER (ORANGE) KIT... 45
 LAMICTAL XR STARTER (BLUE)... 45
 LAMICTAL XR STARTER (GREEN)... 45
 LAMICTAL XR STARTER (ORANGE)... 45
 LAMICTAL... 45
 lamivudine... 15
 lamivudine-zidovudine... 15
 lamotrigine... 45
 LANOXIN PEDIATRIC... 36
 LANOXIN... 36
 lansoprazole... 70
 LANTUS SOLOSTAR... 76
 LANTUS... 76
 larin fe... 76
 larin 1.5/30 (21)... 76
 larin 1/20 (21)... 76
 larin 24 fe... 76
 latanoprost... 67
 LATUDA... 45
 LAZANDA... 45
 LEENA 28... 76
 leflunomide... 85
 LENVIMA... 24
 LESCOL XL... 36
 lessina... 76
 LETAIRIS... 88
 letrozole... 24
 leucovorin calcium... 85
 LEUKERAN... 24
 LEUKINE... 31
 leuprolide... 24
 LEVATOL... 36
 LEVEMIR FLEXPEN... 76
 LEVEMIR FLEXTOUCH... 76
 LEVEMIR... 76
 levetiracetam in nacl (iso-os)... 46
 levetiracetam... 46
 levobunolol... 67
 levocarnitine (with sugar)... 85
 levocarnitine... 85
 levocetirizine... 21
 levofloxacin in d5w... 15
 levofloxacin... 15, 67
 levoleucovorin calcium... 85
 levonest (28)... 76
 levonorgestrel... 76
 levonorgestrel-ethinyl estrad... 76
 levora-28... 76
 levorphanol tartrate... 46
 levothyroxine... 77
 LEVOXYL... 77
 LEVULAN... 94
 LEXIVA... 16
 LIALDA... 70
 lidocaine (pf) in d7.5w... 82
 lidocaine (pf)... 36, 83
 lidocaine hcl... 67, 83

MENVEO A-C-Y-W-135-DIP (PF)... 90
 MENVEO MENA COMPONENT (PF)... 90
 MENVEO MENCYW-135 COMPNT (PF)... 90
 mepivacaine (pf)... 83
 mercaptopurine... 25
 meropenem... 16
 mesalamine with cleansing wipe... 70
 mesalamine... 70
 mesna... 85
 MESNEX... 85
 MESTINON TIMESPAN... 29
 metaproterenol... 29
 metformin... 77
 methadone intensol... 46
 methadone... 46
 METHADOSE... 47
 methazolamide... 67
 methenamine hippurate... 16
 methimazole... 77
 METHITEST... 77
 methocarbamol... 29
 methotrexate sodium (pf)... 25
 methotrexate sodium... 25
 methoxsalen rapid... 94
 methscopolamine... 29
 methyclothiazide... 62
 methylergonovine... 87
 METHYLIN... 47
 methylphenidate... 47
 methylprednisolone acetate... 77
 methylprednisolone sodium succ... 77
 methylprednisolone... 77
 metipranolol... 67
 metoclopramide hcl... 70
 metolazone... 62
 metoprolol succinate... 36
 metoprolol ta-hydrochlorothiaz... 36
 metoprolol tartrate... 36
 metronidazole in nacl (iso-os)... 16
 metronidazole... 16, 95
 mexiletine... 36
 MIACALCIN... 77
 miconazole-3... 95
 MICROGESTIN FE 1.5/30 (28)... 77
 MICROGESTIN FE 1/20 (28)... 78
 MICROGESTIN 1.5/30 (21)... 77
 microgestin 1/20 (21)... 77
 midodrine... 29
 mimvey... 78
 MINI ULTRA-THIN II... 56
 minocycline... 16
 minoxidil... 36
 MIOCHOL-E... 67
 MIOSTAT... 67
 mircette (28)... 78
 mirtazapine... 47
 misoprostol... 70
 mitomycin... 25
 mitoxantrone... 25
 modafinil... 47
 MODICON (28)... 78
 moexipril... 36
 moexipril-hydrochlorothiazide... 36
 mometasone... 95
 mono-lynyah... 78
 MONOJECT INSULIN SAFETY SYRING... 56
 MONOJECT INSULIN SYRINGE... 56
 MONOJECT SYRINGE... 56
 MONOJECT ULTRA COMFORT INSULIN... 56
 MONONESSA (28)... 78
 montelukast... 88
 MONUROL... 16
 morphine (pf)... 48
 morphine concentrate... 48
 morphine... 47
 moxifloxacin... 16
 moxifloxacin-sod.ace,sul-water... 16
 MOZOBIL... 31
 MULTAQ... 36
 multi-vitamin with fluoride... 98
 multivitamin with fluoride... 98
 multivitamins with fluoride... 98
 mupirocin calcium... 95
 mupirocin... 95
 MUSTARGEN... 25
 MVC-FLUORIDE... 98
 my way... 78
 MYALEPT... 78
 MYCAMINE... 16
 mycophenolate mofetil... 85
 mycophenolate sodium... 85
 MYFORTIC... 85

myorisan... 95
 MYOZYME... 65
 MYRBETRIQ... 97
 myzilra... 78
N
 nabumetone... 48
 nadolol... 36
 nadolol-bendroflumethiazide... 36
 nafcillin in dextrose iso-osm... 16
 nafcillin... 16
 naftifine... 95
 NAFTIN... 95
 NAGLAZYME... 65
 nalbuphine... 48
 NALFON... 48
 naloxone... 48
 naltrexone... 48
 NAMENDA XR... 48
 NAMENDA... 48
 naphazoline... 67
 naproxen sodium... 48
 naproxen... 48
 naratriptan... 48
 NASONEX... 67
 NATACYN... 67
 NATAZIA... 78
 nateglinide... 78
 NATPARA... 78
 NATRECOR... 36
 NEBUPENT... 16
 necon 0.5/35 (28)... 78
 necon 1/35 (28)... 78
 NECON 1/50 (28)... 78
 necon 10/11 (28)... 78
 NECON 7/7/7 (28)... 78
 nefazodone... 48
 neo-polycin hc... 67
 neo-polycin... 67
 neomycin... 16
 neomycin-bacitracin-poly-hc... 67
 neomycin-bacitracin-polymyxin... 67
 neomycin-polymyxin b gu... 95
 neomycin-polymyxin b-dexameth... 67
 neomycin-polymyxin-gramicidin... 67
 neomycin-polymyxin-hc... 67, 68
 neosporin (neo-polym-gramicid)... 68
 neostigmine methylsulfate... 29
 NEPHRAMINE 5.4 %... 62
 NESINA... 78
 NEULASTA... 31
 NEUMEGA... 31
 NEUPOGEN... 31
 NEUPRO... 48
 NEUT... 62
 nevirapine... 16
 NEXAVAR... 25
 next choice one dose... 78
 NEXTERONE... 36
 niacin... 36
 niacor... 36
 nicardipine... 36
 NICOTROL NS... 29
 nifedical xl... 36
 nifedipine... 37
 nikki (28)... 78
 NILANDRON... 25
 nimodipine... 37
 NIPENT... 25
 nitrofurantoin macrocrystal... 16
 nitrofurantoin monohyd/m-cryst... 16
 nitrofurantoin... 16
 nitroglycerin in 5 % dextrose... 37
 nitroglycerin... 37
 NITROLINGUAL... 37
 NITROSTAT... 37
 nizatidine... 70
 NOR-QD... 78
 NORA-BE... 78
 norepinephrine bitartrate... 29
 norethindrone (contraceptive)... 78
 norethindrone ac-eth estradiol... 78
 norethindrone acetate... 78
 norethindrone-e.estradiol-iron... 78
 norgestimate-ethinyl estradiol... 78
 NORINYL 1+35 (28)... 78
 NORINYL 1+50 (28)... 78
 norlyroc... 78
 NORMOSOL-M IN 5 % DEXTROSE... 62
 NORMOSOL-R IN 5 % DEXTROSE... 62
 NORMOSOL-R PH 7.4... 62
 NORMOSOL-R... 62
 NOROXIN... 16
 NORTHERA... 29
 nortrel 0.5/35 (28)... 78

| | | |
|---------------------------------|---------------------------------|--------------------------------------|
| nortrel 1/35 (21)... 78 | O-CAL PRENATAL... 98 | OSENI... 79 |
| nortrel 1/35 (28)... 78 | OCELLA... 79 | OSMITROL 10 %... 62 |
| nortrel 7/7/7 (28)... 78 | octreotide acetate... 79 | OSMITROL 15 %... 63 |
| nortriptyline... 48 | OFEV... 88 | OSMITROL 20 %... 63 |
| NORVIR... 16, 17 | ofloxacin... 17, 68 | OSMITROL 5 %... 63 |
| NOVOFINE AUTOCOVER... 56 | ogestrel (28)... 79 | ovcon-35 (28)... 79 |
| NOVOFINE PLUS... 56 | olanzapine... 48 | oxacillin in dextrose(iso-osm)... 17 |
| NOVOFINE 30... 56 | olopatadine... 68 | oxacillin... 17 |
| NOVOFINE 32... 56 | omega-3 acid ethyl esters... 37 | oxaliplatin... 25 |
| NOVOLIN N... 79 | omeprazole... 70 | oxandrolone... 79 |
| NOVOLIN R... 79 | OMNARIS... 68 | oxaprozin... 48 |
| NOVOLIN 70/30... 78 | OMNITROPE... 79 | oxazepam... 49 |
| NOVOLOG FLEXPEN... 79 | ONCASPAR... 25 | oxcarbazepine... 49 |
| NOVOLOG MIX 70-30 FLEXPEN... 79 | ondansetron hcl (pf)... 70 | OXISTAT... 95 |
| NOVOLOG MIX 70-30... 79 | ondansetron hcl... 70 | OXSORALEN... 95 |
| NOVOLOG PENFILL... 79 | ondansetron... 70 | oxybutynin chloride... 97 |
| NOVOLOG... 79 | ONFI... 48 | oxycodone... 49 |
| NOVOPEN ECHO... 56 | ONGLYZA... 79 | oxycodone-acetaminophen... 49 |
| NOVOPEN JR... 56 | OPANA ER... 48 | oxycodone-aspirin... 49 |
| NOVOPEN 3 PENMATE... 56 | OPDIVO... 25 | P |
| NOVOPEN 3... 56 | OPSUMIT... 88 | PACERONE... 37 |
| NOVOTWIST... 56 | oralone... 95 | paclitaxel... 25 |
| NOXAFIL... 17 | ORAP... 48 | paire ob plus dha... 98 |
| NUEDEXTA... 48 | orapred... 79 | pamidronate... 85 |
| NULOJIX... 85 | ORFADIN... 85 | PANDEL... 95 |
| NUTRILIPID... 62 | orphenadrine citrate... 29 | PANRETIN... 95 |
| NUVARING... 79 | orsythia... 79 | pantoprazole... 70 |
| NUVIGIL... 48 | ORTHO EVRA... 79 | paregoric... 70 |
| nyamyc... 95 | ORTHO MICRONOR... 79 | paricalcitol... 98 |
| nystatin... 17, 95 | ORTHO-CEPT (28)... 79 | paroex oral rinse... 68 |
| nystatin-triamcinolone... 95 | ORTHO-CYCLEN (28)... 79 | paromomycin... 17 |
| nystop... 95 | ORTHO-NOVUM 1/35 (28)... 79 | paroxetine hcl... 49 |
| | ORTHO-NOVUM 7/7/7 (28)... 79 | PASER... 17 |

O

PATADAY... 68
PAXIL... 49
PCE... 17
pedi-dri... 95
PEDIAPRED... 79
PEDIARIX (PF)... 90
PEDVAX HIB (PF)... 90
peg 3350-electrolytes... 70
peg-electrolyte soln... 70
peg-3350 with flavor packs... 70
PEGANONE... 49
PEGINTRON REDIPEN... 17
PEGINTRON... 17
PEN NEEDLE... 57
PEN NEEDLE, DIABETIC... 57
penicillin g pot in dextrose... 17
penicillin g potassium... 17
penicillin g procaine... 17
penicillin g sodium... 17
penicillin v potassium... 17
PENTACEL (PF)... 90
PENTAM... 17
PENTASA... 70
PENTIPS... 57
pentostatin... 25
pentoxifylline... 31
PERFOROMIST... 29
PERIKABIVEN... 63
perindopril erbumine... 37
periogard... 68
PERJETA... 25
permethrin... 95
perphenazine... 49
perphenazine-amitriptyline... 49
pfizerpen-g... 17
phenelzine... 49
phenobarbital... 49
phentolamine... 29
phenylephrine hcl... 29
PHENYTEK... 49
phenytoin sodium extended... 49
phenytoin sodium... 49
phenytoin... 49
philith... 79
PHOSLYRA... 63
PHOSPHOLINE IODIDE... 68
PHYSIOLYTE... 63
PHYSIOSOL IRRIGATION... 63
PICATO... 95
pilocarpine hcl... 29, 68
pimtrea (28)... 79
pindolol... 37
pioglitazone... 79
pioglitazone-glimepiride... 80
pioglitazone-metformin... 80
piperacillin-tazobactam... 17
pirmella... 80
piroxicam... 49
PLASMA-LYTE A... 63
PLASMA-LYTE 148... 63
PLASMA-LYTE-56 IN 5 %
DEXTROSE... 63
pnv ob+dha... 98
podofilox... 95
polocaine... 83
polocaine-mpf... 83
polycin... 68
polyethylene glycol 3350... 70
polymyxin b sulf-trimethoprim... 68
polymyxin b sulfate... 17
POMALYST... 25
portia... 80
potassium acetate... 63
potassium chlorid-d5-0.45%nacl...
63
potassium chloride in lr-d5... 63
potassium chloride in 0.9%nacl... 63
potassium chloride in 5 % dex... 63
potassium chloride... 63
potassium chloride-d5-0.2%nacl...
63
potassium chloride-d5-0.3%nacl...
63
potassium chloride-d5-0.9%nacl...
63
potassium chloride-0.45 % nacl...
63
potassium citrate... 63
potassium phosphate dibasic... 63
POTIGA... 49
pr natal 400 ec... 98
pr natal 400... 98
pr natal 430 ec... 98
pr natal 430... 98
PRADAXA... 31
pramipexole... 49
pravastatin... 37
prazosin... 37
PRED-G S.O.P.... 68
PRED-G... 68

prednicarbate... 95
 prednisolone sodium phosphate... 68, 80
 prednisolone... 80
 PREDNISONO INTENSOL... 80
 prednisone... 80
 PREMARIN... 80
 PREMASOL 10 %... 63
 PREMASOL 6 %... 63
 PRENATA... 98
 PRENATABS FA... 98
 prenatal plus (calcium carb)... 98
 prenatal plus with iron (ca)... 98
 PRENATE DHA... 98
 PRENATE ELITE... 98
 PRENATE ESSENTIAL... 98
 PREPIDIL... 87
 preplus... 98
 PREQUE 10... 98
 prevalite... 37
 previfem... 80
 PREZCOBIX... 17
 PREZISTA... 17, 18
 PRIALT... 49
 PRIFTIN... 18
 primaquine... 18
 primidone... 49
 PRIMISOL... 18
 PRISTIQ... 49
 probenecid... 63
 procainamide... 37
 PROCALAMINE 3%... 63
 prochlorperazine edisylate... 71
 prochlorperazine maleate... 71
 prochlorperazine... 71
 PROCRIT... 32
 procto-pak... 95
 PROCTOSOL HC... 95
 proctozone-hc... 95
 PRODIGY INSULIN SYRINGE... 57
 progesterone in oil... 80
 progesterone micronized... 80
 progesterone... 80
 PROGLYCEM... 80
 PROGRAF... 86
 PROLEUKIN... 25
 PROLIA... 86
 PROMACTA... 32
 promethazine... 21
 propafenone... 37
 propantheline... 29
 proparacaine... 68
 propranolol... 37
 propranolol-hydrochlorothiazid... 37
 propylthiouracil... 80
 PROQUAD (PF)... 90
 PROSOL 20 %... 63
 PROSTIGMIN... 29
 protamine... 32
 PROTONIX... 71
 protriptyline... 50
 PROVERA... 80
 psorcon... 95
 PULMOZYME... 88
 PURINETHOL... 25
 PURIXAN... 25
 PYLERA... 18
 pyrazinamide... 18
 pyridostigmine bromide... 29

Q

QNASL... 68
 QUADRACEL (PF)... 90
 QUARTETTE... 80
 quasense... 80
 quetiapine... 50
 quinapril... 37
 quinapril-hydrochlorothiazide... 37
 quinidine gluconate... 37
 quinidine sulfate... 37
 quinine sulfate... 18
 QVAR... 88

R

RABAVERT (PF)... 90
 raloxifene... 80
 ramipril... 37
 RANEXA... 37
 ranitidine hcl... 71
 RAPAFLO... 29
 RAPAMUNE... 86
 REBETOL... 18
 REBIF (WITH ALBUMIN)... 86
 REBIF REBIDOSE... 86
 REBIF TITRATION PACK... 86
 reclipen (28)... 80
 RECOMBIVAX HB (PF)... 90
 RECTIV... 95
 REGONOL... 29
 REGRANEX... 95
 RELENZA DISKHALER... 18

| | | |
|--------------------------|-----------------------------------|--------------------------------------|
| RELION NEEDLES... 57 | ringers... 64 | setonet... 99 |
| RELION PEN NEEDLES... 57 | risedronate... 86 | SETONET-EC... 99 |
| RELISTOR... 71 | RISPERDAL CONSTA... 50 | sevelamer carbonate... 64 |
| relnate dha... 98 | risperidone... 50 | sharobel... 80 |
| REMICADE... 86 | RITUXAN... 25 | SIGNIFOR... 80 |
| REMODULIN... 18 | rivastigmine tartrate... 29 | sildenafil... 38 |
| RENACIDIN... 63 | rizatriptan... 50 | SILENOR... 50 |
| REVELA... 63 | ropinirole... 50 | silver sulfadiazine... 96 |
| REOPRO... 32 | ropivacaine (pf)... 83 | SIMPONI... 86 |
| repaglinide... 80 | ROTARIX... 90 | SIMULECT... 86 |
| RESCRIPTOR... 18 | ROTATEQ VACCINE... 90 | simvastatin... 38 |
| RESECTISOL... 64 | ROXICET... 50 | sirolimus... 86 |
| reserpine... 38 | S | SIRTURO... 18 |
| RESTASIS... 68 | SABRIL... 50 | SIVEXTRO... 18 |
| RETROVIR... 18 | SAFESNAP INSULIN SYRINGE... 57 | sodium acetate... 64 |
| REVATIO... 38 | SAMSCA... 64 | sodium bicarbonate... 64 |
| revia... 50 | SANCUSO... 71 | sodium chloride 0.45 %... 64 |
| REVLIMID... 25 | SANDIMMUNE... 86 | sodium chloride 0.9 %... 64 |
| revonto... 29 | SANDOSTATIN LAR DEPOT... 80 | sodium chloride 3 %... 64 |
| REXULTI... 50 | SANTYL... 96 | sodium chloride 5 %... 64 |
| REYATAZ... 18 | SAPHRIS (BLACK CHERRY)... 50 | sodium chloride... 64 |
| RHEUMATREX... 25 | SAVELLA... 50 | SODIUM EDECRIN... 64 |
| RHOPHYLAC... 90 | se-natal 19 (with docusate)... 99 | sodium fluoride... 86 |
| ribasphere... 18 | se-natal 19... 99 | sodium lactate... 64 |
| ribavirin... 18 | se-tan dha... 99 | sodium nitrite... 86 |
| RIDAURA... 71 | selegiline hcl... 50 | sodium phenylbutyrate... 64 |
| rifabutin... 18 | selenium sulfide... 96 | sodium phosphate... 64 |
| RIFAMATE... 18 | SELZENTRY... 18 | sodium polystyrene (sorb free)... 64 |
| rifampin... 18 | SENSIPAR... 86 | sodium polystyrene sulfonate... 64 |
| RIFATER... 18 | SEREVENT DISKUS... 29 | sodium thiosulfate... 86 |
| riluzole... 50 | SEROQUEL XR... 50 | SOLTAMOX... 25 |
| rimantadine... 18 | SEROSTIM... 80 | SOLU-MEDROL (PF)... 80 |
| RIMSO-50... 95 | sertraline... 50 | SOLU-MEDROL... 80 |

| | | |
|--------------------------------------|--------------------------------------|-------------------------------|
| SOMATULINE DEPOT... 81 | sulfacetamide sodium... 68 | SYNAREL... 81 |
| SOMAVERT... 81 | sulfacetamide-prednisolone... 68 | SYNERA... 96 |
| sorbitol-mannitol... 64 | sulfadiazine... 19 | SYNERCID... 19 |
| SORIATANE... 96 | sulfamethoxazole-trimethoprim... 19 | SYNJARDY... 81 |
| sorine... 38 | SULFAMYLON... 96 | SYNRIBO... 26 |
| sotalol af... 38 | sulfasalazine... 19 | SYNTHROID... 81 |
| sotalol... 38 | sulfazine ec... 19 | SYPRINE... 71 |
| SOVALDI... 18 | sulfazine... 19 | T |
| SPIRIVA RESPIMAT... 30 | sulindac... 51 | TABLOID... 26 |
| SPIRIVA WITH HANDIHALER... 30 | sumatriptan succinate... 51 | TACLONEX... 96 |
| spironolacton-hydrochlorothiaz... 38 | sumatriptan... 51 | tacrolimus... 86 |
| spironolactone... 38 | SUPREP BOWEL PREP KIT... 71 | TAFINLAR... 26 |
| sprintec (28)... 81 | SURE COMFORT ALCOHOL PREP PADS... 96 | TAMIFLU... 19 |
| SPRYCEL... 25, 26 | SURE COMFORT INS. SYR. U-100... 57 | tamoxifen... 26 |
| SPS... 64 | SURE COMFORT INSULIN SYRINGE... 57 | tamsulosin... 30 |
| sronyx... 81 | SURE COMFORT PEN NEEDLE... 57 | TARCEVA... 26 |
| SSD... 96 | SURE-FINE PEN NEEDLES... 57 | TARGETIN... 26, 96 |
| stannous fluoride... 86 | SURE-JECT INSULIN SYRINGE... 57 | tarina fe... 81 |
| stavudine... 18 | SURE-PREP ALCOHOL PREP PADS... 96 | taron-bc... 99 |
| STAVZOR... 50 | SURMONTIL... 51 | taron-c dha... 99 |
| STERILE GAUZE PAD... 87 | SUSTIVA... 19 | taron-prex prenatal-dha... 99 |
| STIMATE... 81 | SUTENT... 26 | TASIGNA... 26 |
| STIVARGA... 26 | syeda... 81 | TASMAR... 51 |
| STRATTERA... 51 | SYLATRON 4-PACK... 19 | TAXOTERE... 26 |
| streptomycin... 19 | SYLATRON... 19 | TAZORAC... 96 |
| STRIANT... 81 | SYLVANT... 26 | taztia xt... 38 |
| STRIBILD... 19 | SYMBICORT... 88 | TECFIDERA... 86 |
| SUBOXONE... 51 | SYMLINPEN 120... 81 | TEFLARO... 19 |
| SUCRAID... 65 | SYMLINPEN 60... 81 | TEGRETOL XR... 51 |
| sucralfate... 71 | SYNAGIS... 19 | TEKAMLO... 38 |
| sufentanil citrate... 51 | | TEKTURNA HCT... 38 |
| sulfacetamide sodium (acne)... 96 | | TEKTURNA... 38 |
| | | telmisartan... 38 |

| | | |
|--------------------------------------|--------------------------------|------------------------------------|
| telmisartan-amlodipine... 38 | THYROLAR-1/2... 81 | torse mide... 64 |
| temazepam... 51 | THYROLAR-1/4... 81 | TOUJEO SOLOSTAR... 81 |
| TEMODAR... 26 | THYROLAR-2... 81 | TOVIAZ... 97 |
| teniposide... 26 | THYROLAR-3... 81 | TPN ELECTROLYTES... 64 |
| TENIVAC (PF)... 90 | tiagabine... 51 | TRACLEER... 88 |
| terazosin... 38 | TIAZAC... 38 | TRADJENTA... 81 |
| terbinafine hcl... 19 | ticlopidine... 32 | tramadol... 51 |
| terbutaline... 30 | TIKOSYN... 38 | tramadol-acetaminophen... 51 |
| terconazole... 96 | tilia fe... 81 | trandolapril... 38 |
| TERUMO INS SYRINGE 0.5CC/27G... 57 | TIMENTIN... 19 | tranexamic acid... 32 |
| TERUMO INSULIN SYRINGE... 57 | timolol maleate... 38, 68 | TRANSDERM-SCOP... 71 |
| testosterone cypionate... 81 | tinidazole... 19 | tranylcypromine... 51 |
| testosterone enanthate... 81 | TIVICAY... 19 | TRAVASOL 10 %... 64 |
| TESTRED... 81 | tizanidine... 30 | TRAVATAN Z... 68 |
| tetanus toxoid,adsorbed (pf)... 90 | TNKASE... 32 | trazodone... 51 |
| tetanus-diphtheria toxoids-td... 90 | TOBI PODHALER... 19 | TREANDA... 26 |
| tetanus,diphtheria tox ped(pf)... 90 | tobramycin in 0.9 % nacl... 19 | TRECTOR... 19 |
| tetrabenazine... 51 | tobramycin sulfate... 19 | TRELSTAR DEPOT... 26 |
| tetracycline... 19 | tobramycin... 68 | TRELSTAR LA... 26 |
| THALOMID... 86 | tobramycin-dexamethasone... 68 | TRELSTAR... 26 |
| theophylline in dextrose 5 %... 97 | TOBEX... 68 | tretinoin (chemotherapy)... 26 |
| theophylline... 97 | tolazamide... 81 | tretinoin... 96 |
| THERACYS... 91 | tolbutamide... 81 | TREXALL... 26 |
| THERMAZENE... 96 | tolcapone... 51 | tri-legest fe... 81 |
| THINPRO INSULIN SYRINGE... 57 | tolmetin... 51 | tri-linyah... 81 |
| THIOLA... 86 | tolterodine... 97 | TRI-NORINYL (28)... 81 |
| thioridazine... 51 | TOPCARE CLICKFINE... 58 | tri-previfem (28)... 81 |
| thiotepa... 26 | TOPCARE ULTRA COMFORT... 58 | tri-sprintec (28)... 81 |
| thiothixene... 51 | topiramate... 51 | tri-vit with fluoride & iron... 99 |
| thrivite-19... 99 | toposar... 26 | tri-vitamin with fluoride... 99 |
| THYMOGLOBULIN... 87 | topotecan... 26 | triadvance... 99 |
| THYROLAR-1... 81 | TOPROL XL... 38 | triamcinolone acetonide... 82, 96 |
| | TORISEL... 26 | |

| | | |
|---|--|---|
| triamterene-hydrochlorothiazid... 64 | TYKERB... 27 | valacyclovir... 20 |
| TRIBENZOR... 38 | TYPHIM VI... 91 | VALCHLOR... 96 |
| triderm... 96 | TYSABRI... 87 | VALCYTE... 20 |
| trifluoperazine... 51 | TYZEKA... 20 | valganciclovir... 20 |
| trifluridine... 68 | TYZINE... 68 | valproate sodium... 52 |
| trihexyphenidyl... 51 | U | valproic acid (as sodium salt)... 52 |
| trilyte with flavor packets... 71 | u-cort... 96 | valproic acid... 52 |
| trimethobenzamide... 71 | ULORIC... 87 | valsartan... 38 |
| trimethoprim... 19 | ULTICARE... 58 | valsartan-hydrochlorothiazide... 39 |
| trimipramine... 51 | ULTILET ALCOHOL SWAB... 96 | VALSTAR... 27 |
| trinatal gt... 99 | ULTILET INSULIN SYRINGE... 58 | vancomycin in dextrose iso-osm... 20 |
| trinatal rx 1... 99 | ULTILET PEN NEEDLE... 58 | vancomycin in d5w... 20 |
| trinatal ultra... 99 | ultimate ob dha... 99 | vancomycin... 20 |
| TRINESSA (28)... 82 | ultimatecare one nf... 99 | VANDAZOLE... 96 |
| TRISENOX... 26 | ultimatecare one... 99 | VANISHPOINT SYRINGE... 59 |
| TRIUMEQ... 19 | ULTIVA... 52 | VAQTA (PF)... 91 |
| triveen-duo dha... 99 | ULTRA CMFT INS SYR HALF UNIT... 58 | VARIVAX (PF)... 91 |
| triveen-prx rnf... 99 | ULTRA COMFORT INSULIN SYRINGE... 58 | VARIZIG... 91 |
| trivora (28)... 82 | ULTRA-THIN II (SHORT) INS SYR... 58 | VASCEPA... 39 |
| TRIZIVIR... 19 | ULTRA-THIN II (SHORT) PEN NDL... 58 | VECTIBIX... 27 |
| TROPHAMINE 10 %... 64 | ULTRA-THIN II INS PEN NEEDLES... 58 | VELCADE... 27 |
| TROPHAMINE 6%... 64 | ULTRA-THIN II INSULIN SYRINGE... 58 | VELETRI... 89 |
| tropicamide... 68 | UNIFINE PENTIPS PLUS... 59 | velivet triphasic regimen (28)... 82 |
| tropium... 97 | UNIFINE PENTIPS... 58 | VELTIN... 96 |
| TRUEPLUS INSULIN... 58 | UNITHROID... 82 | vena-bal dha... 99 |
| TRULICITY... 82 | UNITUXIN... 27 | venlafaxine... 52 |
| TRUMENBA... 91 | ursodiol... 71 | VENTAVIS... 89 |
| TRUVADA... 19 | UVADEX... 96 | VENTOLIN HFA... 30 |
| TUDORZA PRESSAIR... 30 | V | VERAMYST... 68 |
| TWINRIX (PF)... 91 | VAGIFEM... 82 | verapamil... 39 |
| TYBOST... 87 | | VEREGEN... 96 |
| TYGACIL... 20 | | VERIPRED 20... 82 |

| | | |
|------------------------------|-------------------------------------|--------------------------------------|
| VERSACLOZ... 52 | vyfemla (28)... 82 | ZANOSAR... 27 |
| VESICARE... 97 | VYTORIN 10-10... 39 | zarah... 82 |
| vestura (28)... 82 | VYTORIN 10-20... 39 | ZARXIO... 32 |
| VEXOL... 68 | VYTORIN 10-40... 39 | zatean-ch... 99 |
| VGO 20... 59 | VYTORIN 10-80... 39 | ZAVESCA... 87 |
| VGO 30... 59 | W | ZELBORAF... 27 |
| VGO 40... 59 | warfarin... 32 | ZEMPLAR... 99 |
| VICTOZA 2-PAK... 82 | water for irrigation, sterile... 65 | zenatane... 97 |
| VICTOZA 3-PAK... 82 | WEBCOL... 96 | zenchent (28)... 82 |
| VIDEX 2 GRAM PEDIATRIC... 20 | WELCHOL... 39 | zenchent fe... 82 |
| VIDEX 4 GRAM PEDIATRIC... 20 | wera (28)... 82 | zenzedi... 52 |
| VIGAMOX... 69 | WESTCORT... 96 | zeosa... 82 |
| VIIBRYD... 52 | WINRHO SDF... 91 | ZERBAXA... 20 |
| VIMPAT... 52 | WYMZYA FE... 82 | ZETIA... 39 |
| vinblastine... 27 | X | ZETONNA... 69 |
| vincasar pfs... 27 | XALKORI... 27 | ZIAGEN... 20 |
| vincristine... 27 | XARELTO... 32 | zidovudine... 20 |
| vinorelbine... 27 | XENAZINE... 52 | ziprasidone hcl... 52 |
| viorele (28)... 82 | XGEVA... 87 | ZIRGAN... 69 |
| VIRACEPT... 20 | XIFAXAN... 20 | ZOLADEX... 27 |
| VIRAMUNE XR... 20 | XOLAIR... 89 | zoledronic acid... 87 |
| VIRAZOLE... 20 | XTANDI... 27 | zoledronic acid-mannitol-water... 87 |
| VIREAD... 20 | xulane... 82 | ZOLINZA... 27 |
| virt-c dha... 99 | XYREM... 52 | zolpidem... 52 |
| virt-care one... 99 | Y | zonisamide... 52 |
| VITEKTA... 20 | YASMIN (28)... 82 | ZONTIVITY... 32 |
| VIVELLE-DOT... 82 | YAZ (28)... 82 | ZORBTIVE... 82 |
| VIVITROL... 52 | YERVOY... 27 | ZORTRESS... 87 |
| VOLTAREN... 52 | YF-VAX (PF)... 91 | ZOSTAVAX (PF)... 91 |
| VOLUVEN 6 %... 65 | Z | zovia 1/35e (28)... 82 |
| voriconazole... 20 | zafirlukast... 89 | zovia 1/50e (28)... 82 |
| VOTRIENT... 27 | zaleplon... 52 | ZOVIRAX... 97 |
| VPRIV... 65 | ZALTRAP... 27 | |

ZYCLARA... 97

ZYDELIG... 27

ZYKADIA... 27

ZYPREXA RELPREVV... 52, 53

ZYTIGA... 27

ZYVOX... 20

1ST TIER UNIFINE PENTIPS PLUS...
53

1ST TIER UNIFINE PENTIPS... 53

8-MOP... 91

H8145093000PDG1634716C_v6

This formulary was updated on 09/24/2015. For more recent information or other questions, please contact Humana at 1-800-457-4708 or, for TTY users, 711, 7 days a week, from 8 a.m. - 8 p.m. However, please note that our automated phone system may answer your call during weekends and holidays from Feb. 15 - Sept. 30. Please leave your name and telephone number, and we'll call you back by the end of the next business day, or visit Humana.com.

Humana is a Medicare Advantage PFFS organization with a Medicare contract. Enrollment in this Humana plan depends on contract renewal.

This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments and restrictions may apply. Benefits, premium and/or co-payments/co-insurance may change each year. The Formulary may change at any time. You will receive notice when necessary.

This information is available for free in other languages. Please call our customer service number at **1-800-457-4708 (TTY: 711)**.

Esta información está disponible sin costo en otros idiomas. Llame a nuestro departamento de Servicio al Cliente al **1-800-457-4708 (TTY: 711)**.

Humana®

Humana.com